



The Development of Gut 
Hormones as Drugs for the 
Treatment of Obesity 
 
A thesis submitted for the  
Degree of Doctor of Philosophy  










 Division of Diabetes, Endocrinology and Metabolism  
Section of Investigative Medicine  





Obesity is an ever-increasing problem with limited effective treatments available that are 
safe and tolerable. Gut hormones are naturally occurring endogenous satiety factors that 
are released in response to food consumption. As well as playing an important role in the 
regulation of appetite, food intake and body weight, they also have roles in glucose disposal, 
gastric motility, fuel-type utilisation and energy expenditure. These characteristics make gut 
hormones attractive drugable targets for the treatment of obesity. However, the 
vulnerability of gut hormones to degradative enzymes results in rapid clearance rates and 
limited bioactivity which limits their viability as anti-obesity therapies. 
This work aims to address two important properties to consider when developing gut 
hormones as drugs: cause of degradation and immunogenicity. Using pancreatic 
polypeptide (PP), I developed in vitro and in vivo testing systems to identify the 
physiologically important mechanisms involved in PP degradation. DPPIV and NEP were 
identified as important enzymes and enzyme-resistant analogues of PP were designed which 
demonstrated greater efficacy and slower clearance rates. 
Subcutaneous (SC) administration of foreign exogenous peptides is known to potentially 
cause immunogenic reactions against the foreign peptide. The dangers of this reaction can 
range from mild to lethal. Currently peptide therapeutics require SC administration as oral 
bioavailability is low. Therefore, an aim of my studies was to explore the impact of 
modifications to PYY with regard to immunogenicity. To do this I assessed the impact of 
changes to different regions and specific amino acids of PYY. I successfully identified a 
region of PYY which, when modified, caused immunogenicity and what substitutions 
resulted in the most changes to immunogenic properties.  
In summary my work demonstrated that by understanding the causes of peptide clearance 
and immunogenicity, safer and more efficacious analogues of gut hormones can be 





The copyright of this thesis rests with the author and is made available under a Creative 
Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, 
distribute or transmit the thesis on the condition that they attribute it, that they do not use 
it for commercial purposes and that they do not alter, transform or build upon it. For any 




DECLARATION OF CONTRIBUTORS 




Development of the PP analogue was in collaboration with Professor Stephen Bloom. 
Testing of the analogues in animal studies was carried out by the Drug Discovery team, 
Imperial College (Drs. James Minnion, Tricia Tan, Jordan Baxter, Mike Tilby, Sejal Patel and 
Miss Claire Gibbard). Dr. James Gardiner assisted in setting up the over-expressing cell lines. 
Drs. Mélisande Addison and Jordan Baxter assisted in preparations of RBB. MALDI-MS was 
outsourced to the Proteomic facility (ABC, Imperial College, London, UK). 
 
Chapter 4: 
Development of the PYY analogue was in collaboration with Professor Stephen Bloom. 
Testing of the analogues in animal studies was carried out by the Drug Discovery team, 
Imperial College (Drs. James Minnion, Tricia Tan, Mélisande Addison, Mohammed Hankir, 
Samar Ghourab, Natacha Germain-Zito, and Keisuke Suzuki). Dr. James Gardiner assisted in 
setting up the over-expressing cell lines. 
 
All radioimmunoassays were performed under the guidance and supervision of Professor 
Mohammad Ghatei who established and maintained all of the assays.  
Radiolabelled peptides for all competitive assays were also provided by Professor 




I would like to thank Professors Steve Bloom and Mohammad Ghatei for giving me the 
opportunity to carry out this work and for their supervision and encouragement. 
Much appreciation to Dr James Minnion for his supervision, continuing guidance and advice. 
Big thanks to the Drug Discovery Team in all their evolving shapes and guises for all their 
hard work and assistance.  
I am particularly grateful to members of the lab for their support and huge amounts of 
encouragement to the bitter end.  











“Just because it binds, doesn’t mean it’s doing anything. 






5-HT  5-hydroxytryptamine or Serotonin 
5-HT2C  Serotonin receptor type 2C 
AcN  Acetonitrile 
ACTH  Adrenocorticotrophic hormone 
ADA  Anti-drug antibody 
AgRP  Agouti related protein 
AIB  aminoisobutyric acid 
AMP  Adenosine monophosphate 
AMPA/KA Kainate receptor 
ANOVA Analysis of variance 
AP  Area postrema 
ARC  Arcuate nucleus 
ATP  Adenosine triphosphate 
AUC  Area under curve 
BAT  Brown adipose tissue 
BBB  Blod brain barrier 
BDNF  Brain-derived 
BMI  Body mass index 
BPD  Biliopancreatic diversion 
BSA  Bovine serum albumin 
BW  Body weight 
cAMP  Cyclic adenosine monophosphate 
CART  Cocaine- and amphetamine-regulated transcript 
CB1  Canabinnoid receptor 1 
CCK  Cholecystokinin 
CHO  Chinese hamster ovary 
CNS  Central nervous system 
CO2  Carbon dioxide 
CRF  Corticotrophin-releasing factor 
CsCl  Caesium chloride 
CYP  Cytochome 
DMEM  Dulbecco’s modified Eagle medium 
DMF  Dimethylformamide 
DMN  Dorsomedial nucleus 
DMSO  Dimethyl sulphoxide 
DNA  Deoxyribonucleic acid 
DPPIV  Dipeptidyl peptidase IV 
8 
 
DVC  Dorso-vagal comples 
EDTA  Ethylene diamine tetra-acetic acid 
EE  Energy expenditure 
ELISA  Enzyme-linked immunosorbant assay 
EMA  European Medicines Agency 
EtBr  Ethidium bromide 
Ex-4  Exendin 4 
FBS  Foetal bovine serum 
FDA  US Food and Drug Administration 
FGF  Fibroblast growth factor 
FI  Food intake 
Fmoc  Fluorenyl Methoxy-Carbonyl 
FW  Food weight 
GABA  Gamma aminobutyric acid 
GCG  Glucagon 
GDW  Glass distilled water 
GEE  Generalised estimating equations 
GHSR  Growth hormone secretagogue receptor 
GI  Gastrointestinal 
GIP  Glucose-dependent insulinotropic peptide 
GLP-1  Glucagon-like peptide-1 
GLP-1r  Glucagon-like peptide-1 receptor 
GLP-2  Glucagon-like peptide-2 
GPCR  G-protein coupled receptor 
GRPP  Glicentin-related pancreatic polypeptide 
GTE  Glucose tris EDTA 
HEK  Human embryonic kidney 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HPLC  High performance liquid chromatography 
IBMX  3-Isobutyl-1-methylxanthine 
ICV  Intracerebroventricular 
Insl5  Insulin-like peptide 5 
IP  Intraperitoneal 
IV  Intravenous 
LB  Lysogeny broth 
LHA  Lateral hypothalamic area 
MALDI-ToF Matrix-assisted laser desorption/ionisation Time-of-flight 
MCH  Melanin-concentrating hormone 
MCR  Melanocortin receptor 
MC3r  Melanocortin-3 receptor 
MC4r  Melanocortin-4 receptor 
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ME  Median eminence 
MEMRI Manganese-enhanced magnetic resonance imaging 
MPGF  Major proglucagon fragment 
MPOA  Medial preoptic area 
mRNA   Message ribonucleic acid 
m/z  Mass to charge ratio 
MSH  Melanocyte-stimulating hormone 
NB  Naltrexone buproprion 
NDMA  Neurotransmitter glutamate 
NEP   Neprilysin or Neutral endopeptidase 24.11 
NHS  National health service 
NICE  National institute for health and clinical excellence 
NPY   Neuropeptide Y 
NTS   Nucleus of the solitary tract 
Ob-Rb  Leptin receptor 
OXM   Oxyntomodulin 
PBS   Phosphate buffered saline 
PC1/2/3 Prohormone convertase 
PEG   Polyethylene glycol 
PEI   Polyethylenimine 
PMSF   Phenylmethylsulphonylfluoride 
POMC   Proopiomelanocortin 
PP   Pancreatic polypeptide 
PVN   Paraventricular nucleus 
PYY   Peptide tyrosine tyrosine 
RBA   Receptor binding assay 
RBB   Renal brush border 
RIA   Radioimmunoassay 
RIPA  Radioimmunoprecipitation assay 
RLM  Rat liver microsomes 
RNA  Ribonucleic acid 
RT  Retention time 
RYGB  Roux–en-Y gastric bypass 
SC  Subcutaneous 
SDS  Sodium dodecyl sulphate 
SEM  Standard error of the mean 
SP  Spacer peptide 
SPPS  Solid phase peptide synthesis 
T2DM  Type 2 diabetes mellitus 
TAE  Tris, acetic acid, EDTA 
TFA  Trifluoroacetic acid 
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UCP-1  Uncoupling protein 1 
VIP  Vasoactive intestinal peptide 
VMN   Ventromedial nucleus 
VSG  Vertical sleeve gastrectomy 
WHO  World health oranisation 
Y1/2/4/5r NPY1/2/4/5 receptor  
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1.1 OBESITY  
Obesity is one of the world’s largest health concerns. Its prevelance is not only on the rise in 
developed nations but also in developing countries, particularly in urban settings. In 2008, 
the World Health Organisation stated that approximately 1.5 billion adults across the world 
were considered to be overweight and at least 500 million were considered to be obese. 
These figures are set to increase; projections estimate that by 2015, 2.3 billion adults will be 
overweight and 700 million will be obese (WHO, 2011). 
Obesity can lead to serious health consequences such as cardiovascular disease (including 
heart disease and stroke), type 2 diabetes mellitus (T2DM), musculoskeletal disorders 
(especially osteoarthritis), obstructive sleep apnoea, and some cancers (including 
endometrial, breast and colon) (Flegal et al., 2007). These conditions put a tremendous 
financial strain on healthcare systems. In the UK, obesity and associated diseases are 
estimated to cost the NHS at least £4.2 billion each year (DoH, 2011). Recent strategies to 
combat obesity have either proved ineffective or harmful (Sacks et al., 2009, Sjostrom et al., 
2007, Buchwald et al., 2004). New treatments with better efficacy which cause significant 
weight loss long-term would therefore be of great benefit to society. 
The cause of obesity is an imbalance between energy input and energy output. Today, an 
increasingly large percentage of the population live in an obesogenic environment with high 
energy content food readily available plus a sedentary life style (Pearson and Biddle, 2011) 
(Prentice and Jebb, 2004). The biological systems that have evolved to regulate homeostasis 
were designed for a very different environment where food availability was limited and are 
therefore designed to favour body weight gain (Schwartz and Niswender, 2004). 
 
1.1.2 CURRENT THERAPIES  
Although overall life expectancy has continued to increase since the 1950s (Bjorbaek, 2009), 
obesity has been shown to decrease life expectancy by approximately seven years 
(Munzberg, 2010, Caro et al., 1996, Hindlet et al., 2009, Berg et al., 2002, Hu et al., 1996, 
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Walter et al., 2009). The social and economic cost of obesity is great and weight loss in 
overweight and obese patients in encouraged. The first strategy is to modify diet and 
lifestyle by reducing calories ingested and increasing calories expended. It has been shown, 
however, that there is limited compliance with very low calorie or low fat diets (Arita et al., 
1999, Hotta et al., 2001), and there is often weight regain approximately 18 months after 
completion of the diet (Hotta et al., 2001). If diet and lifestyle modifications are ineffective, 
the next step is usually some form of medical treatment to aid weight loss. Medical 
treatments for the treatment of obesity are discussed in section 1.3.4. Currently, the most 
successful method of achieving long term weight loss is through surgery; typically gastric 
banding or gastric bypass (discussed further in section 1.3.2). National Institute for Health 
and Clinical Excellence (NICE) guidelines recommend that bariatric surgery should only be 
carried out if all appropriate non-surgical measures have failed to be effective over 6 
months and if the patient has a BMI >40kg/m2, or a combination of a BMI between 
40>35kg/m2 and other significant diseases (such as T2DM) that could be improved by 
weight loss (NICE, 2006). For individuals with BMI >50kg/m2, NICE recommends bariatric 
surgery as first line treatment. However, there are a number of groups that suggest bariatric 
surgery should be implemented at lower BMI and as first line therapy (Fruebis et al., 2001, 
Qi et al., 2004) as  recommendations  from NICE were based on limitations that are now 
outdated. Surgical techniques have greatly improved, are minimally invasive, and bariatric 
surgery in general has been found to have weight-independent benefits especially on T2DM 
which points to the insufficiency of using BMI as the qualifying criteria for surgery. 
 
1.2 REGULATION OF FOOD INTAKE  
Despite wide variations in daily food intake and energy expenditure, the majority of people 
maintain a stable weight for long periods.  This balance is achieved through complex 
homeostatic mechanisms.  Mechanoreceptors within the gut, and hormonal secretions by 
the intestine and pancreas, signal acute fluxes in energy intake and energy expenditure, 
while adipose tissue produces peptides such as leptin and adiponectin that reflect longer 
term energy stores.  These signals are conveyed via nerve afferents to a variety of central 
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strucures.  The control of food intake is regulated by two complimentary systems:  the 
homeostatic and hedonic pathways. The homeostatic pathway increases the motivation to 
eat (hunger) in conditions of low energy stores, and induce satiety in a post-prandial setting. 
The hedonic control of food intake is rewards-based, and can supersede the homeostatic 
pathway when presented with highly palatable, energy-rich foods (Matsuda and 
Shimomura, 2013). These various regulatory strucutres will now be discussed.  
 
1.2.1 CENTRAL STRUCTURES INVOLVED IN THE ENERGY 
BALANCE  
1.2.1.1 The Hypothalamus  
The hypothalamus regulates many homeostatic processes, including energy balance.  It is 
situated above the pituitary gland and on either side of the third ventricle.  It is composed of 
over forty morphologically distinct nuclei (Jilkova et al., 2013). Those nuclei with a role in 
energy homeostasis will be discussed in sections 1.2.1.1.1 to 1.2.1.1.5 (Fig 1.1).  
 
1.2.1.1.1 Arcuate Nucleus (ARC)  
The ARC is an area of the hypothalamus that has an important role in the regulation of 
appetite and body weight. It lies on either side of the ventral part of the third ventricle, 
towards the base of the hypothalamus and just above the median eminence (ME). The ME 
has an incomplete blood brain barrier (BBB) (Polonsky et al., 1988b, Polonsky et al., 1988a).  
This allows nutrients and hormones within the plasma to activate the ARC (Broadwell and 
Brightman, 1976).  
The hypothalamus contains two distinct neuronal subtypes that regulate energy balance.  
These are the anorexigenic POMC/CART neurons (Porte et al., 2002) and the orexigenic 













Figure 1.1 Schematic tree-diagram of the hypopthalamus and the various nuclei. Blue arrows 
indicate anorexigenic signals and pink arrows indicate orexigenic signals and the different areas they 
signal to. Orexigenic NPY/AgRP neurons of the ARC are also in pink and anorexigenic POMC/CART 
neurons are blue. The ME in the hypothalamus and AP in the brainstem directly oppose areas of 
incomplete BBB where signals released in the periphery below, may pass. The hypothalamus and 
brain stem have neuronal connections, as does the brains stem with the periphery through the 
vagus nerve.  
 
Anorexigenic POMC/CART neurons are located in the ventrolateral region of the ARC and 
co-express pro-opiomelanocortin (POMC) and cocaine and amphetamine-regulated 
transcript (CART). Alpha-melanocyte-stimulating hormone (α-MSH) is a post-translational 
product of the POMC transcript and is the neurotransmitter by which POMC/CART neurons 
exert their anorectic effect through activation of the melanocortin-4 receptor (MC4r) 
(Fekete et al., 2000).  
Orexigenic NPY/AgRP neurons are located in the ventromedial part of the ARC and co-
express neuropeptide Y (NPY) and Agouti-related protein (AgRP), both peptides which 
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potently stimulate feeding (Meister, 2007). AgRP is an inverse agonist at the MC4r, reversing 
the anorectic effects of α-MSH (Bagnol et al., 1999). NPY/AgRP neurones also relesase the 
inhibitory neurotransmitter gamma aminobutyric acid (GABA) which inhibits POMC neurons. 
There is significant interaction between the neuronal populations.  They project to similar 
areas within the brain, and indeed NPY/AgRP neurons synapse with POMC/CART neurons 
and can inibit them. There is also reciprocal regulation of the neurons; for example leptin 
both activates POMC and inhibits AgRP neurons (Cowley et al., 2001, van den Top et al., 
2004). 
 
1.2.1.1.2 Paraventricular Nucleus (PVN)  
The PVN integrates signals from several CNS regions, with particular projections from the 
ARC, LHA and brainstem (Sawchenko and Swanson, 1983b, Sawchenko and Swanson, 
1983a). In particular from the ARC, the PVN receives strong input from POMC/CART and 
NPY/AgRP neurons which release the MC4r agonist (α-MSH) and antagonist (AgRP) (Cowley 
et al., 1999).  
In rodents, destruction of the PVN leads to hyperphagia and weight gain (Aravich and 
Sclafani, 1983, Leibowitz et al., 1981). Injection of orexigenic factors such as NPY, AgRP, 
ghrelin or orexin-A into the PVN stimulates food intake (Stanley and Leibowitz, 1985, Wirth 
and Giraudo, 2000, Melis et al., 2002, Olszewski et al., 2003, Dube et al., 1999), while 
anorectic peptides like leptin and GLP-1 reduce food intake when administered into the PVN 
(Elmquist et al., 1998, McMahon and Wellman, 1998).  
MC4r is highly expressed in the PVN (Siljee et al., 2013) and MC4r-knockout mice exhibit an 
obese and hyperphagic phenotype (Huszar et al., 1997). Though the MC4r is widely 
expressed in the brain (including in the amygdala, cortex, thalamus, striatum, brainstem and 
spinal cord) (Mountjoy et al., 1994), the obese phenotype of MC4r-knockout mice can be 




1.2.1.1.3 Dorsomedial Nucleus (DMN)  
The DMN mainly receives inputs from the lateral hypothalamic area (LHA described in more 
detail in section 1.2.1.1.5) and the ventromedial nucleus (VMN – described in section 
1.2.1.1.4) and has strong projections to the PVN (Ter Horst and Luiten, 1987, Luiten et al., 
1987). DMN lesions cause a short-term decrease in food intake which leads to a loss of body 
weight. This decrease in body mass is sustained even when caloric intake returns to normal 
(Dalton et al., 1981) suggesting that the DMN has regulatory functions concerned with body 
mass and growth rather than food intake. The short-term decrease in food intake is thought 
to be partly due to a decrease in response to mechanisms that would normally increase 
food intake e.g. hypoglycaemia (Bellinger and Bernardis, 2002). Therefore, in the long-term, 
rats with DMN lesions regulate their food intake around a new lower BW as they remain 
susceptible to diet-induced obesity if presented with more palatable food.  
The DMN expresses α-MSH and its receptor, CART, as well as  the orexigenic peptides 
melanin-concentrating hormone (MCH), orexin, and AgRP. When CART and AgRP are 
injected into the DMN, they increase food intake, whereas α-MSH agonists suppress food 
intake. The DMN also contains prolactin-releasing peptide (Roland et al., 1999) which 
suppresses food intake when injected into the DMN, possibly by increasing the release of α-
MSH (Seal et al., 2001). The DMN may also be the site of action of the anorectic peptide 
GLP-2 (Tang-Christensen et al., 2001a). 
 
1.2.1.1.4 Ventromedial Nucleus (VMN)  
The VMN is part of the mid region of the hypothalamus adjacent to the ARC. Ablation of the 
VMN results in hyperphagia and obesity in rodents (Shimizu et al., 1987). POMC/CART and 
NPY/AgRP neurons project from the ARC to the VMN, as do neurons from the LHA, DMN 
and PVN (Ter Horst and Luiten, 1987).  The VMN has receptors for α-MSH and leptin (King, 
2006, Fu and van den Pol, 2008).  MC4r activation stimulates expression of brain-derived-
neurotrophic-factor (BDNF) (Xu et al., 2003); this then acts within the PVN to cause release 
of corticotropin-releasing factor (CRF), which subsequently suppresses food intake (Gotoh et 
al., 2013).  
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1.2.1.1.5 Lateral Hypothalamic (LH) Area  
The LHA has an opposing role to the VMN. The LHA consists of neurons expressing 
orexigenic neuropeptides including orexin-A and -B, MCH, and NPY (Barson et al., 2013, 
Morris, 1989). Bilateral lesion to the LHA leads to an inhibition of food intake (Anand and 
Brobeck, 1951) and stimulation of the LHA, either electrically or with the excitatory 
neurotransmitter glutamate (via the NDMA receptor), causes an increase in food intake 
(Delgado and Anand, 1953, Stanley et al., 1993). The feeding effects of NPY (Lee and Stanley, 
2005) and the orexins (Doane et al., 2007) are also thought to be partly mediated by NDMA 
receptors in the LHA.  
The LHA also plays a role in glucose-sensing, with increased glucose levels causing increased 
neuronal activity in MCH neurons, and decreased activity in orexin and NPY neurons 
(Burdakov et al., 2005). 
 
1.2.1.2 Role of Brainstem and vagus nerve in Energy Homeostasis  
The brainstem is located in the posterior of the brain and is structurally continuous with the 
spinal cord. The brainstem relays information to and from the brain to the periphery via the 
cranial/spinal nerves. The brainstem regulates a number of essential functions, including 
breathing, consciousness, temperature regulation and acute nutritional status (Young, 
2012). Extending from the brainstem, the vagus nerve lies alongside the internal jugular vein 
and into the chest and abdomen. Approximately 80-90% of vagus nerve fibres are afferent, 
conveying sensory information from the periphery to the brain. The vagus nerve plays an 
important role in the gut-brain axis (Laskiewicz et al., 2003), and vagotomy studies suggest it 
is essential for the actions of circulating factors such as ghrelin (Date, 2012), pancreatic 
polypeptide (Astrup et al., 2009), and peptide tyrosine-tyrosine (Lijnen et al., 2010). It has 
also been suggested that the brainstem can mediate the anorectic effects of gut hormones 
independent of the hypothalamus; CCK reduces food intake in decerebrated rats, which lack 
neuronal communication between the brainstem and the hypothalamus (Grill and Smith, 
1988, Grill and Kaplan, 2002). Within the brainstem, the vagus nerve activates neurons in 
the dorsal vagal complex (DVC) which then relay signals to various parts of the brain.  
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The DVC includes the area postrema (AP), nucleus of solitary tract (NTS) and the dorsal 
motor nucleus. The AP is located posterior to the fourth ventricle, and has an incomplete 
blood brain barrier (Fig 1.1). It can therefore receive information from peripheral and 
central chemical mediators, as well as from the vagus nerve.  Receptors for a number of 
peripheral satiety factors have been identified in the AP, including the PP Y4 receptor and 
the GLP-1 receptor (Goke et al., 1995, Menendez and Atrens, 1991, McGowan et al., 1992, 
Obici et al., 2002, Schwartz et al., 1992, Date, 2012, Wang et al., 2008). Lesion studies show 
the AP has a role in feeding and energy balance: ablation attenuates PYY3-36 induced 
inhibition of food intake in rats, and inhibits basal secretion of PP (Benoit et al., 2002). The 
NTS is situated next to the AP, and also lacks a blood brain barrier.  Similarly, it integrates 
peripheral chemical signals and information from the vagus . Lesions here also affect 
feeding behaviour (Laskiewicz et al., 2003, Date, 2012, Yuan et al., 1999) and caused 
significant weight loss in rats (Grill and Smith, 1988).  
 
1.2.2 PERIPHERAL CONTROL  
Peripheral signals affecting caloric intake and energy homeostasis can be broadly divided 
into two categories: 1) those which are released in response to a meal and which act acutely 
to induce satiety (leading to meal termination) and/or satiation (prolonged satiety between 
meals); and 2) those which act over a longer time scale, in proportion to adiposity and 
overall nutritional status, to centrally regulate total body energy homeostasis. The 
interaction of satiety, energy expenditure and even glucose regulation, in turn, leads to the 
regulation of fat mass, body weight and nutrient availability. 
 
1.2.2.1 Adipose-derived signals  
1.2.2.1.1 Leptin  
Leptin is a product of the ob gene which is expressed principally in the adipocytes in the 
white adipose tissue (Zhang et al., 1994). It is released into circulation in proportion to 
adipose tissue mass (Nicolaidis and Rowland, 1976), and as such is a marker of adiposity.  It 
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therefore helps control a number of physiological proceses, including reproduction, the 
immune system, and energy homeostasis (Kojima et al., 1999).  Leptin acts via the long form 
of the leptin receptor, Ob-Rb, which is widely expressed in the ARC, VMN, DMN and LHA of 
the hypothalamus and the medial preoptic area (MPOA) (Date et al., 2000, Fei et al., 1997) 
and in other areas of the CNS such as the brainstem (Mercer et al., 1998).  
With regards to feeding, leptin reduces food intake.  Chronic peripheral administration of 
leptin in rats decreases food intake, body weight and fat mass, and prevents the fall in 
energy expenditure associated with weight loss (Sakata et al., 2002). Circulating levels of 
leptin are suppressed by short term fasting and are restored by refeeding (Hosoda et al., 
2000). Mutations or disruptions of the ob gene, and subsequent leptin deficiency, leads to 
hyperphagia and obesity in both rodents and humans (Jarkovska et al., 2004, Zhang et al., 
1994, Wren et al., 2000), which can be reversed with exogenous leptin administration 
(Cummings et al., 2001, Sakata et al., 2002, Tsubone et al., 2005, Farooqi et al., 1999).  
Leptin affects feeding via receptors in the hypothalamus and the brainstem. Within the ARC, 
leptin receptors are located on both orexigenic NPY/AgRP neurons and anorexigenic 
POMC/CART neurons. POMC/CART neurons are stimulated by leptin, whilst NPY/AgRP 
neurons are inhibited (Thompson et al., 2004, Otto et al., 2001).  Knock-down of leptin 
receptors int the brainstem induces hyperphagia in rats (Hansen et al., 2002).  
As leptin rises in proportion to adiposity, the majority of obese humans have high circulating 
leptin levels (Cummings et al., 2002, English et al., 2002). However, they remain overweight, 
and exogenous leptin is ineffective at reducing body weight in these subjects (Tamura et al., 
2002, Chen et al., 2004). This is due to leptin resistance.  This is caused by  reduced active 
transport of leptin across the blood brain barrier, as well as reduced signalling within the 
hypothalamus (Date et al., 2002). Leptin resistance may also be due down-regulation of 
leptin receptor mRNA expression and leptin receptor protein following exposure to 




1.2.2.1.2 Adiponectin  
Adiponectin is a fat-derived complement-like protein (Wang et al., 2002). In contrast to 
leptin (and insulin as discussed in 1.2.2.2), adiponectin levels are increased in response to 
weight loss and decreased in obesity (Pirnik et al., 2011, Williams et al., 2003, Hotta et al., 
2001). However, perhaps counter-intuitively, peripheral treatment with adiponectin 
decreases weight gain in rodents. It increases EE by increasing fatty acid oxidation, but has 
no effect on food intake (Polak et al., 1975). The elevation of EE is mediated via adiponectin 
receptors in the PVN of the hypothalamus (Liddle et al., 1985). Adiponectin may also play a 
part in low-grade chronic inflammation that is associated with obesity. Resolution of 
inflammation in adipose tissue increases plasma levels of adiponectin (Jilkova et al., 2013). 
Additionally, adiponectin has anti-inflammatory properties (Gibbs et al., 1973) which can 
further help to resolve the inflammation however its physiological role remains unclear and 
requires further investigation.  
 
1.2.2.2 Pancreatic signals  
Insulin is a peptide hormone secreted by the β-cells of the pancreas in response to 
increased glucose levels in the circulation. Insulin regulates glucose homeostasis by 
stimulating glucose uptake and glycogen storage, and suppressing gluconeogenesis. Insulin 
levels increase acutely in response to meal ingestion (Kissileff et al., 1981). Circulating levels 
are proportional to total body fat and fat distribution, and it has been suggested that insulin 
acts as a signal of adiposity (West et al., 1984, West et al., 1987).  However, circulating 
insulin levels are also inversely correlated with insulin sensitivity in the periphery: long term 
elevated circulating insulin levels are linked to insulin resistance and T2DM. 
Insulin acts at the brain to have an anorectic effect and crosses the blood brain barrier via a 
saturable receptor-mediated process (Pardridge et al., 1985). Injection of insulin into the 
third ventricle decreases food intake and decreases overall body weight (Thompson et al., 
1975). Further studies have suggested that the PVN and VMN are critical for this effect 
(Irwin et al., 2013a, McGowan et al., 1992). 
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Insulin binds to a tyrosine kinase receptor, a receptor which is distributed widely throughout 
the brain including sites in the PVN, VMN and the ARC. Stereotactic injection of antisense 
mRNA of the insulin receptor transcript into the ARC reverses the anorectic effect of insulin 
(Obici et al., 2002). Insulin receptors have been found on both POMC/CART and NPY/AgRP 
neurons of the ARC. Central insulin administration prevents the increase in NPY mRNA 
associated with fasting (Schwartz et al., 1992). This suggests that low body fat and, 
therefore, low insulin levels, contribute to fasting-induced increase in NPY and increased 
food intake. In contrast, central administration of insulin increases POMC mRNA expression 
in POMC/CART neurons (Benoit et al., 2002). The effects of central insulin are reversed by 
the administration of an MC4r antagonist, suggesting the anorectic central effects of insulin 
on appetite may be mediated via the the POMC product, α-MSH (Benoit et al., 2002).  
The effect of peripherally administered insulin on the CNS is more difficult to investigate due 
to the peripheral effect of insulin on glucose homeostasis with consequent inhibition of food 
intake independent of any direct central effects. However, the use of a hyperinsulinaemic-
euglycaemic clamp suggests that peripheral insulin inhibits food intake (Irwin et al., 2012).  
 
1.2.2.3 Gastrointestinal-derived signals  
1.2.2.3.1 Ghrelin  
Until the recent discovery of Insl5 (Grosse et al., 2014), Ghrelin was the only known 
peripherally produced orexigenic hormone. It is secreted primarily from the stomach 
(Moran et al., 1998) and also at low levels from the duodenum, ileum, caecum and colon 
(Schwartz et al., 1999, McLaughlin et al., 1985). Circulating ghrelin is found in two forms: 
acylated ghrelin and the non-modified des-acyl ghrelin (Meereis-Schwanke et al., 1998). 
Acylated ghrelin is the active form and has the addition of the acyl side chain, n-octanoic 
acid, which is essential for receptor binding and subsequent effects on food intake (Kojima 
et al., 1999). Ghrelin is an endogenous agonist for the growth hormone secretagogue 
receptor (GHS-R) (Lo et al., 2010) and acts via this receptor to stimulate food intake and 
growth hormone secretion (Jordan et al., 2008). The GHS-R is highly expressed in the 
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anterior pituitary, but also in the ARC and the VMN of the hypothalamus (Tannenbaum et 
al., 1998). 
Diurnal variation is seen in circulating ghrelin levels with the basal levels in humans at their 
highest in the morning and lowest at night (Shiiya et al., 2002). Plasma ghrelin levels also 
appear to increase on fasting and decrease post-prandially with sharp peaks before meals 
(Roses, 2009) suggesting a role for ghrelin in meal initiation. Central or peripheral 
administration of ghrelin dose dependently increases food intake in rats and humans 
(Crawley and Beinfeld, 1983, Matson et al., 2000, Irwin et al., 2013b, Plusczyk et al., 1997). 
As well as stimulating food intake, peripheral administration of acylated ghrelin also 
increases adipogenesis and decreases lipid oxidation and UCP1 expression (Pandol et al., 
1999, Fuhlendorff et al., 1990).  
Basal ghrelin may be a signal reflecting long-term energy stores with levels inversely 
correlating to adiposity. Anorexic individuals have high circulating levels (Gerald et al., 1996) 
while obese subjects have low plasma ghrelin levels (Blomqvist et al., 1992, Germain et al., 
2013). However, obese subjects do not experience the normal rapid post-prandial fall in 
circulating ghrelin, which may contribute to their obesity (Erdmann et al., 2005). 
Ghrelin acts on a number of central strucutres.  Within the hypothalamus, it activates 
NPY/AgRP neurons within the ARC (Chen et al., 2004, Date et al., 2002, Traebert et al., 2002, 
Wang et al., 2002). Genetic ablation, or neonatal ablation with monosodium glutamate, 
abolishes the effects of peripherally administered ghrelin on feeding (Berglund et al., 2003, 
Chen et al., 2004). Peripheral ghrelin also activates neurons of the NTS and AP of the 
brainstem (Cabrele and Beck-Sickinger, 2000). GHS-R are found on peripheral vagal afferents 
and vagotomy in both humans and rodents abolishes the orexigenic effect of peripheral 
ghrelin (Date et al., 2002, Dumont et al., 1998).  
  
1.2.2.3.2 Cholecystokinin (CCK)  
Cholecystokinin (CCK) is produced by mucosal entero-endocrine I-cells of the upper small 
intestine (Ferrier et al., 2002) and was the first gut-derived hormone to be found to inhibit 
food intake (Gibbs et al., 1973). Circulating levels of CCK rise post-prandially, remain high for 
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a number of hours (McTigue et al., 1993). Release  is stimulated by amino acids and free 
fatty acids (FFAs). Peripheral administration of CCK inhibits food intake in rodents (Gibbs et 
al., 1973), and in humans (Gellman and Woolfson, 2002). 
The long-term effects of CCK on energy homeostasis and on body weight regulation are 
unclear. Peripheral CCK has a rapid but relatively short-lived effect on appetite (Shi et al., 
2013, Witteman et al., 1994). While food intake is inhibited by chronic administration of CCK 
in rodent models, a compensatory increase in meal frequency is also observed (West et al., 
1984, West et al., 1987).  In rats, CCK-induced satiety occurs predominantly through the 
CCK-1 receptor (Moran et al., 1998, Feinle-Bisset et al., 2005). Rats lacking the CCK-1 
receptor (CCK1r) are obese and hyperphagic, while CCK antibodies and CCK-1r antagonists 
cause rats to become overweight and obese, although no significant increase of food intake 
was observed (McLaughlin et al., 1985, Meereis-Schwanke et al., 1998). In contrast, CCK-1r  
is not involved in the physiological regulation of satiety in mice as CCK-1r knockout mice 
were not obese compared to wild-type littermates, and are actually resistant to high-fat diet 
induced obesity (Lo et al., 2010).  
CCK-1r also appears to have minimal effects on energy balance in man.  Obese humans 
given highly speciﬁc CCK-1r agonists demonstrated no increased weight loss compared to 
placebo controls, but had many undesirable gastrointestinal side effects (Jordan et al., 
2008). However, it is difficult to draw conclusions from this study as the control group were 
placed on a hypocaloric diet, thus making it difficult to demonstrate a difference between 
the two groups (Roses, 2009). 
The effect of CCK on food intake is transient. Rats given a continuous infusion of CCK-8 (a 
shorter yet active form of CCK) for seven or fourteen days failed to lose weight compared to 
controls, and after only four hours became resistant to the acute anorectic effects of a CCK 
bolus (Adrian et al., 1976). This suggested rapid development of tolerance to CCK and 
desensitisation to its anorectic effects which might explain the lack of efficacy seen in 
human trials of CCK agonists. However, more recent studies show that twice daily (but not 
once daily) administration of a degradation-resistant CCK analogue (with and without 
PEGylation) has been shown to reduce food intake and thus lowering body weight over 28 
and 35 days (Irwin et al., 2012, Irwin et al., 2013a).  
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1.2.2.4 Pancreatic Polypeptide (PP)-fold peptides  
The PP-fold family consists of three peptides each with roles in appetite regulation: NPY, PP 
and PYY. All three show high levels of sequence homology (Blomqvist et al., 1992) (Table 
1.2). The common structures found in these peptides are a left-handed polyproline-like helix 
formed from amino acid residues 2–8 and an α-helix formed from amino acid residues 15-
32. The two helices are connected by a β-turn and together form the PP-fold (Germain et al., 
2013) (Fig 1.2). The fold between these helical structures is strengthened by non-covalent 
interactions between highly conserved residues, in particular Pro2, Pro5, Pro8, Tyr20, Leu24 
and Tyr27 (Nygaard et al., 2006). 
                                           






Figure 1.2 A schematic diagram of the basic structure of PP. The backbone is represented by a 
ribbon, aromatic carbon in grey, oxygen atom in red, and proline atoms in purple. Amino acids 1-8 
make up the polyproline helix, 9-14 for the β-turn and the amphipathic α-helix from position 15-32. 
Adapted from (Adrian, 1978). 
 
In humans, PP-fold peptides mediate their effects on appetite regulation via 4 different G-
protein coupled “Y-receptors”: Y1, Y2, Y4 and Y5 (Taylor et al., 1978). Y receptors are 
coupled to Gi or G0 proteins, which leads to the inhibition of adenylate cyclase and inhibition 
of the secondary messenger cyclic adenosine monophosphate (cAMP) accumulation 
(Berthoud and Powley, 1991).  
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Each receptor has a different affinity for each PP-fold ligand (Table 1.1), different function 
and tissue distribution, thereby presenting a rare example of a multi-ligand/multi-receptor 
system.  
 





NPY = PYY = [Leu31, Pro34]NPY1 > NPY2-36 > NPY3-36 ≥ PP > NPY13-36 
PYY3-36 > NPY ≥ NPY2-36 = NPY3-36 = NPY13-36 >> [Leu31, Pro34]NPY1 
PP > PYY ≥ NPY > NPY2-36 
NPY = PYY = NPY2-36 > hPP > [D-Trp32]NPY2 > NPY13-36 > rPP 
 
Table 1.1 Summary of ligand preferences at the Y receptors. PYY: full lenth PYY1-36. PYY3-36: 
fragment of full length PYY. 1specific Y1 agonist (Feurle et al., 1980). 2specific Y5 agonist (Kojima et 
al., 2007) 
 
Y receptors are mainly expressed in the brain and digestive tract, though the Y1 receptor 
(Y1r) is also found in blood vessels and Y2r in the heart (Deng et al., 2001, Lin et al., 2009). 
Within the hypothalamus, Y1r are found predominately in the ARC, and Y2r in the PVN and 
the ARC (Parker and Herzog, 1999). Y2r are also expressed in the brainstem (Hernandez et 
al., 1994). Y4r is highly expressed in the AP and the dorsal vagal complex of the brainstem 
(Parker et al., 1999, Parker and Herzog, 1999) where there is limited expression of other Y 
receptors.  
 
1.2.2.4.1 Neuropeptide Y (NPY) 
NPY, a 36 amino acid polypeptide (Whitcomb et al., 1990), is most abundant in the CNS and 
acts as an orexigenic neuropeptide in the hypothalamus (Taylor et al., 1985). It acts through 
the Y family of receptors with particular high affinity to Y1r and Y5r. Acute 
intracerebroventricular (ICV) administration of NPY in rats increases appetite (Sainsbury et 
al., 2010) and repeated administration leads to weight gain (Lassmann et al., 1980). As 
mentioned in section 1.2.1.1.1, NPY neurons are found in the ARC with projections 
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throughout the hypothalamus (Morris, 1989). Levels of hypothalamic NPY inversely 
correlate with food intake: NPY levels increase with fasting and decrease post-prandially 
(Uhe et al., 1992). Hormones involved in the control of energy balance, such as insulin and 
leptin (section 1.2.2.1.1), have a negative feedback effect on hypothalamic NPY expression 
(Fujimoto et al., 1997, Stephens et al., 1995). In addition to its effects as an orexigenic 
neuropeptide, NPY also reduces energy expenditure when injected ICV in rats (Egawa et al., 
1991), promotes storage of energy as fat (Kuo et al., 2007), reduces anxiety and stress, has 
affects on the circadian rhythm, alcohol intake, and blood pressure (Tatemoto, 2004), and 
has a role in epilepsy (Colmers and El Bahh, 2003).  
 
1.2.2.4.2 Pancreatic Polypeptide (PP) 
PP is an amidated 36 amino acid PP-fold peptide released from F cells in the islets of 
Langerhans of the pancreas in response to meal ingestion. Protein, and particularly fat, are 
potent stimulators of PP release (Kinzig et al., 2007, Zipf et al., 1981). The magnitude of PP 
secretion is proportional to caloric intake and postprandial circulating PP levels then remain 
elevated for up to 6 hours (Zipf et al., 1983, Berntson et al., 1993). PP secretion is largely 
dependent on a vagal cholinergic mechanism (Schwartz et al., 1978). Vagal afferent 
connections from the GI tract to the NTS and the AP of the brainstem relay to the DMN 
indicating the presence of food in the stomach and intestines while vagal efferents from the 
DMN projecting to the pancreas signal to stimulate PP release (Strodel et al., 1984). PP 
release can, however, also be stimulated by CCK, ghrelin, motilin, secretin as well as in 
response to adrenergic activation during hypoglycaemia or exercise (Adrian et al., 1986).  
PP is involved in a range of functions including inhibition of food intake, pancreatic 
secretions, gastric acid secretions, gallbladder motility and delay of gastric emptying 
(Martella et al., 1997). Lesions to the AP have been shown to ablate the ability of exogenous 
PP to inhibit pancreatic secretions (Deng et al., 2001). 
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 Table 1.2 Amino acid sequence (single letter codes in Appendix A) of Y receptor ligands. Yellow are strongly conserved amino acids throughout all 
species; grey are highly conserved positions 
 
 Amino acid sequence 
Peptides 1    5     10     15     20     25     30     35   
hNPY Y P S K P D N P G E D A P A E D M A R Y Y S A L R H Y I N L I T R Q R Y NH2 
hPYY Y P I K P E A P G E D A S P E E L N R Y Y A S L R H Y L N L V T R Q R Y NH2 
hPP A P L E P V Y P G D N A T P E Q M A Q Y A A D L R R Y I N M L T R P R Y NH2 
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PP has high affinity for the Y4 receptor (Y4r) and its effects on food intake are mediated via 
its activation of the Y4r (Asakawa et al., 1999). Y4r have been observed in the brainstem and 
hypothalamus including the AP and the ARC (Ueno et al., 1999, Jesudason et al., 2007). 
Similarly, peripheral administration of PP at a dose which significantly reduces food intake, 
shows neuronal activation in the lateral aspect of the ARC, the DMH, VMN, and LHA 
(Asakawa et al., 2003). However, the vagus nerve may also be involved since vagotomy 
abolishes the anorectic effects of PP in rats (Asakawa et al., 2003). The effect of PP on 
appetite can thus be mediated through directs actions of circulating hormone at the 
brainstem or hypothalamus, through vagal afferents or through a combination of both. The 
anorexigenic mechanism of PP appears to occur via a decrease orexigenic NPY, orexin and 
ghrelin expression, while increasing the expression of anorexigenic urocortin and BDNF in 
the hypothalamus (Sainsbury et al., 2010). 
Increased basal levels of PP (usually caused by pancreatic endocrine tumours) have often 
been associated with weight loss (Mentlein et al., 1993a, Helou et al., 2008, Ballantyne et 
al., 1993). Exogenous administration of PP reduces food intake in both humans and mice 
(McFadden et al., 1992, Zhang et al., 1993). Infusion of PP which results in supra-
physiological circulating levels reduced acute food intake by 20% compared to saline 
control, and 24 hour food intake by 25% (Batterham et al., 2003b). A lower infusion of PP 
which resulted in circulating levels of PP to within the pathophysiological range of 
pancreatic tumours reduced acute food intake by 10% but had no effect on 24 hour food 
intake (Savage et al., 1987). Over-expression of PP in mice produced a hypophagic and thin 
phenotype, suggesting that chronic exposure to PP does not lead to attenuation of the 
anorectic effect. The administration of anti-PP antiserum restores this phenotype relative to 
wild type controls (Batterham et al., 2003a).  
Obese subjects demonstrate a blunted postprandial PP response (Broberger et al., 1997) 
while subjects with anorexia nervosa have presented with exaggerated postprandial PP 
responses (Abbott et al., 2005a, Abbott et al., 2005b, Gustafson et al., 1997). Chronic PP 
administration to leptin deficient ob/ob mice significantly reduced body weight gain and 
also resulted in improvements in blood glucose and lipid profiles (Asakawa et al., 2003). 
Paradoxically, Prader-Willi patients who are obese and suffer uncontrollable hyperphagia 
have high basal levels of PP. However, they still exhibit the blunted PP response to feeding 
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(Halatchev et al., 2004, Koda et al., 2005) and infusion of PP has been shown to significantly 
reduce acute food intake (Vrang et al., 2006).  
Chronic PP administration also demonstrated an increase in oxygen consumption as well as 
an increase in the discharge rate of sympathetic efferent nerves innervating the adrenal 
medulla and BAT (Asakawa et al., 2003). This suggests that PP may have a role in energy 
expenditure. Combined with the lack of any adverse effects in human studies, PP may have 
potential in the regulation of food intake and the treatment of obesity. 
 
1.2.2.4.3 Peptide YY (PYY) 
PYY is another amidated 36 amino acid PP-fold peptide hormone released post-prandially 
from enteroendocrine L-cells in the distal gut (Adrian et al., 1985). PYY is cleaved by the 
membrane-bound enzyme dipeptidyl peptidase-IV (DPPIV) at the N-terminal tyrosine-
proline to generate PYY3-36, the major circulating form of PYY (Vrang et al., 2006). PYY3-36 
binds selectively to the Y2r whereas full length PYY is a Y1r- and Y5r-preferring ligand. PYY is 
released within 15 minutes of nutrient ingestion and peaks 1-2 hours after, and remains 
elevated for a period of several hours (Adrian et al., 1985). Caloric load, consistency and 
nutrient composition of food have all been seen to affect the resulting levels of circulating 
PYY (Batterham et al., 2006). Vasoactive intestinal peptide (VIP), CCK and vagal impulses 
have also been suggested to regulate PYY secretion (le Roux et al., 2008a, Nannipieri et al., 
2013, Pfluger et al., 2007).  
Before 2002, the main role of PYY3-36 was thought to be in the regulation of gastric motility 
and gastric secretion (Guo et al., 2006). It was described as a mediator of the ‘ileal brake’ 
which slowed the transit of a meal from the stomach into the small intestine in response to 
nutrient sensing. In 2002, Batterham et al. demonstrated that PYY3-36 binds specifically to 
the Y2r in the CNS to cause inhibition of food intake in rodents as well as in both obese and 
normal weight humans (Batterham et al., 2002, Sloth et al., 2007).  
The anorexigenic mechanism of PYY3-36 is thought to act through activation of autoinhibitory 
Y2r found on orexigenic NPY-expressing neurons of the medial ARC to inhibit intracellular 
cAMP accumulation. This inhibits the orexigenic output of these neurons and thus reduces 
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appetite (Boey et al., 2006, Batterham et al., 2007, Bell et al., 1983). The NTS region of the 
brainstem has high expression of Y2r mRNA (Gustafson et al., 1997) thus this area may be 
important in relaying satiety signals from vagal afferents in the gut via projections to the 
hypothalamus. Indeed neuronal activation is seen in the NTS and AP following intravenous 
(IV) infusion of PYY3-36 (Halatchev et al., 2004, Lijnen et al., 2010). However, this area also 
has an incomplete blood brain which means that PYY3-36 action in the hypothalamus may 
not be entirely transmitted through vagal signals. 
In rodents, peripheral administration of PYY3-36 acutely inhibits food intake, and chronically 
significantly reduces body weight and adiposity in normal and obese rodents (Vrang et al., 
2006). Moreover, PYY-null mice are hyperphagic and have increased adiposity suggesting a 
physiological role for PYY as a regulator of energy intake (Batterham et al., 2006, Boey et al., 
2006, Zhang et al., 2012). These effects are both reversed with exogenous administration of 
PYY3-36. 
IV infusion of PYY3-36 also acutely reduces food intake in humans. Healthy volunteers infused 
with physiological doses of PYY3-36 (to mimic post prandial levels), reduced their food intake 
at a buffet meal by 35%. Food consumption is further significantly decreased over the next 
12 hours following the infusion (Batterham et al., 2002). However, supra-physiological doses 
of PYY3-36 are associated with nausea (le Roux et al., 2008a).  
PYY3-36 has been implicated in the long term regulation of body weight  (Speakman et al., 
2011, Sumithran et al., 2011) with high levels of PYY3-36 found in patients suffering from 
anorexia nervosa (Misra et al., 2006) and frequently low levels measured in obese subjects 
(Pfluger et al., 2007). It has been suggested in several studies that PYY3-36 may increase 
energy expenditure and there have been several correlations made between postprandial 
PYY3-36 levels and postprandial thermogenesis, resting metabolic rate and 24 hour 
respiratory quotient (Guo et al., 2006, Sloth et al., 2007). PYY may also have a role for in 
glucose homeostasis as PYY knock-out mice are hyperinsulinaemic (Boey et al., 2006). The 
insulin-lowering effect of PYY after glucose stimulation has been suggested to be the result 
of Y1r agonism by full length PYY, as exhibited in vitro using isolated rat and mouse islets 
(Nieuwenhuizen et al., 1994, Chandarana et al., 2013). Inhibition of insulin secretion by 
islets is not reflected by PYY3-36, which is a selective Y2r agonist. This is consistent with the 
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lack of Y2r present in islets. However, there is evidence in rodent in vivo studies 
demonstrating that PYY3-36 improves glucose tolerance (Pittner et al., 2004, van den Hoek et 
al., 2004). This is suggested be an indirect effect of PYY3-36, and occurs via increased 
hepato-portal active GLP-1 plasma levels (Chandarana et al., 2013). PYY3-36 may also have a 
role in improving insulin sensitivity as it increases glucose disposal rate under 
hyperinsulinaemic conditions (van den Hoek et al., 2004) 
Interestingly, as well as the homeostatic areas of the hypothalamus described so far, 
functional magnetic resonance imaging showed increased neuronal activity with PYY3-36 in 
the caudolateral orbital frontal cortex, an area of the brain involved in the hedonic aspect of 
feeding (Batterham et al., 2007). This fits well with the satiety effect of PYY which may 
include the increase in the reward aspect of food intake following a period of fasting.  
 
1.2.2.5 Proglucagon-derived products  
The proglucagon gene was discovered in 1983 (Bell et al., 1983). Pre-proglucagon is 
expressed in pancreatic α-cells, intestinal L-cells and the NTS of the brainstem (Larsen et al., 
1997a) and then undergoes tissue specific post-translational processing depending on its 
location (Mojsov et al., 1986) (Fig 1.3). In the intestine and CNS, pre-proglucagon is cleaved 
by prohormone convertase 1 (PC1 – also known as PC3) into glicentin, glicentin-related 
pancreatic peptide (GRPP), oxyntomodulin (OXM), glucagon-like peptide 1 and 2 (GLP-1 and 
GLP-2) (Tang-Christensen et al., 2001b, Bonic and Mackin, 2003). In the pancreas, pre-
proglucagon is ultimately processed by PC2 to produce glucagon, GRPP and major 























Figure 1.3 A diagrammatic representation of the tissue-specific processing of preproglucagon in the 
pancreas and the CNS/intestine.  
 
1.2.2.5.1 Glucagon 
Glucagon is a 29 amino acid peptide released from the α-cells of the islets of Langerhans in 
the pancreas. Glucagon opposes the actions of insulin on blood glucose levels, by increasing 
plasma glucose levels through de novo synthesis (gluconeogenensis), and/or the release of 
glucose from storage as glycogen (glycogenolysis). Glucagon binds to the glucagon receptor 
(GCGr), which is a G-protein coupled receptor (GPCR) linked to the activation of cAMP 
(Jelinek et al., 1993). High affinity glucagon binding sites have been identified in the liver, 
kidney, intestinal smooth muscle, brain, adipose tissue and islet β-cells (Moens et al., 1996). 
Glucagon acts primarily at the liver to stimulate gluconeogenesis and glycogenolysis 
(Ikezawa et al., 1998). However, the activation of GCGr on pancreatic β-cells is linked to an 
increase in insulin release. This allows newly available circulating glucose to be taken up by 
insulin-dependent tissues, such as liver and muscle.  
The release of glucagon is stimulated by the direct effect of glucose on α-cells (i.e. in the 
post-prandial state). This occurs through glucose metabolism in the cell where ATP 
production causes opening of ATP-dependent potassium channels in the cell membrane, 
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depolarisation of the cell, and subsequent exocytosis of vesicles containing glucagon (Olsen 
et al., 2005, Salehi et al., 2006). Although this would seem paradoxical, the effect of glucose 
to mediate glucagon release from α-cells is overridden by the incretin effect of glucagon via 
β-cells. The release of insulin as well as GABA from β-cells in response to glucose in turn 
leads to inhibition of glucagon release from α-cells (Rorsman et al., 1989, Wendt et al., 
2004, Xu et al., 2006). In parallel, hypoglycaemia is avoided through autoregulatory 
pathways where GCGr activation in α-cells stimulates further glucagon secretion (Ma et al., 
2005). There also exists an indirect autoinhibitory pathway where L-glutamate released 
from α-cells stimulates GABA release from β-cells and thereby causes a decrease in glucagon 
secretion (Wendt et al., 2004, Uehara et al., 2004). 
Although the primary function of glucagon is the regulation of hepatic glucose metabolism, 
glucagon has also been associated with a role in the regulation of energy expenditure. A 
study in rats where chronic glucagon administration caused a 20% reduction of body weight 
with no change in food intake (Chan et al., 1984) strongly suggests a role for glucagon in 
regulating energy expenditure, although the mechanisms are not fully characterised. The 
role of glucagon in causing an increase in energy expenditure has also recently been 
demonstrated in humans (Tan et al., 2013). 
A possible mechanism for glucagon’s effect on body weight could involve effects on fatty 
acid oxidation and lipogenesis. Fasting, and the subsequent decrease in insulin and increase 
in glucagon levels, leads to increased fatty acid beta oxidation and decreased lipogenesis 
(Pegorier et al., 1989, Longuet et al., 2008). The expression levels of genes related to fatty 
acid oxidation are increased during fasting, increasing the potential for the hepatocytes to 
oxidise fat. The effects of fasting are all reversed in GCGr-null mice. 
The actions of glucagon on increased energy expenditure make it an attractive target for 
anti obesity therapies. However this should be balanced with its effect on glucose 





1.2.2.5.2 Glucagon-like peptide 1 (GLP-1) 
GLP-1(7-36) amide (GLP-1) is a 30 amino acid peptide. It is secreted from enteroendocrine L-
cells of the intestinal tract as two equally bioactive forms of GLP-1 into the circulation 
(Herrmann et al., 1995, Orskov et al., 1993). GLP-1 (7-37) and GLP-1 (7-36)-amide are both 
released in response to the ingestion of nutrients (Orskov et al., 1996). GLP-1 has a very 
short active half-life of less than 5 minutes  due to degradation by the enzyme DPPIV 
(Kieffer et al., 1995, Deacon et al., 1995).  
GLP-1 binds to and activates the GPCR GLP-1 receptor (GLP-1r). GLP-1r is coupled to 
adenylate cyclase and thereby stimulates cAMP production through a Gs alpha subunit. GLP-
1r are expressed in the β-cells and α-cells of the pancreatic islets (Thorens, 1992) as well as 
in the lung in rodents (not in humans) (Richter et al., 1990), brain (Alvarez et al., 1996, Goke 
et al., 1995), heart (Wei and Mojsov, 1995), stomach (Schepp et al., 1994, Schmidtler et al., 
1994), kidney and intestine (Bullock et al., 1996). 
GLP-1 is an incretin, which stimulates glucose-dependent insulin secretion from the 
pancreas and inhibits glucagon secretion (Drucker, 2001). It binds to GLP-1 receptors on the 
β-cells to stimulate insulin release (Kreymann et al., 1987). GLP-1r knockout mice show 
normal feeding behaviour but reduced glucose tolerance and fasting hyperglycaemia 
(Scrocchi et al., 1996).  Antagonism of the GLP-1r by exendin9-39 (Ex9-39) abolishes the 
incretin effect.  GLP-1 also potentiates all steps of insulin biosynthesis (MacDonald et al., 
2002). Activation of the GLP-1r stimulates cAMP and subsequent Protein Kinase A (PKA) 
production which leads to insulin biosynthesis and has a pro-mitotic effect on β cells (Hui et 
al., 2003).  GLP-1r stimulation also causes an increase in intracellular calcium, which leads to 
insulin exocytosis (Gromada et al., 1997). 
As mentioned, GLP-1 is rapidly degraded by  DPPIV. This enzyme cleaves the two N-terminal 
amino acids to produce GLP-1(9-36). GLP1(9-39) was initially shown to have antagonistic 
actions at the GLP-1r (Knudsen and Pridal, 1996) but is now believed to have weak partial 
insulinotropic agonist activities at the GLP-1r (Beinborn et al., 2005). It also has 
extrapancreatic insulin-like actions in the heart, vasculature, and liver, which appear to be 
mediated independently of the GLP-1r (Tomas and Habener, 2010, Beinborn et al., 2005). 
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Post-prandially released GLP-1 promotes satiety as does exogenously administered GLP-1 
(Turton et al., 1996). GLP-1 may increase satiety in two different ways.  The first is via 
inhibition of gastric emptying and secretion of gastric juices (Wettergren et al., 1993, Holst, 
1994, Nauck et al., 1997, Naslund et al., 1999). The second is through central appetite 
regulation. Intracerebroventricular (ICV) GLP-1 potently reduces food intake in fasted rats 
(Tang-Christensen et al., 1996, Tang-Christensen et al., 1998).  Part of the anorectic effect of 
GLP-1 may be through nausea and conditioned taste averson (Seeley et al., 2000, Liang et 
al., 2013); however as low doses of centrally  administered GLP-1 still cause a significant 
anorectic effect without causing taste aversion or altered locomotor behaviour (McMahon 
and Wellman, 1998), this cannot be the only mechanism.  ICV GLP-1 also causes a shift in 
the proportion of carbohydrate to fat utilised as energy substrate (Tachibana et al., 2007).  
The central effectors of GLP-1 action are the brainstem, hypothalamus and vagus. GLP-1r 
have been detected in the brain in regions important in the regulation of energy 
homeostasis including the ARC, and PVN of the hypothalamus, and the AP and NTS of the 
brainstem (Shughrue et al., 1996, Larsen et al., 1997b, Merchenthaler et al., 1999). Animals 
with lesions in the ARC are no longer responsive to the anorectic effects of GLP-1 (Tang-
Christensen et al., 1998), nor are those who have had a vagotomy (Abbott et al., 2005a). 
GLP-1 release and receptor expression in the brainstem and hypothalamus could mean that 
GLP-1 plays a role as a neurotransmitter as well as a circulating hormone (Calvo et al., 1995, 
Jin et al., 1988, Kreymann et al., 1989, Yoshimoto et al., 1989).  
The effect of GLP-1 on overall energy expenditure is not fully understood.  Some studies 
show no effect (Abu-Hamdah et al., 2009), increased EE (Osaka et al., 2005), or reduced EE 
in line with weight loss (Tomas and Habener, 2010). Lockie et al. (van Can et al., 2013) 
suggested increased BAT thermogenesis, caused by central GLP-1r agonism, as the 
mechanism whereby pharmacological GLP-1r activation controls energy balance, and also 
mediates the increased EE seen with oxyntomodulin. 
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1.2.2.5.3 Oxyntomodulin (OXM) 
OXM is a 37 amino acid peptide comprising the entire glucagon structure with an additional 
C-terminal octapeptide extension (Bataille et al., 1981). Radioligand competition binding 
assays reveal that OXM binds to both the GLP-1 receptor and the glucagon receptor (Baggio 
et al., 2004a, Kosinski et al., 2012) though with lower affinity than either cognate ligand. 
OXM is degraded through cleavage by the enzymes DPPIV and NEP (Zhu et al., 2003, Druce 
et al., 2009); this degradation explains its rapid removal from the human circulation (Druce 
et al., 2009). Proglucagon undergoes similar processing in the caudal part of the NTS and 
OXM is also produced here; this leads to the suggestion that OXM may act as a 
neurotransmitter in the NTS (Vrang et al., 2007). 
Physiological release causes an increase in pancreatic endocrine secretions in rats and in 
human volunteers and also leads to increased gastric acid secretion and delayed gastric 
emptying (Biedzinski et al., 1987, Schjoldager et al., 1989). OXM also has a significant role in 
the regulation of energy homeostasis. Commensurate with it being a satiety signal, OXM is 
released post prandially from the intestinal L cells in a proportion to caloric intake (Ghatei et 
al., 1983, Stanley et al., 2004).  Central and peripheral administration of OXM to rats cause 
acute and chronic decreases in food intake, body weight gain and adiposity (Baggio et al., 
2004a, Dakin et al., 2001, Dakin et al., 2002). Acute administration of OXM to humans also 
demonsrated a reduction of FI.  Additionally, OXM causes an increase in energy expenditure.  
Rats given OXM twice per day for one week lost more weight than a pair-fed group, and 
chronic administration in man increased activity-related energy expenditure as measured by 
an Actiheart monitor (Cohen et al., 2003, Wynne et al., 2005, Wynne et al., 2006, Dakin et 
al., 2002). 
Some of the anorectic effect of OXM occurs through the GLP-1r: OXM does not reduce food 
intake in GLP-1r knockout mice and central administration of the GLP-1 antagonist 
Exendin(9-39) prevented the anorectic effects of ICV OXM (Baggio et al., 2004a). OXM and 
GLP-1 reduce food intake to the same extent when administered centrally at equal doses, 
despite the lower affinity of OXM for the GLP-1r than GLP-1 (Fehmann et al., 1994, Dakin et 
al., 2001). However, the anorectic effect of OXM is not exclusively mediated via the same 
pathway as GLP-1. Central Ex(9-39) blocks the anorectic effect of peripherally administered 
54 
 
OXM, but not peripherally administered GLP-1 (Dakin et al., 2004). Furthermore, MEMRI 
scans have shown that the hypothalamic neuronal activity patterns exhibited by OXM and 
GLP-1 in mice differ considerably (Chaudhri et al., 2006, Parkinson et al., 2009). While these 
differences may be simply due to different brain penetration, it is plausible that there is 
engagement of additional receptor(s) and/or that OXM and GLP-1 have different effects on 
the GLP1r signalling pathway (Baggio et al., 2004a, Sowden et al., 2007).    
The differential effect of OXM compared with GLP-1 could be mediated through the GCGr. 
OXM can functionally activate the GCGr and cause hepatic glycogenolysis (Kosinski et al., 
2012). An interesting programme of investigations has been undertaken by the group lead 
by Pocai.  By changing OXM at position 3 from Gln to Glu (OXM-Glu3), they created a 
version of OXM that is a pure GLP-1r agonist (Santoprete et al., 2011) with no GCGr activity. 
OXM stimulates liver ketogenesis, while OXM-Glu3  does not, suggesting this action occurs 
via the GCGr. OXM causes increased EE via the GCGr.  Chronic OXM in DIO mice causes 
greater weight loss compared to those given OXM-Glu3, despite similar decreases in food 
intake, and administration of the GCGr angatonist, Cpd A, reduces the weight loss effect of 
OXM to that of OXM-Glu3 (Kosinski et al., 2012).  In humans, mimicking the dual agnoism of 
OXM by co-infusion of glucagon and GLP-1 caused an increase in EE compared to GLP-1 
alone (Tan et al., 2013). 
The effect of OXM on glucose homeostasis reflects its actions at both the GCG and GLP-1 
receptors.  OXM reduces glucose excursion during a glucose tolerance test in mice 
(Parlevliet et al., 2008, Du et al., 2012).  However, the dose of OXM to completely suppress 
glucose excursion is ten-times higher than when the pure GLP-1 agonist,  OXM-Glu3, is used 
(Du et al., 2012). In a hyperglycaemic clamp, a higher glucose infusion rate was required to 
maintain glucose levels when OXM-Glu3 was infused compared to an OXM infusion.  The 
ratio of GCG and GLP-1 receptor activation is important in determining the effects of OXM-
like compounds.  Balanced agonism shows the best weight loss and glucose lowering effects 




1.3 CURRENT STRATEGIES IN ANTI-OBESITY 
THERAPEUTICS  
1.3.1 LIFESTYLE MODIFICATIONS  
First line treatment for obesity is lifestyle modification with caloric restriction and increased 
physical activity. However, meta-analyses suggest that neither diet or exercise, either alone 
or in combination, are particularly efficacious at causing weight loss (Dombrowski et al., 
2014).  Exercise alone causes minimal weight loss over 12 months.  Calorie restriction alone 
caused 5% weight loss over 6 months, reduced to 3% by the end of two years.  There is no 
difference between types of calorie-restricted diet (Sacks et al., 2009). A combination of diet 
and exercise caused a significant reduction in weight of 8.5% at 6 months; however by 48 
months, this had fallen to 4% (Franz et al., 2007). This lack of success is mostly due to poor 
compliance to treatment (Makris and Foster, 2011). Diet and exercise are therefore often 
recommended only as an aid for weight maintenance once a healthy BMI has been achieved 
(Slentz et al., 2004).  
1.3.2 SURGICAL  
Bariatric surgery is currently the most successful, long-term treatment for obesity (Vines and 
Schiesser, 2014). The Swedish Obesity Study shows weight loss of 18% up to twenty years 
after the procedure (Sjostrom, 2013). However, surgical intervention is not without risk. 
Generally, surgery carries with it high risks of infection, anaesthesia complications and post-
surgical complications such as malnutrition/malabsorption (Gong et al., 2008). Surgery 
related death can occur in up to 0.3% of bariatric surgery operations (Flum et al., 2009). In 
addition, given the size of the obesity problem, it is not economically possible to use 
bariatric surgery to treat all cases (Avenell et al., 2004; Bessesen, 2008). 
There are a number of different surgical options depending on the level of obesity, co-
morbidities, patient preference and the weight loss required. These can generally be divided 
into two categories.  There are procedures which are purely restrictive, such as gastric 
banding and vertical sleeve gastrectomy (VSG) (Fig 1.4 (B)), and those that also bypass part 
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of the gut, including Roux–en-Y gastric bypass (RYGB) and biliopancreatic diversion (BPD) 
with or without duodenal switch (DS). 
The most commonly used bariatric surgery is RYGB (Fig 1.4 (C)).  This contains both 
restrictive and bypass elements.  The stomach is sectioned to produce a small proximal 
pouch which is attached to the distal limb of the jejunum.  This bypasses 95% of the 
stomach, the duodenum and some of the jejunum.  The remaining stomach and intestine is 
then anastomosed to the jejunum, so digestive juices can be channelled here. RYGB causes 
an average of 34% weight loss after one year (Hatoum and Kaplan, 2013). 
The reduction in appetite seen after bariatric surgery, although not completely understood, 
can perhaps be partially attributed to the increased circulating levels of PYY3-36 compared to 
pre-surgery levels (Nannipieri et al., 2013). Following RYGB there are  a number of changes 
that may contribute to weight loss:  
 Reduced food intake due to gastric pouch 
 Increased circulating levels of anorexigenic gut hormones GLP-1, insulin and PYY, and 
decreased levels of orexigenic ghrelin (Morinigo et al., 2004; Korner et al., 2005) 
 Changes in taste (Tichansky et al., 2006) and brain-hedonic responses to food after 
RYGB (Scholtz et al., 2014).  
 Increase in energy expenditure following RYGB surgery in rats (Bueter et al., 2010), 
and in humans (Faria et al., 2012, Faria et al., 2014, Wilms et al., 2013).  























Figure 1.4 Simplified diagrams of (A) a normal uninterrupted GI tract, (B) removal of the majority of 
the stomach in a VSG procedure without any bypass of the gut, and (C) RYGB that removes an even 
greater proportion of the stomach and bypass of the duodenum and part of the jejunum.  
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1.3.3 DRUG TREATMENT  
According to the FDA (FDA, 2007), an anti-obesity medication is considered effective for 
weight management if after 1 year of treatment either of the following occurs: 
1) there is a statistically significant reduction in body weight of ≥5% compared to 
placebo (or a significant weight loss of 5-10% according to the EMA (EMA, 2014)). 
2) if at least 35% of study participants lose ≥5% of their body weight from baseline  
The EMA also requires that, of the responders in the treatment arm of a study, response is 
>10% weight loss at the end of a 12-month period (EMA, 2014). 
The following sections describe the different classes of drugs which have been used or are 
currently in use for the treatment of obesity. 
 
1.3.4 CURRENT AND PREVIOUSLY LICENSED 
PHARMACOLOGICAL TREATMENTS FOR OBESITY 
At present, Orlistat (Xenical - POM & Alli - OTC, Roche pharmaceuticals, Switzerland) is the 
only approved anti-obesity drug in the UK. Orlistat is a pancreatic lipase inhibitor that 
prevents the hydrolysis, metabolism and absorption of dietary fat (triglycerides) (Davidson 
et al., 1999). Its efficacy is limited (Padwal and Majumdar, 2007, Avenell et al., 2004, 
Neovius and Narbro, 2008): over one year it causes 3kg more weight loss than placebo 
controls (Davidson et al., 1999, Sjostrom et al., 1998, Hill et al., 1999, Leung et al., 2003), 
and this weight is regained once treatment with Orlistat is stopped (Sjostrom et al., 1998, 
Svendsen et al., 2008, Rossner et al., 2000, Rucker et al., 2007). It is also associated with 
significant side effects including steatorrhoea, bloating, oily spotting, faecal urgency and 
increased defecation (Guerciolini, 1997, Leung et al., 2003). The EMA is currently reviewing 
reports of possible liver toxicity linked with orlistat (EMA, 2011). There is an associated 
decrease in absorption of fat-soluble vitamins, like vitamin E and β-carotene (Davidson et 
al., 1999), but levels rarely fall outside of the normal limits (Bray and Tartaglia, 2000).  
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Sibutramine (Reductil® (Abbott)) is a monoamine reuptake inhibitor. This causes  a 9.3% loss 
of body weight from baseline (Bray et al., 1999). However, the EMA recommended its 
suspension from sale in 2010 due to concerns over the increased incidence of cardiovascular 
events (Williams, 2010). Rimonabant (Acomplia® (Sanofi-Aventis)) is an antagonist for the 
cannabinoid receptor, CB1. A meta-analysis of rimonabant trials showed a 10% weight 
reduction after 1 year compared with the placebo group (Christensen et al., 2007). 
However, rimonabant had its licence withdrawn in 2009 due to psychiatric adverse reactions 
including depression, anxiety, irritability, aggression and suicide. 
Serotoninin (also called 5-hydroxytryptamine (5-HT)) is a neurotransmitter involved in 
mediating singals related to hunger.  Locaserin (Belviq®) is a specific 5-HT2C receptor agonist 
approved by the FDA for use in the treatment of obesity in July 2012 as a complement to 
lifestyle and behavioural modification (Nigro et al., 2013).  Trials showed it caused  3% body 
weight loss when compared with placebo (Smith et al., 2010). However it did not meet the 
first FDA benchmark (a statistically significant reduction in body weight of ≥5% compared to 
placebo), and the EMA rejected its use on safety grounds. Compounds that stimulate the 
release of serotonin  and/or inhibit its reuptake (such as fenfluramine (L-isomer) and 
dexfenfluramine (D-isomer)) have also been investigated as obesity therapies.  Fenfluramine 
was combined with phentermine (fen-phen) to maximise appetite suppression. Both fen 
and dexfen were removed from the US market in 1997 following reports of valvulopathy 
(Connolly et al., 1997) and pulmonary hypertension (Abenhaim et al., 1996). 
Sympathomimetics (which include phentermine, diethlypropion, benzphetamine, 
phendimetrazine), which increase the release of catecholamines and reduce their reuptake, 
have been licensed as therapy for obesity in the US for many years.  However, they can only 
be prescribed for short term use as they may cause addiction and be open to abuse.  
Phentermine does not appear to enhance release of dopamine (Rothman and Baumann, 
2009), therefore its addiction potential is believed to be less. Qsymia (Vivus) is a 
combination of phentermine and topiramate (phen-tpm) approved in July 2012 by the FDA. 
Topiramate is an anticonvulsant used in seizure disorders and prevention of migraines. Its 
exact mechanism of action is unknown but properties which may contribute to its 
antiepileptic and antimigraine effects include the modification of voltage-dependent sodium 
and calcium channels, enhancement of GABA receptors, antagonism of AMPA/KA receptors, 
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and inhibition of carbonic anhydrase. These properties may also influence its effects as a 
weight loss drug by impeding lipogenesis through the inhibition of carbonic anhydrase 
(Scozzafava et al., 2013), reduction in compulsive or addictive food craving through 
AMPA/KA receptor antagonism and decreased nightmares and sleep deprivation-induced 
feeding may be achieved through GABA receptor activation (Guardia et al., 2011). The 
phenteramine/toparimate combination is expected to produce about 9-10% body weight 
loss. The FDA expressed safety concerns in five areas of phen-tpm use: teratogenicity, 
cardiovascular, cognitive, psychiatric and metabolic acidosis, and the EMA rejected its use 
due to a lack of safety data (Woloshin and Schwartz, 2014).  
The limited options for the management of obesity and the rapidly increasing incidence of 
obesity means there remains a clear unmet clinical need for safe and effective treatments.  
Most of the proposed treatments are centrally acting drugs that interact with appetite 
regulation and hedonic CNS pathways, discussed in more detail below.  
 
1.3.5 DRUG IN DEVELOPMENT FOR OBESITY  
1.3.5.1 Small Molecules  
Contrave (Orexigen Therapeutics) contains sustained release formulations of naltrexone (an 
opioid receptor antagonist) and bupropion (a catecholamine reuptake inhibitor). It is 
currently used as an antidepressant and an aid in smoking cessation. It was noted to also 
reduce food intake (Morton et al., 2006). The effects of naltrexone-bupropion (NB) in 
reward pathways may partly explain the increased ability of participants to control eating 
and avoid responding to food cravings (Greenway et al., 2010). Treatment with NB may aid 
compliance to a mild hypocaloric diet as demonstrated in the latest phase 3 trial (Apovian et 
al., 2013). 
The anti-epileptic drug, zonisamide is being developed as a weight loss therapy  It inhibits 
carbonic anhydrase (Scozzafava et al., 2013) which is implicated in de novo lipogenesis. High 
dose of 400mg zonisamide produces a moderate weight loss of 3.3kg compared to placebo 
after one year. However, there is a high incidence of gastrointestinal, nervous system and 
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neuropsychiatric side effects (Gadde et al., 2012). Despite these serious side effects, current 
patents exist for its use in combination with a sympathomimetic, a 5-HT2C receptor agonist, 
or a CB1 receptor antagonist (Scozzafava et al., 2013). Clinical trials for Orexigen 
Therapeutic’s new drug, Empatic (sustained-release formulations of both bupropion and 
zonisamide) have shown promising phase 2b results with weight loss (9.9% Empatic 360mg 
and 7.7% empatic 120mg vs 1.7% placebo) and no serious side effects (Orexigen, 2009). 
Beloranib (made by Zafgen) is an analogue of the antimicrobial agent fumagillin and is a 
potent and selective inhibitor of MetAP2.  MetAP2 is an essential enzyme in cell growth and 
has been used as an anti-angiogenic, anti-cancer agent. It was shown to prevent diet-
induced obesity through adipocyte hypotrophy (Lijnen et al., 2010). Clinical trials have 
shown dose-dependent weight loss with beloranib treatment but only the highest dose 
produced sustained weight loss over 26 days (Hughes et al., 2013). The highest dose used in 
this study was over 20-times lower than that used in oncology trials, and was therefore not 
associated with anti-angiogenic effects.  
 
1.3.5.2 Biologics  
A class of drugs called biologics, which includes antibodies, proteins and peptides, offer a 
greater degree of specificity by nature of the molecules. As this class of drugs are based on 
naturally occurring peptides that target physiological pathways, they are less likely to have 
side effects. With their high specificity and low toxicity profile, biologicals offer viable 
alternatives to small molecule therapeutics.  
 
1.3.5.2.1 GLP-1 Agonists 
As previously mentioned, GLP-1 is an incretin that stimulates insulin release and improves 
glucose tolerance.  It also acts as a satiety signal and can cause weight loss. There are 
currently five GLP-1 receptor agonists licensed for the treatment of diabetes, based on the 
native GLP-1 peptide.  These include exenatide (Byetta®) and exenatide extended-release 
(Bydureon®); liraglutide (Victoza®),   Lixisenatide (Lyxumia®) and albiglutide (Tanzeum®). 
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Exenatide (Byetta - twice daily, or Bydureon - once weekly (Amylin Pharmaceuticals)) is a 
stable and potent GLP-1 agonist based on a naturally occurring GLP-1 analgoue, exendin. 
Although licensed for the treatment of T2DM, a mean weight loss of 1.4kg versus placebo 
was found with exenatide (Amori et al., 2007). Liraglutide (Novo Nordisk®) is a once-daily 
diabetes therapy. It is 97% homologous to native human GLP-1, changed by substituting 
arginine for lysine at position 34 and attaching palmitic acid (C-16 fatty acid) with a glutamic 
acid spacer on the remaining lysine residue at position 26 of the peptide precursor.  These 
changes improve its stability.  Liraglutide causes a dose dependent decrease in BW which is 
sustained for 2 years with continued use (Astrup et al., 2012). Recently, it has also been 
shown to help with weight maintenance after initial loss of BW using a low calorie diet  
(Wadden et al., 2013). Novo Nordisk filed for regulatory approval of high dose liraglutide 
(3mg) purely for obesity treatment in December 2013. 
Albiglutide and Lixisenatide both received their licenses as diabetes treatments in 2013.  
Lixisenatide (des-Pro38-ex4-Lys39-44) is a once daily agent based on ex-4 but it is superior 
to Byetta at reducing post-prandial plasma glucose levels with less adverse effects and 
equally good as competitors (e.g. Byetta, Bydureon, liraglutide) at regulating HbA1c, fasting 
plasma glucose and body weight (Fisch et al., 1996). Albiglutide is a once weekly GLP-1 
receptor agonist generated by the genetic fusion of a DPP-4-resistant GLP-1 dimer to human 
albumin (Baggio et al., 2004b). Weight loss seen with albiglutide was 0.2kg after 2 years use 
compared with placebo control (Ahren et al., 2014).   
There are many other GLP-1 agonists in development for the treatment of obesity but none 
have yet been approved by regulatory bodies. Indeed, Roche®’s DPPIV-resistant GLP-1 
analogue, taspoglutide, (substitution of Ala2 for the non-natural AIB) was withdrawn from 
late-stage development due to serious adverse events during trials (UKMi, 2010). 
 
1.3.5.2.2 MC4r Agonists 
A new potential peptide target for the treatment of obesity is agonism of the MC4r. In 
humans, MC4r mutations are associated with obesity and preclinical studies demonstrate 
reduction in both food intake and body weight with MC4r stimulation (Kievit et al., 2013). 
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RM-493 (Rhythm®) is a small peptide MC4r agonist in phase 2 clinical trials as a treatment 
for obesity and diabetes that reduces body fat and insulin resistance and improves 
cardiovascular function. Trials using RM-493 for the treatment of obesity in individuals with 
a genetic deficiency in the MC4r pathway has also been initialised to restore function in this 
pathway and improve weight regulation. 
 
1.3.5.2.3 Leptin 
The native hormone leptin is an effective treatment for the small number of subjects with 
obesity due to leptin deficiency (Farooqi et al., 2002). However, the trend for obese and 
overweight individuals to be leptin-resistance (English et al., 2002) has led to the 
unpopularity of leptin-based therapies. Nevertheless, the potential for leptin as an obesity 
treatment is still being explored in the face of understanding of the molecular mechanisms 
of leptin resistance (Jung and Kim, 2013). An example is Fc-leptin where leptin is attached 
on the end of an Fc fragment of an immunoglobulin gamma chain to extend the circulating 
half-life of the peptide (Lo et al., 2005). While this strategy improves the pharmacokinetics 
of leptin as a drug, it still relies on the ability of the peptide to produce an  anorexigenic 
effect in sensitive individuals. Another leptin-based therapy is its coadministration with 
amylin, a peptide co-secreted with insulin from pancreatic β-cells. Amylin appears to restore 
leptin responsiveness in obese rats and humans causing an additional 10% weight loss 
compared to each peptide given individually (Roth et al., 2008, Trevaskis et al., 2008). 
 
1.3.5.2.4 FGF-21 
FGF-21 is a metabolic regulator of glucose and lipid metabolism and is a protein that belongs 
to the “hormone-like” subgroup of fibroblast growth factors (FGFs) .  FGF-21 reduces body 
weight and blood glucose levels in several animal models, including diabetic rhesus monkeys 
(Nygaard et al., 2013). FGFs regulate a diverse range of metabolic pathways (Long and 
Kharitonenkov, 2011).  This presents a challenge in drug development as non-specific, global 
activation of FGF receptors is undesirable. The native FGF-21 protein also demonstrates a 
poor pharmacokinetic profile. However,  as the FGF-21 receptor requires a co-receptor 
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(βKlotho), selectivity can be acquired. A human monoclonal antibody (mimAb1) has been 
developed that only activates the FGFR1c/βKlotho complex (Foltz et al., 2012), and in obese 
monkeys, injection of mimAb1 led to FGF21-like metabolic effects, including decreases in 
body weight, plasma insulin, triglycerides, and glucose. 
 
1.4 DEVELOPMENT OF GUT HORMONES AS 
THERAPEUTIC AGENTS  
The results of GLP-1, PYY, and OXM administration in humans have made these peptides, 
and their receptors, potential targets for the development of therapeutic agents in the 
treatment of obesity (Small and Bloom, 2005, Boggiano et al., 2005, Ueno et al., 2008, 
Vincent and le Roux, 2008, Tan and Bloom, 2013a). However, there are limitations in using 
native hormones as obesity therapies; the problems, and means of overcoming them, will 
be discussed below. 
 
1.4.1 CONFERRING ENZYME RESISTANCE IN GUT 
PEPTIDES  
Gut hormones have short half-lives due to enzymatic degradation (Medeiros and Turner, 
1994). The circulating half-life of GLP-1 is approximately 4 minutes in man (Kreymann et al., 
1987), 12 minutes for OXM (Schjoldager et al., 1988), 7minutes for PP (Adrian et al., 1978), 
and PYY is approximately 8 minutes in rats (Lluis et al., 1989), just to name a few. This 
characteristic limits the use of native hormones as anti-obesity agents. Several strategies 
have been utilised to increase the half-life of peptides.  
Specific amino acid substitutions can alter a peptides susceptibility to proteolytic 
degradation. Exendin-4, a GLP-1r agonist, shares over 50% sequence homology with GLP-1. 
However there are changes, notably at the N terminus (His1-Gly2), that render Exendin-4 
resitant to degradation by DPPIV.  This means exendin-4 has a circulatory half-life of 
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approximately 8 hours (Nielsen et al., 2004) compared to the half-life of GLP-1 that is less 
than 10 minutes (Deacon et al., 1995). This has allowed exendin-4 to be developed and 
marketed as a therapeutic agent (Chen and Drucker, 1997).  
Addition of acyl side chains can increase the half-life of peptides in vivo by promoting 
binding to albumin which restricts access to the N-terminal by DPPIV, allowing the molecule 
to escape renal filtration (Knudsen et al., 2000), and slowing the release of the peptide from 
the extracellular SC compartment (Garber, 2005). However, potential disadvantages in the 
addition of larger side chains are solubility issues and the possible decrease in central 
penetration across the BBB. 
The GLP-1 analogue, liraglutide, differs from GLP-1 by a single amino acid exchange (Lys34 
→ Arg34) as well as the addition of an acyl side chain (Degn et al., 2004).  These 
modifications do not alter the potency of the ligand but increase its plasma half-life to 10-12 
hours in humans (Chang et al., 2003, Juhl et al., 2002, Knudsen et al., 2000).  
Other methods of developing resistance to degradation include conjugation to biotin 
(Chaturvedi et al., 1984), albumin (Burnham, 1994), or polyethylene glycol (PEGylation) 
(Veronese, 2001, Lee et al., 2005) Dependent on the site and degree of conjugation, this has 
the potential to enhance the pharmacological profile while retaining the biological profile.  
PEGylation of PYY3-36, for instance, reduced its affinity to the receptor and therefore its 
bioactivity. However, reversible PEGylation of PYY3-36 ensured release of active PYY3-36 
from the PEG group over an extended time period thereby prolonging its biological effect 
(Lee et al., 2005, Shechter et al., 2005).  Merck have also developed a PEGylated OXM which 
retains the anorectic and glucose-lowering effects of OXM (Bianchi et al., 2013). However 
PEG-OXM has no affinity to the GCGr and is therefore a pure GLP-1 agonist. A conjugated 
peptide most recently licensed for the treatment of T2DM is albiglutide (Tanzeum™) (GSK, 
2014). It is a DPPIV-resistant GLP-1 dimer fused to albumin (Baggio et al., 2004b) and 
therefore has an extended half-life (Matthews et al., 2008) which enables less-frequent 
(once-weekly) dosing (Ahren et al., 2014). 
There are also some GLP-1/GCG receptor co-agonists in development for treatment of 
obesity. Thiakis Ltd developed a degradation-resistant OXM analogue (TKS1225) (Cooke and 
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Bloom, 2006).  Trials by Wyeth Pharmaceuticals, who purchased TKS1225,  showed this 
compound caused significant weight loss and improved glycaemic control.  Oxyntomdulin 
analogues have also been developed by Zealand Pharma. 
 
1.4.2 CONTROLLED RELEASE AND CONJUGATION OF 
DRUGS  
An alternative to altering the half-life of a peptide is to modify its release following 
administration. A system which allows for a controlled release rate in order to attain and 
maintain the desired therapeutic level of the drug can bypass the need for a long circulatory 
half-life and also avoid peak and trough levels following drug administration. For PYY to be 
developed as a drug, for example, a slow release system is essential in order to avoid nausea 
due to the burst release of PYY3-36  to supra physiological level (le Roux et al., 2008b, Degen 
et al., 2005). The theoretical ideal profile of a slow-release analogue of PYY compared with 
the typical sharp increase of PYY3-36 after intravenous, intranasal or subcutaneous 











Figure 1.5 Challenges of formulation. Giving a supra-physiological dose of PYY3-36 in a bolus can cause 
nausea (red). A sustained-delivery formulation would avoid peak and trough levels (blue). 40pmol/l = 
post-prandial levels of PYY(3-36) and also levels found to reduce food intake by 30% by Batterham et 
al, 2002 (Batterham et al., 2002, Adrian et al., 1985). 70pmol/l = plasma levels of PYY(3-36) at which 
nausea was felt after infusion (Degen et al., 2005). 
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An example of the use of slow release formulations to improve drug pharmacokinetics is 
insulin, which in the presence of zinc ions assembles as stable hexamers (Brange and 
Langkjoer, 1993, Brange and Langkjaer, 1997) and forms microcrystalline precipitates which 
have a ‘sustained-release’. Other examples include Bydureon, a slow release preparation of 
exendin-4, where the peptide is encapsulated into bio degradable microspheres and then 
slowly released from these complexes, allowing a once a weekly injection (Neumiller, 2009) 
(Madsbad et al., 2011) (Buse et al., 2010).  
 
1.4.3 TACHYPHYLAXIS  
Gut hormones, as well as other endogenous peptides are considered less likely than small 
chemical entities to have non-specific side effects as they often have greater receptor 
selectivity (Muller, 2006). Tachyphylaxis (a decrease in the response to a drug due to 
previous exposure to that drug), which is a potential risk for any drug development 
programme, is also considered to be a much lower risk for gut hormones as they are 
repeatedly released daily throughout life (Savini, 1964). However, this remains a 
controversial matter as some evidence demonstrates that repeated dosing of PYY, for 
example, may cause tachyphylaxis (Chelikani et al., 2007) whilst other research did not 




1.5 AIMS AND HYPOTHESES  
The overall aim of this thesis is to assess key points in the development of a peptide-based 
anti-obesity agent on its route to clinical trials. 
This thesis hypothesises that a synthetic peptide analogue based on the structure of gut 
hormones may prove to be a valuable therapeutic tool for the treatment of obesity.  
To address this hypothesis, the susceptibility of an endogenous gut hormone to degradative 
enzymes and tissue preparations were determined and vulnerable positions in the molecule 
identified. Rational modifications to the amino acid sequence of the gut hormones were 
designed and then assessed to establish the receptor binding and potencies of the resulting 
analogues. This includes in vivo effects on longevity and efficacy at reducing food intake in 
rodents following acute peripheral administration and effects of chronic administration of 
analogues on food intake and body weight in rodent models of obesity. 
This thesis also hypothesised that the immunogenicity of a novel drug can be identified and 
techniques employed to reduce this unwanted side effect without great negative 
consequences on its potency and pharmacokinetics. To test this hypothesis, the studies 
described in this chapter aimed to identify the immunogenic region of the peptide analogue 






MATERIALS AND METHODS  
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2.1 PEPTIDES  
Human PYY and human PP were purchased from Bachem Ltd. (Merseyside, UK). Synthetic 
human sequence PYY and PP were used in all experiments where stated. Peptide analogues 
were custom synthesised by Bachem Ltd. or BIOMOL International LP.  
2.1.2 CUSTOM SYNTHESIS OF PEPTIDES  
All peptides were synthesised by and purchased from Bachem Ltd or BIOMOL International 
LP. Peptide synthesis was completed using an automated Fluorenyl-Methoxy-Carbonyl 
(Fmoc) solid phase peptide synthesis strategy (SPSS) with each amino acid sequentially 
added from the C to the N terminus. The Fmoc-SPSS method uses repeated cycles of 
coupling and deprotection to create peptides of up to 100 amino acids.  
Briefly, the starting block is a single amino acid joined by covalent bonds to a resin 
(TentaGel® resin). The N-terminal amine of the amino acid attached to the resin is then 
deprotected (removal of the Fmoc group) by the addition of piperidine in 
dimethylformamide (DMF). After deprotection, the resin is washed to remove the Fmoc 
groups, thus allowing the next amino acid to be coupled when added in excess. Subsequent 
amino acids are added in the same deprotection-coupling fashion. While each amino acid 
has the Fmoc to protect the reactive amine group, other side groups are protected as 
follows: t-butyl ethers are used for the protection of hydroxyl side chains of tyrosine, serine, 
and threonine; t-butyl esters protect the side chains of aspartic acid and glutamic acid 
residues; histidine and lysine side chains were protected as their N-tert-butyoxycarbonyl (t-
Boc) derivatives, cysteine as its S-trityl derivative, and the guanidine moiety of arginine 
protected as its Pbf derivative. 
Once the addition of amino acids is completed, the peptide is cleaved from the resin and the 
side chain protecting groups are removed by treatment with aqueous trifluoroacetic acid 
(TFA) (95%) containing triisobutylsilane (TIS) (5%) as a scavenger. TFA and scavengers were 
removed by evaporation and trituration. Peptides were purified by reverse phase 
preparative high performance liquid chromatography (HPLC) followed by lyophilisation.  
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Where used, the polyethylene glycol (PEG) group was N-terminally coupled to the peptide 
via a linker methyl group. The type of PEG used was PEG12 (i.e. the PEG moiety had a carbon 
chain of n=12 in the central core group – molecular weight 570Da) and reverse phase HPLC 
was used to purify the PEGylated peptide from the non-PEGylated peptide after the 
reaction. 
The purified products were subsequently analysed by reverse phase HPLC and by matrix-
assisted laser desorption ionisation mass spectroscopy (MALDI-MS) to confirm the correct 
molecular weight and to assess purity. All peptides supplied had a purity of >95%. The 
amino acid sequences of the peptides discussed in this document are shown in Appendix B. 
 
 
2.2 ANIMAL STUDIES  
All animal procedures performed were approved by the British Home Office under the 
Animals (Scientific Procedures) Act 1986 (Project licence number 70/6402 and 70/7236). 
 
2.2.1 ANIMALS  
2.2.1.1 C57BL/6 mice  
Adult male C57BL/6 mice (Harlan, UK) weighing 20-45 g were maintained in individual cages 
under controlled temperatures of 21-23°C and controlled light cycles, each lasting 12 hours, 
with lights on at 0700. Animals had ad-libitum access to water at all times, and ad libitum 
access to standard chow diet (pelleted rodent chow, RM1 diet SDS, UK Ltd., Witham UK) 
outside of study periods. Prior to commencement of studies, animals were regularly 
handled and received at least two subcutaneous (SC) or intraperitoneal (IP) saline injections 




2.2.1.2 Diet-induced obese (DIO) C57BL/6 mice 
Adult male C57BL/6 mice (Harlan, UK) aged 8 weeks old were group housed under 
controlled temperatures of 21-23°C and controlled light cycles, each lasting 12 hours, with 
lights on at 0700. For approximately 8 weeks prior to the start of the study, animals had ad-
libitum access to water at all times, ad libitum access to high fat diet (energy content: 60% 
from fat, 20% from protein, 20% from carbohydrate – Research Diets Inc., NJ, USA) and 
remained on this diet until the end of the study. Prior to commencement of studies, animals 
were singly housed for two weeks and the individual cages maintained under the same 
conditions. Animals were regularly handled and acclimatised to receive SC or IP saline 
injections to minimise any non-specific stress effects at the time of the study. At the start of 
the study, the mice had a mean body weight of 38g (36-40g), which is approximately 35% 
more than the average weight of a mouse at 15 weeks old fed a standard chow diet 
(www.harlan.com). 
 
2.2.1.3 Wistar rats  
Adult male Wistar rats (Charles River Ltd., Margate, Kent, UK) weighing 300-500 g were 
maintained in individual cages under controlled temperatures of 21-23°C and controlled 
light cycles, each lasting 12 hours, with lights on at 0700. Animals had ad-libitum access to 
water at all times, and ad libitum access to standard chow diet (pelleted rodent chow, RM1 
diet SDS, UK Ltd., Witham UK) outside of study periods. Prior to commencement of studies, 
animals were regularly handled and received at least two subcutaneous (SC) or 
intraperitoneal (IP) saline injections to acclimatise them to the study procedures and to 





2.3 ACUTE FEEDING STUDIES  
Anorectic compounds were tested under a fasted paradigm. This model was used to 
eliminate the natural nocturnal feeding habits of mice and to allow them to consume their 
food during daylight hours in which the experimental procedure is conducted. 
 Individually-housed male C57BL/6 mice (Charles River Ltd., Kent UK) weighing between 24-
45g were used for acute feeding studies. Mice were fasted from 16:00 on the day 
immediately before an acute feeding study. Animals were then randomised into groups of 
approximately equal mean body weight. Mice received a single SC injection (in the flank 
region of the animal) of vehicle (0.9% w/v NaCl) or peptide using a 0.5ml insulin syringe with 
a 29 gauge needle during the early light phase (0800-0900) after which the animals were 
returned to their home cages with free access to a known amount of food. Remaining food 
was reweighed at 1, 2, 4, 8, and 24hours post-injection by using a balance accurate to 0.01g 
and a visual inspection of the cage made for any small pieces of food. All studies were 
conducted under condition in which all external disturbances were minimised. A maximum 
injection volume of 50l was used and injection volume adjusted by body weight. 
 
2.4 CHRONIC FEEDING STUDIES  
2.4.1 CHRONIC ADMINISTRATION TO DIO MICE 
DIO mice were randomised into groups of approximately equal mean body weight. A single 
daily SC injection of either vehicle or peptide in a maximum volume of 50µl, adjusted by 
body weight was administered at 15:00-16:00 daily. DIO mice had ad libitum access to high 
fat diet for the duration of the study (28-29 days). Group sizes ranged from 7-14 
mice/treatment depending on study. Body and food weights of each mouse were measured 




2.4.2 CHRONIC ADMINISTRATION TO RATS 
Male Wistar rats weighing 300-350g were randomised into groups with approximately equal 
mean body weight. Rats had ad libitum access to pelleted rodent chow (RM1 diet). They 
were administered with a single daily SC injection in the flank region of the animal (15:00-
16:00), for up to 28 days of either vehicle or peptide. Group sizes ranged from 6-14 
rats/treatment depending on study. The body and food weights of each rat were measured 
immediately prior to injection. 
 
2.5 RAT PHARMACOKINETICS  
To determine the clearance of peptides in plasma following SC administration, group 
housed male Wistar rats (Charles River Ltd) were used, with no more than 5 rats per cage, 
and each animal weighing 200-300g. Rats had free access to water and standard chow diet 
(pelleted rodent chow, RM1 diet SDS) at all times. On the study day, each rat received a 
single SC injection of known amount of peptide (1-4mg) dissolved in 20µl of either 0.9% w/v 
NaCl or ZnCl2 solution in sterile water for injections, which contained 1mol of ZnCl2 for every 
1mol of peptide (1:1 molar ratio). Different formulations were used, depending on the aim 
of the study. A group size of 3 or more animals was used for each study group. Peptide was 
injected at time=0 and a 200µl blood sample from each rat was taken through superficial 
venesection of the lateral tail vein at time points such as 0.5, 3, 24, 48, 96hours,  7 and 10 
days following peptide administration. Blood was collected into heparinsed microtubes 
(10% v/v heparin in 0.9% w/v saline) to prevent clotting. Each tube also contained 4µl of a 
stock solution (10x stock solution: 1 tablet of S8820 SIGMAFAST™ Protease Inhibitor Tablets 
in 10ml distilled water (dH2O)) to prevent post-sampling degradation of the injected 
peptide. Blood samples were stored on ice immediately after collection for a maximum of 
15minutes before they were centrifuged at 6000g for 10minutes at 4°C (Sigma Laboratory 
centrifuges 3 K18, Rotor No. 19777-H). After centrifugation, the upper plasma layer was 
separated and kept at -20°C until analysed for plasma peptide concentrations as determined 




2.6 PRODUCTION OF HUMAN Y2 AND HUMAN Y4 
RECEPTOR OVEREXPRESSING CELL LINES  
2.6.1 PRODUCTION OF COMPETENT BACTERIA  
E. coli bacteria were made competent to allow entry of DNA (plasmids) through treatment 
with cations (Mandel and Higa, 1992, Hanahan, 1996, Wood, 1983). 
Materials  
LB (Appendix C)  
Tetracycline (Sigma, Poole, Dorset, UK) 10 mg/ml in absolute ethanol  
TFB I (Appendix C)  
TFB II (Appendix C)  
XL1-Blue Escherichia coli (Stratergene Ltd)  
 
Method  
100ml LB supplemented with 5μg/ml tetracycline (LBtet) was inoculated with a colony of 
XL1-Blue and incubated overnight, with vigorous shaking, at 37°C. One millilitre of this 
culture was inoculated into 100 ml of fresh LBtet (pre-warmed to 37°C) and incubated at 
37°C, with vigorous shaking, until the bacteria were in log phase growth (OD550 = 0.4-0.5) as 
actively growing cells in early log phase are more susceptible to transformation. The 
bacteria were recovered by centrifugation at 800g for 15 minutes. The bacteria were 
resuspended in 40 ml ice cold TFB I and incubated on ice for 10 minutes. The bacteria were 
recovered as before and resuspended in 4 ml TFB II and incubated on ice for 15 minutes. 




2.6.2 TRANSFORMATION OF COMPETENT BACTERIA  
Transformation of competent bacteria increases efficiency of DNA entry into the bacteria. 
Incubation on ice of the plasmid with the competent bacteria is believed to allow 
attachment of the plasmid to the bacterial cell wall. Subsequent heat shock allows efficient 
transport of the plasmid into the interior of the bacteria. Finally, incubation allows 
expression of the resistance genes before exposure to the antibiotic. 
Materials  
LB  
LB(amp) agar plates  
Competent bacteria (section 2.6.1)  
human Y2 receptor (cDNA.org, Missouri S&T cDNA Resource Center, University of Missouri-
Rolla) (Appendix D) 
human Y4 receptor (cDNA.org, Missouri S&T cDNA Resource Center, University of Missouri-
Rolla) (Appendix D) 
 
Method  
An aliquot of competent bacteria was thawed on ice and 10ng of plasmid (5μl) added and 
the mixture incubated on ice for 20 minutes. The reaction was then incubated at 42°C for 
two minutes followed by incubation on ice for two minutes. 200μl of LB was added and the 
reaction incubated at 37°C for 30 minutes. Simultaneously, agar plates (supplemented with 
ampicillin) were dried and the transformed bacteria added to the plate. The bacteria were 
streaked over the surface of the agar, the plates inverted and incubated at 37°C overnight.  
 
2.6.3 SMALL SCALE PREPARATION OF PLASMID  
Individual colonies of bacteria were isolated and prepared on a small scale to allow several 
clones to be analysed simultaneously. To obtain cDNA from the bacteria, the cell wall was 
disrupted and contaminating proteins, genomic DNA and RNA removed (as most genomic 
DNA in bacteria is anchored to the cell wall). This is done through treatment with alkaline 
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SDS followed by precipitation of bacterial debris with potassium acetate. The RNA is 




GTE (Appendix C)  
Alkaline SDS (Appendix C)  
5M potassium acetate pH 4.6 
Phenol/chloroform (VWR)  
Propan-2-ol  
0.3M sodium chloride  
Absolute ethanol  
 
Method  
2ml of LB supplemented with 0.05 mg/ml ampicillin (LBAmp) were inoculated with a single 
bacteria colony and incubated overnight at 37°C with vigorous shaking. 1.5ml of the culture 
was centrifuged for 2 minutes at 12300g to pellet the bacteria. The supernatant was 
discarded and the pellet resuspended in 100μl GTE. 200μl of alkaline SDS was added and the 
sample incubated on ice for 5 minutes before the addition of 150μl 5M potassium acetate 
and further 5 minute incubation on ice. The precipitated bacterial debris was removed by 
centrifugation for 5 minutes at 12300g at room temperature and 350μl of supernatant was 
transferred to a clean tube. An equal volume of phenol/chloroform was added and the 
sample mixed. The phases were separated by centrifugation for 3 minutes at 12300g and 
the aqueous phase (top layer) transferred to a fresh tube. The DNA was precipitated by the 
addition of 0.6 volumes of propan-2-ol and incubated at room temperature for 10 minutes. 
The DNA was pelleted by centrifugation for 7 minutes at 12300g at room temperature and 
the pellet resuspended in 100μl 0.3M sodium chloride and 250μl of ice cold absolute 
ethanol and the solution incubated at -20°C for at least one hour. The DNA was recovered 
by centrifugation for 7 minutes at 12300g at room temperature and the pellet dissolved in 
10μl GDW.  
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2.6.4 RESTRICTION ENDONUCLEASE DIGESTION OF 
PLASMID DNA  
In order to select which clones contained the correct plasmid, DNA was digested with 
restriction endonuclease enzymes and analysed by gel electrophoresis. Clones containing 
the correct size inserts were chosen for large scale preparation.  
 
Materials  
Plasmid DNA  
Restriction endonucleases: EcoR I and Xho I (New England Biolabs, Hitchin, Hertfordshire, 
UK)  
10x restriction buffer (as supplied)  
10x BSA  
 
Method  
In separate reaction tubes, the products of small scale preparation of plasmid were diluted 
in GDW, BSA and restriction buffer added to give a final concentration of 1x BSA and 1x 
restriction buffer. Restriction endonucleases were added to five times excess however the 
volume of enzyme added was kept below 10% of the final volume. The reaction was 
incubated for a minimum of one hour at 37°C.  
 
2.6.5 ELECTROPHORESIS OF DNA FRAGMENTS  
After restriction digestion, the DNA was size fractionated by electrophoresis on an agarose 
gel to confirm if the correct size insert was present.  
 
Materials  
Agarose, type II-A medium EEO  
50x TAE (Appendix C)  
Ethidium bromide (10mg/ml)  
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DNA marker (1KB ladder, Invitrogen)  
Gel loading buffer  
 
Method  
A 0.7% (w/v) agarose gel was prepared by dissolving the agarose in 1x TAE using a 
microwave oven. The gel was cooled to 45°C and ethidium bromide added to achieve a final 
concentration of 0.5μg/ml and allowed to set in a mould. 3μl of loading buffer (appendix C) 
was added to 10μl of restriction enzyme digest, 1μl of DNA marker was added to 9μl GDW 
and treated the same way. The samples were loaded onto the gel and electrophoresed at 
1.5V/cm. The DNA was visualised by illumination with UV light (300nm).  
 
2.6.6 LARGE SCALE PLASMID PURIFICATION  
Following small scale preparation of the plasmid, the size of the insert was confirmed by 
restriction digest (2.6.4). A large scale preparation of the plasmid is then carried out prior to 
purification using a caesium chloride gradient. This step is a larger scale procedure of the 
previously described method (section 2.6.3.) but it is followed by a caesium chloride 




GTE: lysis solution for large scale preparation (Appendix C) 
Lysozyme (Sigma)  
Alkaline SDS  
5M potassium acetate pH 4.6  
Propan-2-ol 
1x TE (Appendix C) 
DNase free RNaseA (Sigma)  
Phenol/Chloroform  




A small quantity of bacteria containing the plasmid with the correct insert size was 
inoculated into 500 ml LBAmp and incubated at 37°C overnight with vigorous shaking. The 
bacteria were recovered by centrifugation for 8 minutes at 3000g (HS-4 rota in RC-5B super 
speed centrifuge, Du Pont) at 4°C. The pellet was resuspended in 25 ml GTE supplemented 
with 2mg/ml of lysozyme and the samples incubated at room temperature for 5 minutes. 
Alkaline SDS (50ml) was added, the sample mixed until clear and incubated on ice for 5 
minutes. Then 38ml of 5M potassium acetate was added, mixed and incubated on ice for 10 
minutes. Bacterial debris was removed by centrifugation for 15 minutes 9000g (HS-4 rota in 
RC-5B super speed centrifuge) at 4°C. The supernatant was filtered through nylon gauze to 
remove cell debris and transferred to a clean tube. 0.6 volumes of propan-2-ol was then 
added and samples incubated on ice for 15 minutes. As before the DNA was recovered by 
centrifugation for 15 minutes (9000g, 4°C). The pellet was dissolved in 10ml 1x TE and RNase 
A added to a concentration of 0.1mg/ml and the reaction incubated at 37°C for 30 minutes. 
Addition of an equal volume of phenol/chloroform terminated the reaction, the mixture 
mixed and the phases separated by centrifugation for 20 minutes at 10000g and 4°C. The 
aqueous phase (top layer) was removed and 0.1 volume of 2M sodium acetate, pH 5.2 and 
one volume propan-2-ol was added. The reaction was then incubated at -20°C for at least 
one hour.   
 
2.6.7 CAESIUM CHLORIDE GRADIENT PURIFICATION  
This procedure was used to purify large quantities of plasmid. Under high centrifugal force, 
a solution of caesium chloride (CsCl) molecules will dissociate, and the heavy Cs+ atoms are 
forced towards the bottom (outer) end of the tube, thus forming a shallow density gradient. 
DNA molecules in this gradient will migrate to a point where they have equal density (the 
neutral buoyancy or isopycnic point). When nucleic acids bind ethidium bromide (EtBr), it 
affects their density as EtBr binds by intercalation into the DNA thereby causing the DNA 
helix to partially unwind. Binding occurs to a higher degree in linear genomic DNA or nicked 
plasmid DNA than with closed circular supercoiled plasmid DNA. Therefore, different states 
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of DNA form separate bands in the CsCl gradient. EtBr however damages DNA and is 
therefore immediately and thoroughly removed once purification is complete. 
 
Materials  
TES (Appendix C) 
Caesium chloride  
Ethidium bromide (10mg/ml)  
Caesium chloride saturated propan-2-ol (Appendix C)  
1x TE (Appendix C)  
Paraffin 
2M sodium acetate, pH 5.2 
Absolute ethanol  
 
Method  
The DNA obtained from section 2.7.6. was recovered by centrifugation at 4°C for 20 minutes 
at 24000g (HB4 rotor in RC5B super speed centrifuge, Du Pont) and dissolved in 8.25ml TES. 
To the solution of DNA, 8.4g of CsCl and 150μl EtBr was added and the solution mixed. The 
sample was loaded into a polyallomer centrifuge tube (Ultracrimp, Du Pont), overlaid with 
paraffin, crimp sealed and centrifuged for 16 hours at 20°C and 185500g (A1256 rotor, OTD-
55B centrifuge, Du Pont). After centrifugation, the DNA bands were visualised by UV light 
and the band containing the closed circular DNA removed using a 20G needle and a 2ml 
syringe. The EtBr was removed from the plasmid by repeated extraction with an equal 
volume of caesium chloride saturated propan-2-ol, until both phases were colourless. The 
DNA was precipitated by addition of two volumes of GDW and six volumes of room 
temperature absolute ethanol. The DNA was recovered by centrifugation for 15 minutes at 
room temperature and 24000g, the supernatant containing CsCl was removed and the pellet 
dissolved in 0.4ml GDW. The DNA was ethanol precipitated by adding 0.1 volume of 2M 
sodium acetate, 2.5 volumes of absolute ethanol and the mixture incubated at -20°C for at 
least one hour. The DNA was recovered by centrifugation for 10 minutes at 12300g, 




2.6.8 QUANTIFICATION OF DNA BY 
SPECTROPHOTOMETER  
The DNA was diluted 1:1000 in GDW and 1ml placed into a quartz cuvette. The absorbance 
was measured at 260 and 280nm (UV-160 spectrophotometer, Shimadzu, Kyoto, Japan) 
where the ratio A260:A280 was checked to be 2:1 (DNA:RNA). The concentration of DNA was 
calculated using the following formula: concentration (μg/ml) = (A260 x dilution factor) x 50.  
 
2.6.9 POLYETHYLENIMINE (PEI) MEDIATED IN VITRO 
GENE TRANSFER  
Stable, over-expressing cell lines for hY2 and hY4 were created by transfection of plasmids 
containing cDNA for hY2 and hY4 receptors into HEK 293 cells using the PEI transfection 
method. Cationic polymers like PEI can tightly associate with negatively charged nucleic 
acids. The DNA:PEI complex is positively charged and can come into close association with 
the negatively charged cellular plasma membrane. The DNA:PEI complex is then taken up 
into cells by pinocytosis across the cell membrane in the presence of glucose. This mixture 
produces small stable particles which is an advantage in their uptake into cells.  
 
2.6.10 MAINTENANCE OF CELLS  
Materials  
HEK-293 cells (ATCC® CRL-1573™) (ATCC, LGC Standards, Middlesex, UK)  
Dulbecco’s modified medium (DMEM) without sodium pyruvate containing 4.5g/l glucose 
(Invitrogen)  
Foetal bovine serum (FBS) (Invitrogen)  
100x antibiotic (10,000 units/ml of penicillin and 10,000 µg/ml of streptomycin) (Invitrogen) 





HEK 293 cells were cultured in DMEM media supplemented with 10% FBS and final 
concentration of 100units/ml penicillin and 100 µg/ml streptomycin (standard media). Cell 
media was changed every 2-3 days and the cells sub-cultured when 70% confluent using a 
non-enzymatic cell dissociation buffer. Briefly, the medium was aspirated from the flask and 
3ml cell dissociation buffer at room temperature added to a 175cm2 flask of cells and 
incubated at room temperature until they detached from the flask. Fresh medium was 
added to the flask to quench the dissociation reaction and cells recovered by centrifugation 
for five minutes at 100g and the supernatant discarded. The pelleted cells were 
resuspended in fresh media and transferred to a new flask at a dilution of 1:5.  
 
2.6.11 TRANSFECTION OF CELLS  
Materials  
0.1M 25kDa PEI (Aldrich Chemical Company) pH 7 (Appendix C)  
GDW  
10% w/v glucose (sterile filtered) 
Plasmid DNA (pcDNA3.1+ human NPY2R or pcDNA3.1+ human NPY4R)  
G418 antibiotic (50mg/ml Sigma)  
 
Method  
Prior to transfection, HEK-293 cells were plated at a density of 20000 cells/well of a 6-well 
plate (Nunc) in standard DMEM media (as described in 2.6.10). Transfections were carried 
out when the cells were 40% confluent. The plasmid DNA was transfected at a 
concentration of 6μg DNA/well in 5% glucose. PEI:DNA complexes were made with PEI 
(average MW ~ 25kDa) according to the method described by (Abdallah et al., 1995, 
Abdallah et al., 1998). PEI is a cationic polymer in which every third atom is an amine 
nitrogen residue. PEI was added to the DNA at different ratios of PEI nitrogen to DNA 
phosphate (N:P ratio). The cells were transfected with N:P ratios of 6, 9 and 12 nitrogen 
equivalents of PEI. A volume of 1μl of 0.1M PEI (prepared as described in Appendix C) 
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contains 100nmol amine nitrogen while 10μg DNA contains 30nmol of DNA phosphate. Thus 
6μg DNA (18nmol DNA phosphate) needs 108nmol amine nitrogen for a N:P ratio of 6 (or 
1.08μl of 0.1M PEI). To prepare the transfection mix, PEI solution was added slowly to the 
DNA in glucose solution, vortexed for 30 seconds and allowed to stand at room temperature 
for 10 minutes before use. Prior to transfection, the media on the cells was replaced and the 
DNA/glucose/PEI mix was slowly added to each well and gently swirled. Cells were 
incubated at 37°C, 5% CO2 for 3 hours, after which the media was removed and replaced 
with fresh media and the cells allowed to grow for 2 days. At least 6 wells were transfected 
with the plasmid DNA for each receptor and 2 control wells with just PEI in glucose. Forty 
eight hours later, media was supplemented with 0.8mg/ml G418 (geneticin), and media 
replaced every 48 hours with fresh G418 antibiotic until all control cells were dead (typically 
10 days after the start of treatment). G418-resistant cells were transferred from the wells to 
25cm2 flasks (1 well to 1 flask), and then maintained as described in 2.7.10. The population 
of mixed clones in each flask was tested for receptor expression by measuring change in 
specific binding of radiolabelled PYY3-36 (for hY2r cell lines) or PP (for hY4r cell lines). Mixed 
clones with the highest specific binding of radiolabelled ligand were selected for use in 
receptor binding studies.  
 
 
2.7 RECEPTOR BINDING ASSAYS  
Cell membrane suspensions were prepared from both hY2r and hY4r over-expressing HEK-
293 cell lines. The subsequent binding studies tested the specific binding of peptides to the 




2.7.1 PREPARATION OF MEMBRANES FROM CELLS  
2.7.1.1 Maintenance of cells  
HEK-293 cells (ATCC® CRL-1573™) (ATCC, LGC Standards, Middlesex, UK) transfected with 
either hY2r or hY4r plasmid/cDNA were maintained in standard DMEM media and were 
passaged as described in section 2.6.10.  
 
 
2.7.1.2 Receptor purification  
Materials  
1x 0.01M phosphate buffered saline (PBS) (10x in Appendix C) 
1mM HEPES buffer (Appendix C)  
Homogenisation buffer (Appendix C) 
 
Method  
From a minimum of 30 x 175cm2 flasks, culture medium was removed and the cells 
detached by scraping into ice cold 0.01M PBS). Cells were centrifuged at 100g for 5 minutes 
(Sigma Laboratory Centrifuges 3, K18, rotor No. 19777-H), the supernatants discarded and 
the cell pellets put onto ice. Pellets were resuspended in 2 ml of ice-cold PBS and cells 
osmotically lysed by dropwise addition to 1mM HEPES solution containing protease 
inhibitors and left to stir for 5minutes. The solution was centrifuged at 3000rpm (Beckman 
J2-21, rotor JS-13.1) for 20 minutes at 4°C and the supernatant discarded. 20ml of 
homogenisation buffer was added and the cells homogenised for 20s with an Ultra Turrax 
homogeniser (IKA Labortechnik) and then put onto ice for 1minute. Mechanical 
homogenisation was repeated a second time before the homogenates were further 
centrifuged at 2500rpm (Beckman J2-21, rotor JS-13.1) for 20 minutes at 4°C. Membrane 
homogenates present in the resultant supernatant were collected and pelleted through 
centrifugation at 100,000g (Sorvall OTD 55B ultra-centrifuge, DuPont) for 60 minutes at 4°C. 
Finally, pellets were resuspended to a final protein concentration of 1-2mg/ml and stored at 
-80°C. Protein concentration was measured by Bradford assay (section 2.7.1.3.). 
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 2.7.1.3 Bradford Assay  
0.1ml cell membrane solution (purified from cells over-expressing hY2r or hY4r) was added 
to 3ml of Bradford reagent (Sigma). A standard curve with known concentrations of bovine 
serum albumin (BSA) (Sigma) (0.1ml 0, 0.25, 0.5, 1.0, 1.5 mg/ml solution) was added to 3ml 
of Bradford reagent. All solutions were incubated at room temperature for 45 minutes. A 
sample of each solution was added to a cuvette and absorbance was measured at 595nm 
using a spectrophotometer (UV-160, Shimadzu, Kyoto, Japan). The standard curve was used 
to determine the unknown concentration of protein in the membrane samples.  
 
2.7.2 IODINATION OF PEPTIDES  
Iodination of a peptide enables it to be used as a tracer in displacement assays. It involves 
the introduction of the radioactive isotope of iodine (125I) into certain amino acids (usually 
tyrosine) in a peptide. Iodination takes place at the positions adjacent to hydroxyl groups on 
the tyrosine molecule which indicates that mono- or di-substitutions can occur.  
Radioactive 125I can be incorporated into peptides either by enzymatic or chemical 
oxidation. In the chemical oxidation (or direct iodogen) method, sodium iodide (Na125I) is 
converted to its corresponding reactive iodine form, which then spontaneously incorporates 
into tyrosine hydroxyl groups. While necessary for iodine activation, oxidising reagents (such 
as chloramine T) are potentially damaging to proteins.  
3nmols (15μg) of peptide in 10μl of 0.2M phosphate buffer pH 7.2 was reacted with 37MBq 
of Na125I (GE healthcare) and 23nM (10μg) of the milder oxidising reagent 1,3,4,6,-
tetrachloro-3α, 6α-diphenylglycoluril (Iodogen, Pierce Chemical Co, Perbio Science UK Ltd., 
Cramlington, UK) for 4 minutes at 22°C. The 125I-peptide was purified by reverse-phase HPLC 




2.7.3 Y1, Y2 AND Y4 RECEPTOR BINDING STUDIES  
Cell membranes from hY2, mY2, or hY4 receptor overexpressing HEK-293 cell lines, or the 
SK-N-MC cell line (source of hY1 receptor), were used for these studies. The assays were 
performed in 1.5ml siliconised microtubes (Sigma), with a final volume of 500μl. 125I-PYY in 
50µl assay buffer (appendix C) with an activity of 1kBq was incubated with 10μl of the 
membrane suspension (at protein concentration 1-2μg/ml as determined by Bradford assay 
in section 2.7.1.3). Microtubes contained increasing concentrations of non-radiolabelled 
competing peptide. Each peptide concentration was assayed in duplicate or triplicate. Once 
the competing non-radiolabelled and tracer radiolabelled ligands were added, microtubes 
were each vortexed and incubated at room temperature for 90 minutes. After incubation, 
microtubes were centrifuged at 15781g (Sigma Laboratory Centrifuge 3 K18) for 3 minutes 
at 4°C, the supernatant removed and discarded, and the pelleted receptors washed with 
500μl of fresh assay buffer to wash the pellet of any unbound radio-ligand. The tubes were 
centrifuged as before and the supernatant was again discarded and the pellets measured for 
γ-radiation for 240 seconds (Gamma counter, NE 1600, NE Technology Ltd, Reading, UK).  
The half-maximal inhibition concentrations (IC50) were calculated and compared for each 
peptide tested. IC50 values were calculated using the Prism 5.01 program (GraphPad 
Software Inc. San Diego, USA) using a three-parameter logistic equation for the non-linear 
regression fit: Y=Bottom + (Top-Bottom)/1+10^(LogEC50-X). 
 
2.8 PROTEOLYTIC DEGRADATION OF PEPTIDES 
The general model of enzymatic cleavage (Fig 2.1) states that amino acid residues in a 
substrate undergoing cleavage are designated P1, P2, P3, P4 etc. in the N-terminal direction 
from the cleaved bond. The residues in C-terminal direction from the cleaved bond are 








Figure 2.1 Schematic diagram depicting the nomenclature for enzyme cleavage sites within a 
substrate. Positions Pn to Pm’ are counted from the bond where enzymatic cleavage occurs between 
P1 and P1’ (Schechter and Berger, 2012). 
 
2.8.1 LIVER MICROSOMES PREPARATION  
The preparation of rat liver microsomes (RLM) by homogenisation and differential 
centrifugation was based on the method of Leadbeater and Davies (Leadbeater and Davies, 
1964). RLM were prepared from 250-300g male Wistar rats. The rats were humanely killed 
by CO2 asphyxiation, the liver removed and snap-frozen in liquid nitrogen and stored at -
80°C. After collecting livers from 20 rats, they were thawed and rinsed in 0.10 M Tris-HCl 
buffer, pH 7.5, then homogenized using an Ultra Turrax homogeniser (IKA Labortechnik). 
The homogenates were centrifuged at 10,000 g (Beckman J2-21, rotor JS-13.1) for 20 min to 
spin down the nuclei, mitochondria and unbroken cells. The microsomal and soluble 
fractions of the liver were in the supernatant. The preparation was further purified by 
centrifuging the supernatant at 10,000 g (Beckman J2-21, rotor JS-13.1) for 20 min. The 
resultant supernatant (S-10 fraction) was then centrifuged at 100,000g (Sorvall OTD 55B 
ultra-centrifuge, DuPont, St. Neots, Cambridgeshire, UK; rotor A-841) for 60min to spin 
down the microsomes. After decanting the supernatant the microsomal pellet was 
resuspended in fresh buffer and stored at -80°C until use. The microsomes were stored in 
aliquots so that each assay was carried out with microsomes which had been frozen and 




2.8.1.1 Biuret assay  
RLM was quantified for protein content using a BSA (Sigma) standard curve at 0, 1, 2, 3, 4 
and 5mg of protein/500μl with dH2O. RLM was assayed at 20μl and 200μl and volumes 
adjusted to 500μl with dH2O. Biuret reagent (3ml – Sigma) was then added to all tubes and 
incubated at room temperature for 30 min. Absorbance of each sample at 540nm was 
measured using a spectrophotometer (UV-160, Shimadzu) using dH2O as the zero reference. 
The absorbance values of the membrane samples were converted to mg protein by linear 
regression analysis of the standard curve and interpolation of the unknown samples to be 
quantified.  
 
2.8.2 LIVER MICROSOME HYDROLYSES  
Digest buffer (0.10 M Tris-HCl buffer, pH 7.5) with a total volume of 110μl containing 2nmol 
of peptide and 1mg/ml (10ug/reaction) of RLM preparation (prepared as described in 
section 2.8.1) was incubated at 37°C. The reaction was terminated by addition of 5μl of 10% 
v/v trifluoroacetic acid (TFA) and the RLM removed by centrifugation at 21,000 g for 
1minute. The incubation time and RLM concentration were selected based on studies that 
demonstrated differences in susceptibility to degradation between peptides. 
The reactions were analysed using reverse phase HPLC (Jasco HPLC system: solvent delivery 
system PU-2080 plus, autosampler AS-2057 plus, degaser DG2080-53, dynamic mixer 2080-
32 UV detector uv-2075. Column: Phenomenex Gemini  C18 column containing 5μm 
particles, 250 mm x 4.6 mm). The samples were loaded onto the column and eluted using an 
acetonitrile (AcN)/water gradient, both acidified with 0.05% v/v TFA. The gradient 
characteristics were 15-60% AcN over 35 minutes as shown in Fig 2.2. The eluted peptides 
were detected spectrophotometrically by the UV detector set to read at a wavelength of 
214 nm as this is the point where the peptide bond absorb, minimising any change in 
absorbance caused by quantity of any one amino acid. Percentage degradation was 
calculated by comparing area under peak of the original peptide in the presence and 
absence of RLM. Percentage degradation values were calculated from a minimum of three 











Figure 2.2 Graphical representation of the AcN gradient in water. Peptides eluted in the linear 
gradient between 5 and 40 minutes. The flow rate was set at 1ml/min.  
 
2.8.3 RENAL BRUSH BORDER (RBB) MEMBRANE 
PREPARATION  
Rat RBB membranes were prepared based on the method described by Booth and Kenny 
(Booth and Kenny, 1974). Briefly, rats were killed by decapitation and kidneys removed and 
snap-frozen in liquid nitrogen and stored at -70°C. Kidneys were placed in cold 0.5M sucrose 
solution and the renal cortices dissected out and weighed. The cortices were finely sliced 
and gently homogenised at a ratio of 1g tissue to 6ml 0.5M sucrose using a 15ml hand-
homogeniser (Jencons, UK). Tissue was then further homogenized using a motorised 
homogeniser (Ultra Turrax, IKA Labortechnik) with a tight fitting Teflon coated pestle 
(Jencons) at 1000rpm. Following this, 1M MgCl2 was added to the homogenate to achieve a 
final concentration of 10mM MgCl2. This solution was stirred in an ice bath for 15 minutes to 
remove subcellular structures from the brush border cells through their aggregation by 
bivalent metal ions. The subcellular structures were removed by centrifugation at 1500g 
(Beckman J2-21, rotor JS-13.1) at 4°C for 20 minutes. The resulting supernatant containing 
RBB was collected and subsequently centrifuged at 15000g (Beckman J2-21, rotor JS-13.1) 
for 12 min at 4°C to remove the sucrose. The supernatant containing sucrose was discarded 
and the RBB pellet resuspended in fresh buffer of 100μl of 300mM mannitol in 12mM Tris-Cl 

















(pH7.4), with 10mM MgCl2. This suspension was first centrifuged at 2200g at 4°C (Sigma 
Laboratory Centrifuge 3 K18), the supernatant collected and centrifuged a second time for 
12min at 15000g at 4°C. The resultant RBB pellet was then resuspended in 300mM mannitol 
in 12mM HEPES (pH7.4). Protein content was measured by Biuret assay as described in 
2.8.1.1. 
 
2.8.4 RENAL BRUSH BORDER MEMBRANE HYDROLYSES  
Digest buffer (12mM HEPES, 300mM Mannitol pH7.4) containing 2nmol of peptide and 
1mg/ml of RBB membrane preparation (prepared as described in section 2.8.3) was 
incubated at 37°C. The reaction was terminated at 30minutes by addition of 5μl of 10% 
trifluoroacetic acid (TFA). The incubation time and RBB concentration were selected based 
on studies that demonstrated differences in susceptibility to degradation between peptides. 
The reactions were subsequently analysed using reverse phase HPLC using the same column 
and AcN gradient profile to analyse the RLM digests (section 2.8.2). Again, the eluted 
peptides were detected spectrophotometrically by the UV detector set to 214nm and 
percentage degradation was calculated by comparing area under peak of the original 
peptide in the presence and absence of RBB. Percentage degradation values were calculated 
from a minimum of three experiments and chromatograms shown are representative 
examples. 
 
2.8.5 DIPEPTIDYL-PEPTIDASE IV (DPPIV) HYDROLYSES 
Digest buffer (100 mM TRIS-HCl, pH8) containing 2 nmol of peptide and 10-50 mU of porcine 
kidney DPPIV (Sigma) was incubated at 37°C. The reaction was terminated at 120 minutes 
by addition of 5μl of 10% TFA. The reactions were initially analysed using reverse phase 
HPLC (section 2.8.2).  
Samples were centrifuged at 12500xg for 5 minutes at room temperature prior to HPLC 
analysis. The samples were applied to a C18 column and eluted using a linear AcN/water 
gradient acidified with 0.05% TFA. The gradient characteristics were 31.5-33.5% AcN over 45 
92 
 
minutes. The eluted peptides were detected spectrophotometrically at a wavelength of 214 
nm. Percentage degradation of peptide was unable to be calculated by comparing area 
under peaks of reactions with and without enzyme as metabolites and parent compound 
eluted at the same retention time and there were no additional degradation peaks 
detected. Therefore, analysis by MALDI-TOF was used for these hydrolyses.  
 
2.8.5.1 Matrix-assisted laser desorption/ionization-Time of flight (MALDI-
TOF) analysis of DPPIV proteolytic breakdown products 
MALDI-TOF mass spectrometry (MS) analysis of digests was performed at the Proteomic 
facility by the Advanced Biotechnology Centre (ABC, Imperial College, London, UK). Digests 
were performed as described in section 2.8.5, except 5nmol of peptide was digested by 
25mU of DPP IV in a reaction volume of 340 µl for 240 minutes. Digests were dried down 
using a SpeedVac sample Concentrator (Savant SPD2010, Thermo Electron Co., MA, USA) 
and spotted on an α-cyano-4-hydroxycinnamic acid (HCCA) matrix for MALDI TOF analysis 
using an Ultra Flex MALDI-TOF (Germany). In MALDI-TOF MS, the peptides are ionised on a 
plate and the ions are then accelerated through a vacuum tube by an electrical field towards 
a detector. Smaller fragments are accelerated to higher velocities than heavier ones, and 
the “time of flight” (TOF) is proportional to the mass:charge ratio (m/z). The charge of the 
ionised proteins is often +1, making the m/z value equal to the mass value. If the molecule 
obtains a +2 or +3 charge, the resulting value will be incorrect and care is needed to analyse 
this data. Assuming monoisotopic mass, theoretical masses for peptide breakdown products 
were calculated using the program FindPept (http://web.expasy.org/findpept/) with a mass 






2.8.6 HUMAN TRYPSIN HYDROLYSES  
Trypsin is a highly active and specific protease which cleaves the C-terminal to lysine and 
arginine residues of a protein to generate peptides that fall within the mass range of 500-
5000 Da.  
The trypsin protease assay was carried out as the DPPIV assay protocol above, except for 
the digest buffer used (10 mM TRIS-HCl, 10mM CaCl2 pH7), with 0.1mU of human trypsin 
(Sigma) in a volume of 120μl. The assay was incubated for 15 minutes before the reaction 
was terminated with 5μl of 10% TFA. The incubation time and enzyme concentration were 
selected based on studies that demonstrated differences in susceptibility to degradation 
between peptides. The reactions were subsequently analysed using reverse phase HPLC 
using the same column and AcN gradient profile to analyse the RLM digests (section 2.8.2). 
Eluted peptides were detected spectrophotometrically by the UV detector at 214nm and 
percentage degradation was calculated by comparing area under peak of the original 
peptide in the presence and absence of trypsin. Percentage degradation values were 
calculated from a minimum of three experiments and chromatograms shown are 
representative examples. 
Digests were also sent for a MALDI TOF analysis by the Proteomic facility at the ABC 
(Imperial College, London, UK) as described in section 2.8.5.1. 
 
2.8.7 HUMAN RECOMBINANT NEPRILYSIN HYDROLYSES  
The NEP protease assay was completed as the trypsin digest protocol above, except for 
digest buffer used (25 mM TRIS-HCl, 0.1M NaCl pH8), with 200ng of human recombinant 
NEP (R&D systems, Germany) in a volume of 130μl. The assay was incubated for 10-120 
minutes before the reaction was terminated with 5μl of 10% TFA. The reactions were 
subsequently analysed using reverse phase HPLC as described in section 2.8.6 with a slight 
change to the gradient (15-55% AcN in 35mins). Eluted peptides were detected 
spectrophotometrically by the UV detector at 214nm and percentage degradation was 
calculated by comparing area under peak of the original peptide in the presence and 
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absence of NEP. Percentage degradation values were calculated from a minimum of three 
experiments and chromatograms shown are representative examples. 
 
 
2.9 RADIOIMMUNOASSAY (RIA)  
All RIAs used (including iodination of peptides, production of antibodies, arranging synthesis 
of custom peptides) were derived and maintained by Professor MA Ghatei (Professor of 
Regulatory Peptides, Section of Investigative Medicine, Division of Diabetes, Endocrinology 
& Metabolism, Imperial College London).  
 
2.9.1 PRODUCTION OF PP-x AND PYY2-36(αLTX-4H) 
POLYCLONAL ANTIBODY 
PP analogues with mid-section modifications and the PYY analogue, PYY2-36(αLTX-4H) did not 
cross-react with antibodies raised to either human PP or porcine PYY respectively, even 
when the concentration of competing standard peptide was increased 10-fold. Therefore 
new antibodies were raised against PP-x (sequence detailed in appendix B) and PYY2-
36(αLTX-4H). Sheep (Scotland Blood Transfusion Service, Penicuik, Scotland) were inoculated 
with 200µg PP-x or PYY2-36(αLTX-4H) conjugated to BSA (Sigma) as the carrier protein using 
carbodiimide (Sigma) as the coupling agent. Booster inoculations were conducted 
fortnightly and test bleeds were done 2 weeks after the third booster injection and every 
month thereafter. Each bleed was tested by incubating the sera (neat) with 125I-PP-x (for 
sheep inoculated with PP-x) or 125I-PYY2-36(αLTX-4H) (for sheep inoculated with PYY2-36(αLTX-
4H)) for 2 hours, to test for excess binding of label as with the immunogenicity protocol 
described in section 2.10.  
The unbound radiolabelled peptide was separated from the bound radiolabelled peptide by 
dextran-coated charcoal separation. Following centrifugation at 1000 x g for 20 minutes at 
4°C, free label is contained in the charcoal pellet and label bound to the antibody remains in 
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the supernatant. Both the bound and free fractions of label are counted in a γ-counter 
(model NE1600, Thermo Electron Corporation) and the amount of bound label is calculated 
as a percentage of the total counts. 
A population of sheep plasma was chosen for the highest levels and most specific antibodies 
produced. A titre test of the chosen plasma was then conducted to determine the correct 
titre of antibody to use for the RIA. 
 
2.9.2 PYY AND PYY ANALOGUES RIA 
A specific and sensitive RIA (principles of which are described in Appendix E) was used to 
determine the levels of PYY and PYY analogues in plasma. Plasma samples from animals 
injected with PYY3-36, PYY2-36(4H), PYY2-36(αLTX-4H) or PYY2-36(αLTX-4H)-PEG were assayed 
using the conditions described in Table 2.1. All peptides cross reacted 100% with the 
antibody used.  




Animals injected with 
PYY2-36(αLTX-4H) 
Antibody Anti-porcine PYY Anti-porcine PYY Anti-PYY2-36(αLTX-4H) 






PYY1-36 PYY2-36(4H) PYY2-36(αLTX-4H) 
Concentration  of  
standard curve 
1pmol/ml 2pmol/ml 2pmol/ml 
Method of 
separation 
2° antibody 2° antibody Dextran-coated 
charcoal 
 





The anti-PYY antibody was produced in sheep against purified porcine PYY (differs from the 
human sequence by 2 amino acids at positions 3 and 18) coupled to bovine serum albumin 
(BSA) by glutaraldehyde and used at a final dilution of 1:7000 to measure PYY3-36, or at a 
final dilution of 1:47000 to measure PYY2-36(4H). This antibody cross reacts to PYY and PYY2-
36(4H) and has very poor cross-reactivity with the PYY analogue PYY2-36(αLTX-4H).  
As described in section 2.9.1, the anti-PYY2-36(αLTX-4H) antibody was produced in sheep 
against purified PYY2-36(αLTX-4H) coupled to BSA by carbodiimide and used at a final dilution 
of 1:230000. This antibody cross reacts to PYY2-36(αLTX-4H) and has poor cross-reactivity 
with native PYY and PYY2-36(4H). Both anti-PYY and anti-PYY2-36(αLTX-4H) antibodies do not 
cross-react with other known gastrointestinal hormones. 
A radiolabelled form of PYY was prepared by the direct iodination method and purified by 
reverse phase high-pressure liquid chromatography. 
Assays were performed in 0.06M phosphate EDTA buffer (0.05M Na2HPO4.2H2O, 0.6mM 
KH2PO4, 0.01M disodium-EDTA.2H2O, 8mM NaN3), at pH7.4 with 0.3% BSA. All samples were 
assayed in duplicate in a final volume of 700µl per tube. 
Standard curves for each assay were prepared in assay buffer at the concentrations given in 
the table above and added in duplicate at volumes of 1, 2, 3, 5, 10, 15, 20, 30, 50 and 100μl. 
A sample volume of 1, 3, 5, 10, 50, or 100μl of plasma was used. The assays were incubated 
for 72 hours at 4°C before the separation of free- and antibody-bound radiolabel. 
Free label was separated from bound using either 2° antibody precipitation or charcoal 
adsorption. For 2° antibody separation, samples were pre incubated for 1hour with 100µl of 
0.1% goat anti-rabbit 2° antibody at room temperature. Immediately prior to centrifugation, 
500µl of 0.01% Triton-X-100 (Sigma) was added to each tube, and then spun at 1500g, for 
20minutes at 4°C. For charcoal separation, 250µl of dextran-coated charcoal solution (2.4g 
activated charcoal, 0.24g dextran, 100ml 0.06M phosphate EDTA buffer pH7.4 with gelatin) 
was added to each tube. The assay was then centrifuged also at 1500g, for 20minutes at 
4°C. 
Bound and free label were separated and both the pellet and supernatant counted for 180 
seconds in a γ-counter (model NE1600, Thermo Electron Corporation). Peptide 
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concentrations in the samples were calculated using a non-linear plot (RIA Software, 
Thermo Electron Corporation) and results calculated in terms of the standard.  
Noncompartmental analysis of drug exposure was calculated using the trapezoidal rule to 
establish the area under curve (AUC) using GraphPad Prism 5 software. 
 
2.9.3 PP AND PP ANALOGUES RIA  
PP plasma levels were measured using established methods (Adrian et al., 1976). The anti-PP 
antibody was produced in rabbits against human PP coupled to bovine serum albumin (BSA) 
by glutaraldehyde and used at a final dilution of 1:50000 to measure PP. This antibody cross 
reacts to PP and has very poor cross-reactivity with PP analogues.  
RIA component Animals injected with 
PP 
Animals injected with 
PP analogues 
Antibody Anti-PP Anti-PP-x 
Antibody titre 1:50000 1:13000  
Radiolabel 125I-PP 125I-PP-x 
Peptide for standard 
curve 
PP PP analogue 










Table 2.2 Components of the PP and PP analogues radioimmunoassay used. 
The anti-PP analogue antibody was produced in sheep against purified PP-x coupled to BSA 
by carbodiimide and used at a final dilution of 1:13000. This antibody cross reacts to PP 
analogues which have poor cross-reactivity to the anti-PP antibody, and therefore has poor 
cross-reactivity with native PP. Both anti-PP and anti-PP-x antibodies do not cross-react with 
other known gastrointestinal hormones. 
A radiolabelled form of PP and PP-x was prepared by the direct iodination method and 
purified by reverse phase high-pressure liquid chromatography. 
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PP RIAs were performed in 0.06M phosphate EDTA buffer (pH7.4) with 0.3% BSA and 
0.002% Tween-20. All samples were assayed in duplicate in a final volume of 700µl per tube. 
Standard curves for each assay were prepared in assay buffer at the concentrations given in 
the table above (Table 2.2) and added at the same volumes as the PYY RIA (section 2.9.2).  
Sample volumes of 1, 3, 5, 10, 50, or 100μl of plasma were used. The assays were incubated 
for 72 hours at 4°C before the separation of free- and antibody-bound radiolabel by charcoal 
adsorption. 
Bound and free label were separated and both the pellet and supernatant counted for 180 
seconds in a γ-counter (model NE1600, Thermo Electron Corporation). Peptide 
concentrations in the samples were calculated using a non-linear plot (RIA Software, 
Thermo Electron Corporation) and results calculated in terms of the standard.  
Noncompartmental analysis of drug exposure was calculated using the trapezoidal rule to 
establish the area under curve (AUC) using GraphPad Prism 5 software. 
 
2.10  DETECTION OF IMMUNOGENICITY OF PYY 
ANALOGUES 
The presence of anti-analogue (anti-PYY2-36(4H), anti-PYY2-36(αLTX-4H)) or anti-PYY 
antibodies were measured using a Radioimmunoprecipitation Assay (RIPA). Briefly, 20µl 
plasma of animals treated with PYY2-36(4H) or anti-PYY2-36(αLTX-4H) was incubated with 
either 125I-PYY2-36(4H), 
125I-PYY2-36(αLTX-4H), or 
125I-PYY1-36 respectively. This mixture was 
incubated overnight at 4°C and the free label separated from the bound through dextran-
coated charcoal separation (unbound radiolabel is found in the charcoal pellet following 
centrifugation at 1500g for 20minutes at 4°C). Both the bound and free fractions of label are 
counted in a γ-counter and the amount of bound label is calculated as a percentage of the 
total counts (bound + unbound label). Positive samples were identified as those with ≥4-fold 




2.10.1 ADA COMPETITION ASSAY WITH PYY ANALOGUES 
“Zero” binding (Z) was defined as the binding of 125I-PYY2-36(αLTX-4H) to plasma containing 
anti-drug (PYY2-36(αLTX-4H)) antibodies (ADAs) in the absence of any competing non-
radiolabelled PYY2-36(αLTX-4H) peptide. Binding sites on the ABs would therefore solely be 
occupied by 125I-PYY2-36(αLTX-4H).  
Known and increasing amounts of non-radiolabelled PYY2-36(αLTX-4H), fragments of PYY2-
36(αLTX-4H), or analogues of PYY2-36(αLTX-4H) were then used to compete with a constant 
quantity of 125I-PYY2-36(αLTX-4H) peptide. This should dose-dependently decrease the 
amount of binding of radiolabelled peptide if the non-radiolabelled peptide and fragments 
compete at the same binding sites.  
The difference of this decrease in binding (drop from Z) was compared across all known 
doses of non-radiolabelled PYY2-36(αLTX-4H), against the different fragments/analogues of 
PYY2-36(αLTX-4H) synthesised, amongst plasma samples which tested positive for PYY2-
36(αLTX-4H) ABs.  It is then expressed as a ratio compared with binding of full length PYY2-
36(αLTX-4H) at the same concentration (equation below). If the ratio is close to 1, it suggests 
silimilar displacement of 125I-PYY2-36(αLTX-4H) compared to the full length peptide. 
Fragments which do not compete as well with 125I-PYY2-36(αLTX-4H) binding for the ADAs will 
have a ratio <1. 
 
 
Ratio =  (Z binding  –  binding of ᵡ pmol non-radiolabelled peptide/fragment) 
  (Z binding  –  binding of ᵡ pmol non-radiolabelled PYY2-36(αLTX-4H)) 
 
Figure 2.3 Equation to measure relative displacement strength of various PYY analogues or 
fragments against radiolabelled drug. 
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2.11  STATISTICAL ANALYSIS  
For animals studies, power calculations were used to determine the minimum sample size 
needed to reject the null hypothesis, assuming the null hypothesis is false (i.e. to be able to 
detect an effect, if the effect exists). 
(https://www.dssresearch.com/KnowledgeCenter/toolkitcalculators/samplesizecalculators.
aspx). Factors which influence this include variance and magnitude of the effect. Assuming 
standard deviation is constant, experiments where a big effect was expected (e.g. using high 
doses of drug or making big changes to a peptide), sample size was reduced to limit the use 
of animals. 
 All data are expressed as the mean value ± standard error of the mean (SEM). In acute 
feeding studies, food intake was compared by one-way ANOVA followed by Dunnett’s post-
hoc test (to determine the significance in the difference of food intake between the groups 
being tested and the saline group) or Bonferroni’s or Tukey’s post-hoc tests (to determine 
the significance in the difference of food intake between the different treatment groups). In 
pharmacokinetic studies, plasma levels of peptide hormone were compared by one-way 
ANOVA followed by Dunnett’s or Bonferroni’s post-hoc tests. 
Continuous or longitudinal data was analysed using the generalized estimating equation 
(GEE) with the Mann-Whitney U adjustment or using a two-way ANOVA followed by a 
Tukey’s post-hoc test.  GEE data analysis was performed using STATA 9 (StataCorp LP, 
College Station, TX) and all other statistical analyses used GraphPad Prism Version 5.01 
(GraphPad Software Inc. San Diego, USA). 






DEVELOPING ANALOGUES OF 
PANCREATIC POLYPEPTIDE AS 





Satiety factors such as gut hormones, which are released in response to a stimulus (e.g. food 
intake), are transient signal molecules released in response to food intake and are required 
to be cleared quickly so as to modify behaviour for relatively short periods of time. Short 
half-life and limited efficacy and potency, are properties which have to be 
considered/modified when developing gut hormones as potential therapeutics.  
There are several methods by which gut hormones can be modified in order to address their 
limitations as drug candidates. Coupling hormones to larger molecules such as albumin or 
fatty acid side chains has been successfully applied to increase half-life, for example the 
GLP-1r agonists albiglutide and liraglutide. Large side chains can extend the molecules half-
life in circulation by reducing the rate of renal filtration through steric hindrance, or by 
reducing the metabolic clearance rate. Steric hindrance may also make a hormone less 
available to the active site of an enzyme and thus reduce its susceptibility to enzyme 
degradation.  
Another method of enhancing the longevity of gut hormones is through substitution of 
amino acid residues (as in the case of taspoglutide) or by the addition of short sequences 
(e.g. lixisenatide) to reduce the peptides susceptibility to proteolytic degradation. Modifying 
the amino acid sequence can also result in an improvement of plasma circulatory half-life by 
increasing the affinity of the peptide to large plasma proteins such as serum albumin and 
lipoprotein. 
For the gut hormones to physiologically exhibit their effects, they have to both bind to and 
activate their respective receptor. All of the gut hormones bind to GPCRs and any change of 
conformation to the ligand can alter its interaction with the receptor. The sensitivity of the 
receptor to changes in ligand structure cannot be overestimated. Small changes, such as the 
loss of the C-terminal amide group of PP, are enough to almost completely stop the 
molecule binding to the Y4r (Gehlert et al., 1996). On the other hand, there are examples 
where large changes, such as the addition of a fatty acid moiety to GLP-1 as with liraglutide, 
have very little effect on receptor affinity (Knudsen et al., 2000).  
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As well as affecting receptor affinity, changes to a ligand can also affect the molecule’s 
ability to activate the receptor, as with the conversion of the potent GLP-1r agonist exendin-
4 to the N-terminal truncated form, exendin-9-39, which is a GLP-1r antagonist (Schirra et 
al., 1998). In addition, as seen in plieotropically  coupled receptors such as GLP-1r (Koole et 
al., 2013), there may be ligand-directed stimulus bias. Although most GLP-1r agonists 
preferentially activate cAMP over other signalling pathways in vitro, the degree of bias 
between the pathways varies between ligands with truncated GLP-1 and ex-4 having a 
greater bias towards cAMP than full length GLP-1 and OXM (Koole et al., 2010, Koole et al., 
2012a, Koole et al., 2012b). 
Receptor specificity is another feature which may be altered when making changes to a 
ligand. This is exemplified by the change in receptor preference by PYY1-36 (which binds 
preferentially to the Y1r) compared with PYY3-36 (which binds with greater affinity to the Y2r) 
(Grandt et al., 1992). In contrast, the C-terminal fragment, PYY30-36, has a much lower 
affinity at the Y2 receptor, but maintains much of the biological activity of PYY3-36, as 
shown in the bioassay using contractile effects in Y2r-enriched rat vas deferens (Fournier et 
al., 1994, Barden et al., 1994). The demonstrates how ligand activity can also be affected by 
peptide modification. 
Increasing half-life and improving efficacy and potency may reduce the dose and frequency 
of drug administration, which may improve complicance with the dosing regimen, increase 
the attractiveness of the therapeutic option (where a choice is available), help tolerability, 
and reduce the cost of drug manufacturing. With improved pharmacokinetic profiles of the 
peptide analogue (gradual increase in systemic exposure with no abrupt peaks), side effects 
such as nausea may also be reduced 
In this chapter I will describe the investigations I completed on pancreatic polypeptide (PP) 
to exemplify the design of an analogue with an extended circulatory half-life. PP is a 
member of the PP-fold family of peptides and is released post-prandially from pancreatic F 
cells (Adrian et al., 1976, Adrian, 1978). When PP is administered to healthy adults via a 
90minute IV infusion, there is a 16-fold rise in circulating PP compared to basal levels, which 
significantly reduces food intake over 24 hours compared to a saline control (Batterham et 
al., 2003b, Jesudason et al., 2007). This anorectic effect suggests that PP may have potential 
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as an obesity treatment. It is a relatively small peptide, and is susceptible to a number of 
degradative enzymes and other eliminating mechanisms; PP consequently has a short 
circulating half-life of around 7 minutes (Adrian et al., 1978). This short half-life limits the 
use of native PP as an economically viable and tolerable obesity treatment. 
Previous studies on other gut hormones including GLP-1, oxyntomodulin and PYY3-36 have 
shown that small regulatory peptides are susceptible to degradation by a number of 
membrane bound ectopeptidases and other membrane bound enzymes, limiting their 
circulating half-life (Kenny, 1986, Roques et al., 1993). As the PP family of peptides show 
strong sequence homology and are thought to be derived from a common ancestor, it is 
likely that the peptidases that break down other members of the PP-fold family will also 
degrade PP (Ekblad and Sundler, 2002, Blomqvist et al., 1992, Larhammar, 1996a, 
Larhammar, 1996b).  
Therefore, the enzymes investigated in this chapter are those relevant to the degradation of 
PYY and other gut hormones such as those contained in preparations of rat liver 
microsomes (RLM), rat kidney brush border (KBB) membrane, trypsin, DPPIV, neprilysin, and 
meprin. 
 
3.1.1 HEPATIC METABOLISM 
The liver acts as the waste management system of the body, breaking down waste and 
detoxifying compounds. The “first pass effect” of hepatic metabolism mostly reduces the 
availability of many orally administered drugs. Most of the venous system of the GI tract 
enters the hepatic portal vein, and subsequently the liver. Consequently, after absorption in 
the intestine, most drugs pass through the liver and are degraded. Subcutaneously 
administered drugs initially enter systemic circulation but eventually reach the portal vein to 
undergo hepatic metabolism. 
The liver eliminates most drugs by metabolism, biliary excretion or both. Rane et al. (Rane et 
al., 1977) discovered the potential for an in vitro-in vivo hepatic clearance prediction. 
Models for prediction of hepatic clearance include the use of liver microsomes, isolated 
hepatocytes, recombinant (heterozygously expressed) cytochrome P450 (CYP) isozymes, 
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liver slices and ex vivo liver perfusion preparations. All methods have their limitations; for 
example, recombinant heterozygously expressed CYPs are not predictive of intrinsic 
clearance because of contributions of several CYPs in the metabolism of different drugs and 
because metabolic rates differ with the expression system used. Liver slices are not useful in 
kinetic predictions due to a lack of uniform diffusion of compounds into all the cells within 
the slice. The in vitro methods using hepatic microsomes or hepatocytes are the most widely 
used approaches for estimating hepatic clearance.  
Houston et al. (Houston, 1994) found that intrinsic hepatic clearance is a pure measure of 
enzyme activity towards a drug and is independent of hepatic blood flow and protein 
binding. They also demonstrated that it was possible to predict in vivo metabolic clearance 
over four orders of magnitude using in vitro techniques. A good correlation was found 
between in vitro and in vivo results with most compounds being within 3-5-fold range of 
intrinsic to in vivo clearance values. However, there was a tendency for the in vivo metabolic 
clearance to be higher than the estimated in vitro intrinsic metabolic clearance. These 
differences could be due to possible factors from in vivo contributions from other organs, 
presence of active transport mechanisms and inter-individual differences (Ito et al., 1998, 
Chaturvedi et al., 2001).  
Investigating hepatic metabolism may therefore be a good predictor of in vivo metabolism 
when considering the design of proteolytic-resistant PP analogues. Although there is 
evidence to suggest that hepatic metabolism is not involved in the initial clearance of PP-
fold peptides (Boden et al., 1980, Hagopian et al., 1983, Cohen et al., 1984, Beckh et al., 
1992), it may have a role in the secondary phase of PP metabolism (e.g. secondary to 






3.1.2 RENAL METABOLISM 
The exact mechanisms of PP clearance are unknown. PYY, another member of the PP-fold 
family, has been more widely studied and is broken down by a number of enzymes and 
peptidases located in the kidney (Medeiros and Turner, 1994, Medeiros Mdos and Turner, 
1994, Mentlein et al., 1993b). As PP and PYY have a high degree of sequence homology, it is 
therefore likely that the kidneys are also responsible for the clearance of PP. The kidney is 
thought to play a major role in the degradation of a number of other peptide hormone 
(Bastl et al., 1977, Ruiz-Grande et al., 1990) and enzymes located in the brush border, in 
particular metallopeptidases, are central to this route of peptide degradation. Enzymes 
including aminopeptidase N, aminopeptidase A, DPPIV, and neprilysin are all located within 
membranes of renal brush border (RBB) (Stephenson and Kenny, 1987, Kenny and 
Stephenson, 1988, Vanneste et al., 1988, Hupe-Sodmann et al., 1995, Medeiros and Turner, 
1995, Bertenshaw et al., 2001). Interestingly, it has been suggested that the levels of certain 
enzymes within the RBB are dependent upon nutritional status. For example, starvation 
increases the levels of DPPIV in rats (Ihara et al., 2000). A consequence of this would be a 
decrease in circulating levels of GLP-1 which would result in a reduced satiety signal. This 
suggests a mechanism by which nutritional status regulates circulating gut peptide levels. 
The kidneys may therefore be a key site for the breakdown of PP, and the reabsorption of 
amino acids, and preparations of RBB may be a useful tool (Kenny and Stephenson, 1988) to 
investigate the breakdown of PP and PP analogues. 
 
3.1.3 DPPIV DEGRADATION 
DPPIV is a member of the serine family of peptidases which acts to cleave the first two 
amino acids at the N-terminus of small (0.5kDa) to medium sized peptides (5kDa) (Mentlein 
et al., 1993b, Mentlein, 1999, Drucker et al., 1997). It is a membrane bound enzyme 
targeting peptides comprised of less than 80 amino acids and with a N-terminal sequence of 
either X-Pro, X-Ala, X-Ser or X-Gly (where ‘X’ is any amino acid except proline), and a 
hydrophobic amino acid such as tyrosine at the P3 position (Bongers et al., 1992, Proost et 
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al., 1999, Lambeir et al., 2002). DPPIV is an ectopeptidase highly expressed in endothelial 
cells and also present in plasma (De Meester et al., 1999, Ohkubo et al., 1994).  
DPPIV has a number of hormone substrates, including NPY, PYY and GLP-1 (Mentlein et al., 
1993b, Mentlein et al., 1993a). DPPIV is generally considered a peptidase which inactivates 
peptides by degrading them as in the case of GLP-1. However, it does also activate peptides: 
when PYY1-36 is cleaved by DPPIV, it forms PYY3-36, a highly active hormone, with high affinity 
for the Y2 receptor (Grandt et al., 1993) and a potent anorectic satiety factor. 
The importance of DPPIV in degrading GLP-1 is highlighted by the emergence of DPPIV 
inhibitors such as Sitagliptin (Januvia, MSD) and Vildagliptin (Galvus, Norvartis) which 
prolong the half-life of endogenously released GLP-1 and are now approved drugs for 
treating T2DM (Davidson et al., 2008). They act to inhibit the breakdown of GLP-1, resulting 
with increased circulating levels and lowered blood glucose levels. The long lasting GLP-1 
analogue exenatide is a GLP-1r agonist which is DPPIV resistant (first three amino acid 
sequence of His-Gly-Glu), and has therefore significantly increased plasma half life (Nielsen 
et al., 2004, Green et al., 2003). The sequence of PP (first three amino acid sequence is Ala-
Pro-Leu) suggests it is a likely candidate for DPPIV proteolysis and this could be a mechanism 
by which the peptide is inactivated (as with PYY1-36 and NPY).  The role of DPPIV degradation 
in PP will be important to establish when designing PP analogues with a longer half-life. 
 
3.1.4 NEPRILYSIN DEGRADATION 
Neprilysin (NEP) is a 94kDa metallopeptidase enzyme with a zinc core. It is usually found 
bound to membranes, and is expressed throughout the body. NEP was originally discovered 
in purified kidney brush border (Gee et al., 1985, Roques et al., 1993, Hupe-Sodmann et al., 
1995), and the enzyme is found at a high concentration in the kidneys, brain, and lungs. NEP 
has a wide number of substrates, including GLP-1, Neurokinin A and B, Neurotensin, 
Oxytocin and Gastrin (Erdos and Skidgel, 1989). NEP cleaves peptide chains on the amino 
side of hydrophobic residues. This has been demonstrated in GLP-1, in which a number of 
peptide bonds are cleaved by NEP. Notably, the Glu27-Phe28 and the Trp31-Leu32 bonds of 
GLP-1 were cleaved most readily (Hupe-Sodmann et al., 1995).  
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Another GLP-1 receptor agonist, Exendin-4, does not possess some NEP target sites present 
in GLP-1, yet, despite having some potential NEP degradation sites, it remains a poor 
substrate for the enzyme and this partly explains its extended half-life (Hupe-Sodmann et 
al., 1995, Goke et al., 1993). In addition, its larger size of 39 amino acids, and its greater 
propensity at forming a stable α-helix may contribute to it being a poor substrate for NEP. 
This demonstrates that properties of peptides other than sequence can influence a peptides 
susceptibility to degradation; properties such as tertiary structure which can block access of 
the enzyme to the substrate.  
However, substituting amino acids susceptible to attack by peptidases may increase peptide 
hormone bioactivity. PYY and NPY have also been shown to be cleaved by NEP, suggesting 
that PP may also be processed by NEP (Medeiros Mdos and Turner, 1994, Medeiros and 
Turner, 1994, Medeiros Mdos and Turner, 1996). Establishing the importance of NEP in the 
clearance of PP may help the development of PP analogues with a long half-life. 
 
3.1.5 TRYPSIN DEGRADATION 
Parenteral routes of drug administration (IV, IM or SC) generally avoid the first-pass 
metabolism of the liver because it bypasses the GI tract. It introduces drugs directly across 
the body’s barrier defences and into systemic circulation. Unlike the IV route, IM and SC 
require absorption of the drug from the injection site and are therefore slower than IV 
administration. Absorption of drugs from an aqueous solution is fast, whereas absorption 
from depot preparations (as when the drug precipitates at the site of injection) is slow. 
Skin consists of 3 layers: the epidermis, dermis and hypodermis (Fig 3.1). The location of 
subcutaneous administration is between the dermis (a matrix of connective tissue, blood 
vessels, nerves and lyphatics) and hypodermis (an insulating layer of connective tissue 
containing many adipose cells). Metabolism of a drug at this level can constitute first-pass 
metabolism which may result in sub-therapeutic doses reaching the systemic circulation. 
The metabolic activity of the skin enzymes may mean that different doses of the drug are 
delivered resulting in toxicity or apparent decreased effectiveness. Particular regard must 










Figure 3.1 Diagrammatic representation of the 3 layers which comprise the skin.  
 
Despite enzyme activity within the skin approaching and sometimes exceeding that of the 
corresponding hepatic enzyme (Bashir S J and Maibach H. 1999) Cutaneous metabolism of 
xenobiotics. In RL Bronaugh and HI Maibach (Eds), Percutaneous absorption, Dekker, New 
York, 1999, pp65-85), first-pass effects of skin normally play a minor part in systemic drug 
metabolism (Benet, 1978) (Martin R et al. 1987 Int J Pharmaceutics). Nevertheless, if a 
subcutaneous depot is likely to form as a result of a controlled-release drug formulation, 
consideration should be made for the potential for enzymatic modification during this 
process. Indeed, slow release could lead to extensive first-pass metabolism whereas instant 
release could cause saturation of enzyme systems resulting in the availability of large 
amounts of drug going into systemic circulation.  
Viable skin possesses enzyme activity that can hydrolyse peptides such as insulin which is 
rapidly degraded in the dermal side of rat skin. This degradation is strongly inhibited by 
PMSF (a serine protease inhibitor of enzymes such as trypsin and chymotrypsin) and 
phenanthroline (inhibitor of metalloenzymes such as aminopeptidases and endopeptidases) 
(Ogiso et al., 1997). Both inhibitors completely inhibit the proteolytic enzymes in skin and 
viable tissues where the peptides are metabolized, thus effectively abolishing degradation in 
the skin (Ogiso et al., 2000). Enzyme activities of cathepsin-B, collagenase-like peptidases, 
and DPPIV were also found to be high in rat subcutaneous tissue (Komada et al., 1985).  
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Trypsin cleaves peptide chains predominantly at the carboxyl side of the basic amino acids 
arginine or lysine, except when either is followed by proline (Ortiz et al., 2007) although 
there is evidence to suggest that cleavage occurs even with proline (Rodriguez et al., 2008). 
Due to the ubiquity of trypsin in cells (cytoplasm, nucleus and nucleolar) (Hodges et al., 
1973), extracellular matrix (Didangelos et al., 2010), and the nature of its characteristic 
cleavage sequence of amino acids, trypsin was an ideal enzyme to investigate when 
designing a long-acting PP analogue for subcutaneous administration. 
 
 
3.1.6 DESIGN OF ENZYME-RESISTANT PEPTIDE 
ANALOGUES  
A number of hormone analogues which are more resistant to enzymatic breakdown than 
the native forms have already been developed. One example is the GLP-1 analogue exendin-
4 that has a significantly increased half life compared to native GLP-1 (Goke et al., 1993). 
This is, at least, partly due to increased resistance to peptidases including NEP and DPPIV 
(Hupe-Sodmann et al., 1995). The oxyntomodulin analogue, OXM6421, has a longer half life 
than native OXM following peripheral administration (Druce et al., 2009, Liu et al., 2010), 
which correlates with the removal of sites susceptible to cleavage by peptidases including 
NEP and DPPIV. Using enzyme resistant analogues of gut hormones such as PP would allow 
a decrease in the frequency of administration while still maintaining receptor specificity and 




3.1.7 HYPOTHESIS AND AIMS 
The breakdown of native human PP will be investigated using hepatic microsomes and RBB 
membrane preparations, and a number of purified recombinant degradative enzymes to 
establish which amino acid sites are targeted. 
Once sites identified for susceptibility to proteolytic enzymes are established, PP analogues 
with rational amino acids substitutions at these sites will be tested for their ability to 
withstand enzymatic degradation. Using efficacy studies, capability of receptor affinity, and 
measurement of peptide levels following a single administration, an assessment of the 
physiological relevance of analogues with increased resistance to degradation will be made. 
 
3.1.7.1 Hypothesis  
The substitution of amino acids at key sites targeted by hepatic microsomes, RBB membrane 
preparations, DPPIV, trypsin and neprilysin will produce PP analogues that are resistant to 
enzymatic degradation, maintain greater levels in circulation, and possess longer duration of 
action (bioefficacy) following a single administration.  
 
3.1.7.2 Aims 
1) To determine the effects on native PP of incubation with rat liver microsomes 
(RLM) and renal brush border (RBB) membrane, trypsin, DPPIV and neprilysin, 
using high performance liquid chromatography (HPLC) and matrix-assisted laser 
desorption/ionization time of flight (MALDI-TOF) mass spectroscopy. 
2) To establish if amino acid substitutions can prevent degradation  
3) To investigate if the changes made improve biological actions of the peptide by: 
a. Binding affinity at the human and mouse Y4 receptor 
b. Acute feeding studies in C57BL/6 mice 




3.2.1 CHARACTERISATION OF PP DEGRADATION BY TISSUE ENZYME 
PREPARATIONS 
3.2.1.1 Investigation into RBB-mediated breakdown of PP (HPLC) 
HPLC analysis of PP in RBB buffer alone showed a single peak with a retention time of 
25minutes (RT=25m). Incubation of PP with RBB membrane in the same digest buffer at 
37oC over a range of times from 15- to 60mins demonstrated a time dependent decrease in 
the parent peptide peak (Fig 3.2). The peak area of the parent molecule was reduced by 8% 
after 15 minutes incubation with RBB, 32% at 30 minutes and 67% after a 60 minute 
incubation with RBB at 37oC (Fig 3.2). In addition to the reduction in size of the primary PP 
peak, additional peaks with earlier retention times were observed. Five major UV-absorbing 



















3.2.1.2 Identification of RBB target sites on PP (MALDI) 
Analysis of PP incubated with RBB using MALDI-TOF MS indicated that there were a number 
of PP breakdown products detectable following a 10 minute or 60 minute incubation with 
RLM. At 10 minutes incubation of PP with RBB, shown in Fig 3.3(A), peaks with mass to 
charge ratios of 3259, 4015 and 4183 M/Z were detected. These masses are consistent with 
full length PP and the PP fragments 6-33/10-36 and PP3-36.  
At 60 minutes incubation of PP with RBB, shown in Fig 3.3(B), peaks with mass to charge 
ratios of 1867, 3097, 3259, 3853, 4015 and 4183 M/Z were detected. These masses are 


























4183 4183 0 1-36 
4015 4015 0 3-36 
3853 3851 2 3-35 




3096 -1 3-29 
3098 1 5-31 











Figure 3.3 MALDI MS analysis of PP in the presence of RBB for (A) 10mins or (B) 60mins at 37°C.  (C) 
table (Table 3.1) of identified peaks correlated with PP fragments of known mass;  (D) schematic 
diagram of PP fragments lined up against the corresponding PP sequence 
C
  A 
D
  A 
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3.2.1.3 HPLC analysis of PP degradation by RLM 
HPLC analysis of the control sample PP reconstituted in RLM buffer showed a single peak 
with a retention time of 25minutes (RT=25m). Incubation of PP with RLM preparation in 
RLM buffer at 37oC over a range of times from 15-60minutes demonstrated a time 
dependent decrease in the parent peptide peak with the retention time of 25 minutes (Fig 
3.4(A)). The peak area of the parent molecule was reduced by 8% after 15 minutes 
incubation with RLM, 10% at 30 minutes and 35% after a 60 minute incubation with RLM at 
37oC (Fig 3.4 (C) and (D)). In addition to the reduction in size of the primary PP peak, 
additional peaks with earlier retention times were observed. Two major UV-absorbing peaks 
were observed at retention times of 16.5 and 21 minutes (Figure 2.1). 
Figure 3.4 HPLC chromatogram of PP incubated in the presence of RLM at 37oC after (A) 0mins, (B) 















1 4184 4183 1 1-36 
2 4060 4052 8 1-35(2Met-O) 
3 4022 4020 2 1-35 
4 2758 2757 1 6-29 
5 2601 2597 4 15-35 
6 2094 2094 0 3-21 
7 2068 2070 -2 14-30 
Figure 3.5 MALDI MS analysis of PP in the presence of RLM for 10mins at 37°C. (A) MALDI spectra; (B) 
table (Table 3.2) of identified peaks correlated with PP fragments of known mass; (C) schematic diagram 
of PP fragments lined up against the corresponding PP sequence 
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MALDI-TOF analysis of PP incubated with RLM showed fewer peaks at 60 minutes compared 
to 10 minutes incubation. At 60 minutes, peaks with mass to charge ratios of 2030, 2068, 
2105, 4016, and 4185 M/Z were detected (Fig 3.6(A)). These masses are consistent with PP 
and the PP fragments PP1-19, PP14-30, PP8-26 and PP1-35/3-36 (Fig 3.6 (B)).  
The heaviest fragment (fragment 1 for both time points) corresponds to the molecular 
weight of full length PP(1-36) as shown in Fig 3.5 and 3.6. PP1-36 was present at both the 10 
and 60 minute time points but at different peak intensities (100% and 20% respectively).  
Peak 2 from both 10 and 60min PP digests corresponds to PP2-36 and is present at both 
time points however this peak exhibited the greatest mass difference (>50 Da) when 
compared to its theoretical mass. Due to this large mass difference, peak 2 from both time 
points could also correspond to PP1-35(2Met-O) where both Met residues are oxidised 
(expected mass of 4052 Da).  
PP1-35 and PP3-36 are candidates for peak 3 from the 60 minute sample. PP1-35 also 
represents peak 3 from the 10 minute time point where it is observed with increased peak 
intensity.  
Peak 4 of the 10 minute sample has 3 possible candidates: PP4-27, PP6-29, and PP15-36. 
They all have similar mass (±2 Da) however PP6-29 has the least difference compared to the 
m/z value (1 Da). The m/z value for peak 4 in the 10 minute sample has no equivalent in the 
60 minute time point. Peak 5 from the 10 minute sample corresponds to PP15-35 and is also 
unique to this time point. 
Peak 6 from the 10 minute sample corresponds to PP3-21 which matches exactly the 
theoretical mass. However, it is also similar to PP8-26 (mass difference 10 Da) which is 
present as peak 4 of the 60 minute sample. Peak 7 (10 minutes) and 5 (60 minutes) are 
common in both time points and corresponds to the mass of PP14-30. In both sample 
















1 4185 4183 2 1-36 
2 4055 4052 3 1-35(2Met-O) 
3 4016 4015 1 3-36 
4 2106 2104 2 8-26 
5 2068 2070 -2 14-30 
6 2030 2028 2 1-19 
Figure 3.6 MALDI MS analysis of PP in the presence of RLM for 60mins at 37°C.  
(A) MALDI chromatogram; (B) table (Table 3.3) of identified peaks correlated with PP fragments of 
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3.2.1.5 Identification of RLM target sites on PP – mass spectrometry of 
HPLC fractions 
In an attempt to further characterise the breakdown products of PP after incubation with 
RLM, the digests were chromatographed by HPLC and discrete fractions (RT: 16-17m, 21-
22m, and 24-25m) collected and analysed by MALDI-TOF MS. Incubation of PP at 37C with 
reaction buffer alone for 60 minutes produced a single peak with an identical elution time 
(RT=25m) to that of freshly dissolved PP was detected. This single peak (RT=25m) was still 
observed when PP was incubated with RLM preparation for 60 minutes (Fig 3.7). This time 
point was chosen as there was still what appeared to be native PP present (represented by 
the peak at RT=25m) but also the appearance of extra peaks representing breakdown 
products by RLM incubation. RLM was also incubated in the absence of PP to serve as a 









Figure 3.7 HPLC chromatogram of PP incubated with RLM at 37oC for 60mins 
 
MALDI-TOF MS analysis of the RT=16-17m sample showed the presence of 4 major peaks 
corresponding to PP25-32/PP26-33 (equal mass), PP29-36, PP15-21, and PP6-11 (Table 3.4, 
Fig 3.8).  







2) RT=21-22m 3) RT=24-25m
RLM alone
PP + RLM 60mins





















1 1067 1066 1 
25-32 
26-33 
2 1051 1050 1 29-36 
3 839 840 -1 15-21 












  A 
C
  A 
Figure 3.8 PP in the presence of RLM for 60mins at 37°C. After HPLC separation, this fraction (RT=16-
17m) was collected and MALDI MS analysis performed. (A) MALDI chromatogram; (B) table (Table 3.4) 
of identified peaks correlated with PP fragments of known mass; (C) schematic diagram of PP fragments 
lined up against the corresponding PP sequence 
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The fragments detected in sample 1 are schematically shown in Fig 3.8(C). Two are 
fragments of the C-terminal (PP25-32/PP26-33 (equal mass) and PP29-36), while two other 
fragments are from the N-terminal). Fragments PP25-32 and PP26-33 are indistinguishable 
by MALDI-TOF MS therefore, either or both of these species could be the result of PP 
degradation by RLM. Both fragments are the result of cleavage on either side of Arg25, 
Arg26 and Arg33. Incidentally, PP29-36 is part of the PP molecule just after the classic PP-












Figure 3.9 Diagram of the PP sequence showing the tertiary structure with the stabilising bonds 
(represented by the dashed lines) between known residues. Pro2-Pro8 comprises the polyproline-
like helix and Glu15-Thr32 makes up the α-helix. Gly9-Pro14 encompasses the β-turn. The grey 
suares indicate fragments identified by MALDI-MS from RLM digests of PP.
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The second sample consisted of fractions RT=21-22m (Fig 3.7). Mass analysis of this sample 
showed the presence of 8 major peaks (Table 3.5, Fig 3.10).  
The fragments detected in sample 2 are shown in the schematic diagram Fig 3.10(C) Peak 1 
(PP8-31) corresponds to a mid-section of the PP molecule that encompasses the β-turn and 
α-helix (just after the polyproline-like helix). However this peak could also correspond to 
PP1-25(1Met-O) where Met17 is oxidised. Peak 2 (PP1-24) corresponds to the N-terminal 
region of PP after cleavage at the amino side of Arg25. This peak could also correspond to 
PP3-25(1Met-O) where Met17 is oxidised.  
Peak 3 (PP14-26) is a section just after the β-turn of the PP molecule (induced by Pro14) to 
Arg26. Peak 4 has an m/z value which is similar to both fragments PP1-13 and PP17-27. PP1-
13 consists of the N-terminal region of PP in which the polyproline-like helix exists, while 
PP17-27 is made up of the mid-section α-helix. 
Peak 5 has the highest signal intensity (Fig 3.10(A))  and also has two candidates: PP21-31 
and PP24-33. Both fragments are C-terminal sections and are just variations of from the 
middle to the end of the α-helix.  
Peaks 3-5 have the greatest signal intensity. Peaks 4 and 5 each have two possible 
candidates contributing to that signal whereas peak 3 has only one possible sequence 
(PP14-26). This could indicate PP14-26 as the main breakdown product of PP at RT=21-22m.  
Peak 6 is PP29-36, a C-terminal fragment that was also found in the sample 1 (RT=16-17m). 
This was not expected as it is unusual for a fragment with same molecular weight to elute in 
two different HPLC fractions at different retention times. However, it could be due to the 
high concentration of peptide that was needed to run on the HPLC to obtain adequate signal 
for subsequent MALDI-TOF MS.  
Peak 7 has two candidates: PP15-20 and PP17-23. Both peptide fragments occur at the 
beginning of the α-helix just after the β-turn. Finally peak 8 is a pentapeptide of PP19-23. 
With the frequency of fragments around position 23 of the PP molecule (both peak 7 and 8 
of sample 2), this could either be a secondary breakdown product (the case with the shorter 

















2739 -4 8-31 
2734 1 1-25(1Met-O) 
2 2567 
2562 5 1-24 
2566 1 3-25(1Met-O) 
3 1554 1549 5 14-26 
4 1351 
1343 8 1-13 
1358 -7 17-27 
5 1335 1336 
-1 21-31 
-1 24-33 
6 1052 1050 5 29-36 
7 768 769 
-1 15-20 
-1 17-23 


















  A 
C
  A 
Figure 3.10 MALDI MS analysis of fraction RT=21-22m of PP in the presence of RLM for 60mins at 37°C. 
(A) MALDI chromatogram; (B) table (Table 3.5) of identified peaks correlated with PP fragments of 
known mass; (C) schematic diagram of PP fragments lined up against the corresponding PP sequence 
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The final sample consisted of fractions RT=24-25m (fig 3.7) which contained the peak for 
native PP. Mass analysis of this sample showed the presence of 5 major peaks (Table 3.6, Fig 
3.11(A)) demonstrating that some PP breakdown products have equal RT as PP1-36 by HPLC 
separation. 
The fragments detected in sample 3 are shown in the schematic diagram Fig 3.11(C). Peak 1, 
with an m/z value of 4056 does not closely correspond to any peptide fragment of PP (> ±5 
Da). The nearest fragments from the MALDI spectra output correspond to PP2-36(desNH2) 
(Δ mass: -21 Da) and PP1-35 (Δ mass: +36 Da). However if the oxidation of methionine 
residues are taken into account, the fragment PP1-35(2Met-O) is a close match (a difference 
of -4Da) to peak 1. 
Peak 2 is identified as PP24-34. Peak 3 has a similar m/z value to 4 PP fragments: PP21-31, 
and PP24-33 (C-terminal fragments), and PP13-24 and PP10-21 (mid-section fragments). As 
peak 3 has the highest intensity, it is possible that all 4 fragments contribute to this signal 
and MALDI MS cannot resolve the difference between these different species of fragments. 
Peak 4 could correspond to PP10-20(1Met-O) which has a difference of 1Da, or PP5-16. 
Finally peak 5 only has a similar molecular weight to that of PP18-27 which comprises the α-


















1 4056 4052 4 1-35(2MetO) 





1337 0 13-24 
1338 -1 10-21 
4 1284 
1283 1 10-20(1MetO) 
1287 -3 5-16 













Figure 3.11 MALDI MS analysis of fraction RT=24-25m of PP in the presence of RLM for 60mins at 37°C. 
(A) MALDI chromatogram; (B) table (Table 3.6) of identified peaks correlated with PP fragments of 







3.2.2 CHARACTERISATION OF PP DEGRADATION BY INDIVIDUAL RECOMBINANT 
ENZYMES 
3.2.2.1 Investigations into the breakdown of PP by DPPIV 
3.2.2.1.1 Breakdown of PP by DPPIV 
Whole intact PP eluted at 21.8 min (RT=21.8m) on the 32-35% AcN over 45 min gradient 
used to examine DPPIV degradation. Following the incubation of PP at 37°C with DPPIV 
buffer alone for 120 minutes, a single peak with a retention time identical to that of freshly 
dissolved PP was detected (Fig 3.12). A peak at RT=21.8m was also observed when PP was 
incubated in the presence of DPPIV, and no secondary peaks were observed. There was no 
change in peak area between PP incubated in the presence or absence of DPPIV therefore 

















Figure 3.12 HPLC analysis of PP with 10, 20 and 50mU DPPIV for 2h at 37°C run on a shallow 
acetonitrile/water/0.05% TFA gradient of 31-35% acetonitrile over 45mins. 
  














MALDI-ToF analysis of PP incubated with DPPIV indicated that the peptide eluting at the 
same position as native PP was not intact. Following incubation of PP alone at 37°C for 
120mins, the single peak observed had a mass to charge ratio of 4188 m/z (Fig 3.13(A)) 
consistent with the molecular mass of full length native PP1-36 within the error of ± 5 Da. 
After a 120mins incubation of PP with 10mU DPPIV, the single peak detected by HPLC had a 



















3.2.2.1.2 Effect of PP and DPPIV fragment PP3-36 on acute food intake in mice 
PP and PP3-36 at 50nmol/kg both significantly reduced food intake in mice at 0-1 and 1-2h 
post injection (0-1h: saline: 0.71 ± 0.07g vs. PP: 0.19 ± 0.05g p < 0.01; vs. PP3-36: 0.41 ± 
0.04g p < 0.05.   1-2h: p < 0.01 vs. saline for both peptides). Both peptides additionally 
reduced food intake during the 2-4h time period although this did not reach significance. 
Only PP significantly reduced food intake in the 4-8h interval (p < 0.01 compared with saline) 
(Fig 3.14). Over the entire 8h period, both PP and PP3-36 significantly reduced food intake 
(saline: 2.92 ± 0.29g vs. PP: 0.93 ± 0.10g p < 0.01; vs. PP3-36: 1.71 ± 0.29g p < 0.05). There 
were no significant changes in food intake at any other time point between PP and PP3-36 





















Figure 3.14 The effect of SC administration of PP and PP3-36 (50nmol/kg) on food intake in C57/BL6 
mice fasted overnight A) 0-1, 1-2, 2-4, 4-8 hour intervals post injection, B) 0-8 hours post injection. 
PP and PP3-36 compared to saline (*) using oneway ANOVA with Bonferroni post hoc test *p≤0.05, 


































































3.2.2.1.3 Effect of N-terminal modifications on DPPIV-mediated degradation 
DPPIV-resistant analogues of PP were designed through N-terminal extension (PP-Ala0) and 
N-terminal truncation (PP2-36) to eliminate the DPPIV target sequence of proline at position 
2 of the molecule.  After a 120 minute incubation of each analogue with 10mU DPPIV, the 
single peaks detected (as determined by MALDI-TOF) had a mass to charge ratio of 4255 
m/z which is consistent with the theoretical mass of PP-Ala0 (Fig 3.15(A)) and 4112 m/z (Fig 
3.15(B)) which is consistent with the theoretical mass of PP2-36. These mass to charge ratios 















Figure 3.15 MALDI-TOF MS analysis of (A) PP-Ala0 + 10mU DPP4, and (B) PP2-36 + 10mU 





3.2.2.1.4 Effect of N-terminal modifications on Y4 receptor affinity  
PP bound to the hY4r with an IC50 of 0.26 ± 0.04nM. Both N-terminal modifications of PP 
had similar binding affinities which were approximately 1.3-fold worse (PP-Ala0 IC50: 0.35 ± 












Figure 3.16 Binding affinities of PP and analogues to human Y4r expressed as IC50 values calculated 
from the mean ± SEM of 3-5 separate experiments  







PP IC50: 0.26  0.04nM
PP-Ala0 IC50: 0.35  0.05nM
















3.2.2.1.5 Effect of N-terminal modifications on acute food intake in mice  
Whilst a single SC injection of PP at 150nmol/kg did not  result in a significant reduction of 
food intake at any time point, PP2-36 at the same dose, significantly reduced food intake at 
2-4h post injection when compared with saline control (saline: 0.57 ± 0.05g vs. PP2-36: 0.19 
± 0.03g, at 2-4h p < 0.001).  
PP2-36 significantly reduces food intake compared to the saline control over a 24h period 
(saline: 6.16 ± 0.22g vs. PP2-36: 4.98 ± 0.22g, at 0-24h p < 0.05). There were no significant 













Figure 3.17 The effect of SC administration of PP and PP2-36 (150nmol/kg) on food intake in 
C57/BL6 mice fasted overnight A) 0-1, 1-2, 2-4 hour intervals post injection, B) 0-24 hours post 
injection. PP and PP2-36 compared to saline (*) using oneway ANOVA with Dunnett’s post hoc test 




























































PP and PP-Ala0 at 300nmol/kg both significantly reduced food intake in mice at 0-1 and 1-2h 
post injection (p < 0.001 vs. saline for both peptides). Both peptides additionally reduced 
food intake to a significant degree during the 2-4h time period (saline: 0.61 ± 0.05g vs. PP: 
0.41 ± 0.04g p < 0.05; vs. PP-Ala0: 0.36 ± 0.06g p < 0.01). Only PP-Ala0 significantly reduced 
food intake over the whole 0-24h period (p < 0.01 compared with saline) (Fig 3.18). There 
were no significant changes in food intake at any other time point between PP and PP-Ala0 
























Figure 3.18 The effect of SC administration of PP and PP-Ala0 (300nmol/kg) on food intake in 
C57/BL6 mice fasted overnight A) 0-1, 1-2, 2-4 hour intervals post injection, B) 0-24 hours post 
injection. PP and PP-Ala0 compared to saline (*) using oneway ANOVA with Dunnett’s post hoc test 





























































3.2.2.2 Investigations into the breakdown of PP by Trypsin 
3.2.2.2.1 Breakdown of PP by trypsin 
 Trypsin is a highly active and specific protease which cleaves the C-terminal to lysine and 
arginine residues of a protein. The sequence below highlights the predicted digest sites of 
PP: 
 
Following the incubation of PP at 37°C with trypsin buffer alone for 15 minutes, a single 
peak with a retention time identical to that of freshly dissolved PP was detected (Fig 3.19) 
by HPLC when run on an AcN of 15-60% over 35 minutes. The peak at retention time 24 
minutes (RT=24m) was not observed when PP was incubated with 0.1mU of trypsin for 15 
minutes. Instead, two major peaks were observed at the earlier retention times of 14 and 
18minutes (called PPF1 and PPF2 respectively (Fig 3.19). These peaks were collected and 














Figure 3.19 HPLC analysis of PP with 0.1mU trypsin for 15mins at 37°C run on an 
acetonitrile/water/0.05% TFA gradient of 15-60% acetonitrile over 35mins. 
 
















MS analysis of PPF1 identified a peak with a mass to charge ratio of (1) 1642 and (2) 1165 
m/z (Fig 3.20). A mass of 1462 is consistent with the molecular mass of the fragment PP25-
36. Several potential fragments of PP: 25-36, 27-35, 26-34, and 28-36 have a molecular mass 
of 1165 ± 5 Da (Table 3.7). The presence of trypsin-sensitive Arg residues at position 25, 26, 











Figure 3.20 MALDI MS analysis of fraction PPF1 of PP in the presence of trypsin for 15mins at 37°C 



















1166 1 16-25 
135 
 
MS analysis of PPF2 showed four peaks with mass to charge ratio of (1) 2875, (2) 1958, (3) 
1481 and (4) 1165 m/z (Fig 3.21). These peaks were consistent with the molecular mass of 
fragments PP1-26 for peak 1, PP2-19 and PP16-31 for peak 2, PP26-36 for peak 3, and 
fragments PP16-25, 26-34, 27-35, and 28-36 for peak 4. All candidate fragments were within 




Figure 3.21 MALDI MS analysis of fraction PPF2 of PP in the presence of trypsin for 15mins at 37°C 
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3.2.2.2.2 Effect of modifications at trypsin-target sites on Y4 receptor affinity 
PP bound to the hY4r with an IC50 of 0.23 ± 0.03nM and PP-Lys25 had an IC50 which was 
approximately 1.5-fold worse (PP-Lys25 IC50: 0.36 ± 0.03nM) than that of the endogenous 
ligand (Table 3.9). However, substituting the native Arg25 with Ala25 produced an analogue 
which bound 3-fold worse at the hY4r. 
Similar substitutions at position 26 with positive amino acids (Lys26 and His26) bound with 
affinities 2-fold worse to the hY4r (PP-Lys26 IC50: 0.47 ± 0.04nM and PP-His26 IC50: 0.49 ± 
0.01nM) as did the hydrophobic substitution of PP-Ala26 (IC50: 0.45 ± 0.03nM) (Table 3.9).  
Double substitutions at position 25-26 from the native Arg-Arg to Gln25,26 or His25,26 
decrease binding affinity 5 fold (PP-Gln25,26 IC50: 1.10 ± 0.01nM and PP-His25,26 IC50: 1.21 
± 0.14nM). 
Substitutions at position 33 from native Arg to a similarly positive amino acid Lys33 
decreased the binding affinity 2-fold however, an Ala33 substitution, decreased binding 
affinity 38-times (PP-Lys33 IC50: 0.42 ± 0.09nM and PP-Ala33 IC50: 8.80 ± 0.70nM). 
Finally, substitutions at position 35 with either Lys35 or His35 only had a 2.5-3-fold decrease 
in binding affinity to the hY4r (PP-Lys35 IC50: 0.57 ± 0.01nM, PP-His35 IC50: 0.72 ± 0.17nM), 
while an Ala35 substitution has a 10-fold decrease in binding affinity. Combination 
substitutions at positions 26 and 35 decreased binding affinity by 28.5-fold (PP-Ala26,His35 













Table 3.9 Binding affinities of PP and analogues to human Y4r expressed as IC50 values calculated 
from the mean ± SEM of 3-5 separate experiments. Affinity ratios were then used to demonstrate 
relative affinity to the Y4r compared to native PP. 
 
3.2.2.2.3 Breakdown of PP analogues by trypsin 
As demonstrated in section 3.4.1, PP can be degraded by trypsin in an in vitro setting. 
Analogues with substitutions at the residues known to be possible cleavage points by 
trypsin were made. Incubation of PP-Lys25 (Fig 3.22(B)) and PP-Lys26 (Fig 3.22(C)) with 
0.1mU of trypsin for 15 minutes resulted in the complete degradation of the peptide into 
two detectable fragments as determined by HPLC. However, substitution of both position 25 
and 26 (as with PP-Gln25,26) results in 100% retention of the original peak of the compound 








 IC50 (PP) 
PP 0.23  0.03 1 
Lys25 0.36  0.03 1.5 
Ala25 0.69  0.02 3 
Lys26 0.47  0.04 2 
His26 0.49  0.01 2 
Ala26 0.45  0.03 2 
Gln25,26 1.10  0.01 5 
His25,26 1.21  0.14 5 
Lys33 0.42  0.09 2 
Ala33 8.80  0.70 38 
Lys35 0.57 0.01 2.5 
His35 0.72 0.17 3 
Ala35 2.20 0.19 10 












Figure 3.22 HPLC analysis of (A) PP, (B) PP-Lys25, (C) PP-Lys26 and (D) PP-Gln25,26 with 0.1mU 
trypsin for 15mins at 37°C run on an acetonitrile/water/0.05% TFA gradient of 15-60% acetonitrile 
over 35mins. 
 





















3.2.2.2.4 Effect of modifications at trypsin-target sites on acute food intake in mice 
A single SC injection of PP at 150nmol/kg did not significantly reduce food intake at 0-1 and 
1-2h time points, however it did reduce food intake significantly at 2-4 and 4-8h post 
injection when compared with saline control (saline: 0.51 ± 0.05g vs. PP: 0.21 ± 0.05g, at 2-
4h p < 0.01 and saline: 0.77 ± 0.04g vs. PP: 0.50 ± 0.02g, at 4-8h p < 0.05). PP-Lys26 at the 
same dose, significantly reduced food intake at 0-1 and 2-4h post injection when compared 
with saline control (saline: 0.67 ± 0.05g vs. PP-Lys26: 0.32 ± 0.11g, at 0-1h p < 0.001; saline: 
0.51 ± 0.05g vs. PP-Lys26: 0.31 ± 0.03g, at 2-4h p < 0.05). PP-Lys25, also at the same dose, 
only significantly reduced food intake at the 0-1h time point (saline: 0.67 ± 0.05g vs. PP-
Lys25: 0.42 ± 0.10g, at 0-1h p < 0.05). 
Overall, there were no significant differences in food intake over a 24h period compared to 











Figure 3.23 The effect of SC administration of PP, PP-Lys25 and PP-Lys26 (150nmol/kg) on food 
intake in C57BL/6 mice fasted overnight. (A) Food intake at 0-1, 1-2, 2-4, 4-8 hour intervals post-
injection, (B) 0-24 hours post-injection. PP, PP-Lys25 and PP-Lys26 compared to saline (*) using 





















































As the receptor affinity of analogues with substitutions at position 25 or 26 decreased by 2-3 
fold (with Ala substitutions in particular), acute feeding studies using doses double that of 
PP were conducted.  A single SC injection of PP at 150nmol/kg caused a significant reduction 
of food intake at the 0-1 and 1-2h time point when compared with saline control (saline: 
1.06 ± 0.04g vs. PP: 0.85 ± 0.08g, at 0-1h p < 0.05; saline: 0.86 ± 0.04g vs. PP: 0.11 ± 0.06g, at 
1-2h p < 0.001). Both analogues at 300nmol/kg also significantly reduced food intake at 0-1 
and 1-2h time points when compared with the saline control group; however PP-Ala26 
reduced food intake to a greater degree in the 1-2h time point compared with PP-Ala25 (PP-
Ala26: 0.18 ± 0.05g vs. PP-Ala25: 0.50 ± 0.11g, at 1-2h p < 0.05) 
Over the 0-24h time period, only PP and PP-Ala26 reduced food intake significantly when 
compared to the saline control group. PP-Ala25 did not have a significant change in food 
intake compared to any of the groups, at any of the time intervals measured except when 











Figure 3.24 The effect of SC administration of PP (150nmol/kg), PP-Ala25 and PP-Ala26 
(300nmol/kg) on food intake in C57BL/6 mice fasted overnight. (A) Food intake at 0-1 and 1-2 hour 
intervals, (B) 0-24 hours post-injection. PP, PP-Ala25 and PP-Ala26 compared to saline (*) using one-










































































To assess the effect of the type substitution at position 26, PP-His26 was tested against PP 
but again at double the dose as the receptor binding affinity was decreased by 2-3 fold.  A 
single SC injection of PP at 150nmol/kg caused a significant reduction of food intake at the 
0-1 and 1-2h time point when compared with saline control (saline: 0.84 ± 0.06g vs. PP: 0.53 
± 0.04g, at 0-1h p < 0.001; saline: 0.37 ± 0.07g vs. PP: 0.05 ± 0.04g, at 1-2h p < 0.001). PP-
His26 at 300nmol/kg also significantly reduced food intake at 0-1 and 1-2h time points when 
compared with the saline control group (saline: 0.84 ± 0.06g vs. PP-His26: 0.64 ± 0.05g, at 0-
1h p < 0.05; saline: 0.37 ± 0.07g vs. PP-His26: 0.04 ± 0.04g, at 1-2h p < 0.001). 
Over the 0-24h time period, both PP and PP-His26 reduced food intake significantly when 
compared to the saline control group (saline: 5.78 ± 0.18g vs. PP: 5.25 ± 0.17g and PP-His26: 











Figure 3.25 The effect of SC administration of PP (150nmol/kg) and PP-His26 (300nmol/kg) on food 
intake in C57BL/6 mice fasted overnight. (A) Food intake at 0-1 and 1-2 hour intervals, (B) 0-24 hours 
post-injection. PP and PP-His26 compared to saline (*) using one-way ANOVA with Bonferroni’s post 




















































To assess joint substitutions at position 25-26, PP-His25,26 was tested against PP. The effect 
of substitution at position 35 was also assessed. A single SC injection of PP at 300nmol/kg 
caused a significant reduction of food intake at 1-2h time point when compared with saline 
control (saline: 0.46 ± 0.07g vs. PP: 0.09 ± 0.03g, at 1-2h p < 0.01). PP-His25,26 at 
300nmol/kg only significantly reduced food intake at the 0-1h time point when compared 
with the saline control group (saline: 1.14 ± 0.08g vs. PP-his25,26: 0.82 ± 0.06g, at 0-1h p < 
0.01) (Fig 3.26(A))  
Over the 0-24h time period, only PP reduced food intake significantly when compared to the 
saline control group (saline: 6.01 ± 0.16g vs. PP: 5.36 ± 0.16g at 0-24h p < 0.05) (Fig 3.26(B)). 











Figure 3.26 The effect of SC administration of PP, PP-His35, and PP-His25,26 (300nmol/kg) on food 
intake in C57BL/6 mice fasted overnight. (A) Food intake at 0-1 and 1-2 hour intervals, (B) 0-24 hours 
post-injection. PP, PP-His35, and PP-His25,26 compared to saline (*) using one-way ANOVA with 





















































To assess the effect of the type of joint substitution at position 25-26, PP-Gln25,26 was 
tested against PP.  Alanine substitution at position 35 was also assessed. PP at 150nmol/kg 
did not cause a significant reduction of food intake at any of the time intervals measured. 
PP-Gln25,26 at 150nmol/kg only significantly reduced food intake at the 0-1h time point 
when compared with the saline control group (saline: 0.90 ± 0.09g vs. PP-Gln25,26: 0.52 ± 
0.05g, at 0-1h p < 0.01). 
Over the 0-24h time period, none of the peptides tested reduced food intake significantly 
when compared to the saline control group (Fig 3.27) 
PP-Ala35 at 600nmol/kg (4-times higher dose than PP), did not significantly reduce food 
intake at any of the time intervals measured. However, it did cause a significant increase in 
food intake at the 1-2h time point when compared with the saline control group (saline: 











Figure 3.27 The effect of SC administration of PP and PP-Gln25,26 (150nmol/kg), and PP-Ala35 
(600nmol/kg) on food intake in C57BL/6 mice fasted overnight. (A) Food intake at 0-1 and 1-2 hour 
intervals, (B) 0-24 hours post-injection. PP, PP-Gln25,26, and PP-His35 compared to saline (*) using 



















































To assess the effect of the type of substitution at position 35, PP-Lys35 was tested against 
PP.  Alanine substitution at position 33 was also assessed, as was the effect of a similarly 
charged amino acid substitution (PP-Lys33). PP at 150nmol/kg caused a significant reduction 
of food intake at 0-1 and 2-4h time points (saline: 0.91 ± 0.08g vs. PP: 0.67 ± 0.05g, at 0-1h p 
< 0.05; saline: 0.65 ± 0.07g vs. PP: 0.24 ± 0.04g, at 2-4h p < 0.001). All PP analogues tested at 
300nmol/kg significantly reduced food intake at the 0-1h time point when compared with 
the saline control group (saline: 0.91 ± 0.08g vs. PP-Ala33: 0.55 ± 0.05g; PP-Lys35: 0.55 ± 
0.05g; PP-Lys33: 0.54 ± 0.05g at 0-1h p < 0.001). At the 2-4h time point, the only analogue 
that still significantly reduced food intake was PP-Ala33 (saline: 0.65 ± 0.07g vs. PP-Ala33: 
0.39 ± 0.06g at 2-4h p < 0.05). As with PP-Ala35, PP-Lys35 also significantly increased food 
intake at the 1-2h time point when compared with the saline control group (saline: 0.09 ± 
0.03g vs. PP-Lys35: 0.21 ± 0.05g, at 1-2h p < 0.05) (Fig 3.28(A)). 
Over the 0-24h time period, none of the peptides tested significantly reduced, or increased, 










Figure 3.28 The effect of SC administration of PP (150nmol/kg), PP-Ala33, PP-Lys35, and PP-Lys33 
(300nmol/kg) on food intake in C57BL/6 mice fasted overnight. (A) Food intake at 0-1, 1-2, 2-4 hour 
intervals, (B) 0-24 hours post-injection. PP, PP-Ala33, PP-Lys35, and PP-Lys33 compared to saline (*) 























































3.2.2.3 Investigations into the breakdown of PP by neprilysin (NEP) 
3.2.2.3.1 Breakdown of PP by NEP 
Neprilysin has many targets but structural studies show that it preferentially cleaves on the 
amino side of hydrophobic amino acid residues from internal sites of peptides. The 
sequence below highlights the hydrophobic amino acids of PP: 
 
Freshly reconstituted PP peptide produced a single peak with a retention time of 28mins 
(RT=28m) when analysed by HPLC. Incubation of PP at 37°C with NEP buffer alone for 120 
minutes also produced a single peak only. When PP was incubated with the NEP enzyme for 
increasing amounts of time between 15 and 120 minutes (Fig 3.29), there is a reduction in 
size of the peak at RT=28m as well as the appearance of additional peaks with earlier 
retention times. 
By comparing the area of the peak at RT=28m from a control sample of PP under the same 
conditions but not containing NEP enzyme, PP incubated with NEP for 15 minutes was 
broken down by 4%. At 45 minutes this had increased to 20% breakdown, and at 60 minutes 
to 25% (Fig 3.29). By 120 minutes, there was approximately 47 ± 3.5% degradation of PP. 
In addition to the peak at RT=28m, five major UV-absorbing peaks could be observed 
following incubation of PP with 200ng of NEP for 120 minutes. These fractions had retention 
































Figure 3.29 HPLC analysis of PP with 200ng of NEP for 15 (black), 45 (red), 60 (blue), and 120mins 




A complete digest of PP by NEP was analysed by MALDI-MS (Fig 3.30(A)) where just 1 
fragment was detected (Table 3.10) at both 30m and 120m incubations. From the analysis of 
whole digest, position 3 and 22 appear to be a common target sites as demonstrated by the 
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Figure 3.30 MALDI MS analysis of PP in the presence of NEP for (A) 30 and 120mins at 37°C.   
(B) table (Table 3.10) of identified peaks correlated with PP fragments of known mass;  
(C) schematic diagram of PP fragments lined up against the corresponding PP sequence 
148 
 
When individual fractions of PP digests by NEP were analysed by MALDI-MS, fraction RT=12-
15m (Fig 3.29) generated 2 major peaks: PP5-10 (647 Da) and PP12-26 (1721 Da) or PP7-22 
(1727 Da). MALDI-MS analysis of fraction RT=17-19m (Fig 3.29) generated 3 major peaks: 
both the fragments present in RT=12-15m with the addition of fragment PP1-12 (1242 Da). 
Based on the predictions of target sites in the PP molecule and the fragments identified 
from the NEP digest of PP, position 6 could be a potential NEP substrate site as 
demonstrated by the appearance of fragment 5-10. Other susceptible sites of NEP 
degradation on the PP molecule are positions 7, 12, 22, and 27. These are in addition to 
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Figure 3.31 MALDI MS analysis of RT=17-19m in the presence of NEP for (A) 120mins at 37°C.   
(B) table (Table 3.11) of identified peaks correlated with PP fragments of known mass;  
(C) schematic diagram of PP fragments lined up against the corresponding PP sequence 
150 
 
3.2.2.3.2 Effect of NEP inhibition on acute food intake in mice 
At a dose of 150nmol/kg, PP did not significantly reduced of food intake at any time point 
measured. Phosphoramidon alone also did not cause a significant reduction of food intake 
at any of the time intervals measured.  
PP in combination with phosphoramidon significantly reduced food intake from 8-48h 
period when compared to saline (saline 24h: 3.47 ± 0.22g vs. PP+phosphoramidon 24h: 2.60 
± 0.18g, p>0.01). PP + phosphoramidon significantly decreased food intake compared to PP 
alone at 48h post-injection (PP 48h: 6.52 ± 0.14g vs. PP+phosphoramidon 48h: 5.63 ± 0.21g, 












Figure 3.32 The effect of SC administration of PP (150nmol/kg), phosphoramidon (5mg/kg), and PP 
+ phosphoradmidon on food intake in C57BL/6 mice fasted overnight. Cumulative food intake shown 
up to 48 hours post-injection. Significance analysed using two-way ANOVA with Bonferroni’s post 
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3.2.2.3.3 Pharmacokinetics of PP in mice  
The Cmax observed following a single SC injection of 1000nmol/kg PP resulted in a Cmax of 
36769 ± 7861pmol/L at 30minutes post injection (Fig 3.33). Plasma levels of PP decreased by 
23% from Cmax by 1h (28169 ± 5285pmol/L). PP plasma levels were significantly reduced at 
the 2, 4 and 8h compared to Cmax (2h: 7477 ± 5270pmol/L; 4h: 6528 ± 5200pmol/L; 8h: 1513 
± 654pmol/L; 80-96% reduction from Cmax). Plasma levels of PP were also significantly 
reduced at the 2, 4 and 8h compared to levels at 1h (respectively 73, 77 and 95% reduction 














Figure 3.33 Pharmacokinetic profile of a single subcutaneous injection of PP at 1000nmol/kg to 
male C57BL/6 mice. Basal plasma samples were collected from naïve mice. Latter plasma samples 
were collected at 30minutes, 1, 2 4 and 8h post injection (n=11). Data are shown as mean plasma 
levels of PP ± SEM as determined by RIA. LLOD: 40pmol/L. Significance analysed using one-way 





























* significance vs basal
$ significance vs PP plasma level at 30mins






























3.2.2.3.4 Effect of phosphoramidon on plasma levels of PP in mice  
The NEP inhibitor, phosphoramidon, was administered at 3 different doses as a single IP 
injection 15minutes prior to SC administration of PP. Following the SC injection of 
150nmol/kg of PP, plasma levels were measured at 45 and 90minues post-injection. Mice 
given PP alone (no phosphoramidon) were given an equal volume IP injection of vehicle 15 
minutes prior to peptide administration.  
Levels of PP after 45mins (Fig 3.34(A)) did not differ significantly between PP administered 
alone (25480 ± 2053pmol/L) and PP in combination with any dose of phosphoramidon 
(7mg/kg: 30233 ± 4752pmol/L; 20mg/kg: 24075 ± 1564pmol/L; 60mg/kg: 27140 ± 
2993pmol/L). After 90mins (Fig 3.34(B)), plasma levels of PP were significantly higher when 
given in combination with any dose of phosphoramidon compared to PP given alone (PP no 
phosphoramidon: 1920 ± 134pmol/L vs PP + phosphoramidon at 7mg/kg: 5460 ± 
807pmol/L; 20mg/kg: 5297 ± 461pmol/L; 60mg/kg: 5525 ± 348pmol/L). Across all doses of 
phosphoramidon, plasma levels of PP at 90mins were significantly lower compared to PP 






























Figure 3.34 Plasma levels of PP following a single subcutaneous injection of PP at 150nmol/kg to 
male C57BL/6 mice in combination with a single IP injection of phosphoramidon at 7mg/kg, 20mg/kg 
and 60mg/kg. Blood samples were collected at (A) 45 and (B) 90 minutes post-injection (n=2-4). Data 
is shown collectively in graph (C). Data are shown as mean plasma levels of PP ± SEM as determined 
by RIA. LLOD: 70pmol/L. Significance analysed using one-way ANOVA (graphs (A) and (B)) and two-
way ANOVA (graph (C)), both with Bonferroni’s post hoc test *p≤0.05, **p≤0.01, or *** p≤ 0.001 
  


























































3.2.3 EFFECT OF PP MODIFICATIONS ON RBA, NEP DIGESTS, ACUTE FEEDING AND 
PHARMACOKINETICS 
Susceptibility of PP analogues to degradation by NEP was measured using the method 
previously described (section 2.8.3).  Samples of each PP analogue in the presence and 
absence of enzyme was analysed by HPLC after incubation at 37°C for 1h. Peptide peak 
areas were measured and percentage degradation calculated as:  
 
            100 -  peak area + NEP        x 100% 
 peak area no NEP 
 
Initially, PP analogues with single substitutions were screened against binding affinity to the 
Y4r, NEP degradation, and in vivo efficacy (Table 3.12). N-terminal modifications (which 
included N-terminal extensions, truncation, and dimerisation) generally decreased Y4r 
affinity by 1.2-1.7 fold. Extension of His0 increased Y4r affinity the most (IC50 PP-His0 
0.16nM vs 0.23nM PP) and the Cys0-dimer of PP reduced Y4r affinity the greatest (IC50 
0.58nM). The N-terminal modification that reduced degradation by NEP the most was His0 
and Cys0-dimer (5% and 0% degradation respectively), followed closely by Pro0, Thr0, Asp0, 
Glu0, and the N-terminal truncation Des-Ala1 (Table 3.12). PP analogues Ala0, Ala-1,0, Gly0, 
and Lys0 did not greatly alter PP susceptibility to NEP degradation.  
In vivo bioefficacy as measured by acute feeding studies was calculated as below for each 
time point, where the time points measured are 0-4h, 4-8h, and 8-24h: 
 Ratio of food intake of Food intake (PP) 
analogue compared to PP  Food intake (analogue) 
An average of the ratios from all 3 time points are then expressed as the mean in vivo 





In vivo bioefficacy in mice for PP analogues with N-terminal modifications was generally 
well-maintained but was unfavourable with His0 and Lys0 N-terminal extensions 
(respectively 0.5- and 0.1-times the bioefficacy of native PP). Pro0 extension increased 











Table 3.12 Position 0 (N-terminal) modifications of PP and the effects on hY4r affinity compared to 
native PP which has a ratio of 1. Ratios <1 bind better to the Y4r relative to native PP and ratios >1 
bind have lower affinity. The potency ratio is the effect on the reduction of food intake by native PP 
normalised to 1. Ratios <1 have a weaker effect on the reduction of food intake compared to native 
PP over a 24h period while ratios >1 have a stronger effect on the reduction of food intake which is 
proportional to the number given (e.g. ratio of 3 is a reduction in food intake over 24h which is 3-










Ratio of bioefficacy  
(as measured by food intake) 
compared to PP over 24h 
Native PP 1 47 1 
    
Des-Ala1 1.4 23 1.4 
Ala0 1.6 30 1.0 
Ala-1,0 1.2 33 1.0 
Asp0 1.6 22 1.2 
Gly0 1 33 1.5 
Glu0 1.5 23 1.2 
His0 0.7 5 0.5 
Lys0 0.9 43 0.1 
Pro0 0.9 13 2.0 
Thr0 1.7 19 1.0 
Cys0 (dimer) 2.5 0 3.0 
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Another example to demonstrate that protecting against DPPIV prolongs bioefficacy in 
acute feeding studies, PP at 300nmol/kg and PP-Pro0 at 150nmol/kg both significantly 
reduced food intake in mice at 0-1, 1-2, 2-4, and 4-8h post injection (p ≤ 0.05 vs. saline for 
both peptides). Only PP-Cys0 dimer at 100nmol/kg significantly reduced food intake over 













Figure 3.35 The effect of SC administration of PP (300nmol/kg), PP-Pro0 (150nmol/kg) and PP-Cys0 
dimer (100nmol/kg) on food intake in C57BL/6 mice fasted overnight A) 0-1, 1-2, 2-4 and 4-8 hour 
intervals post injection, B) 0-24 hours post injection. PP, PP-Pro0, and PP-Cys0 dimer were compared 
































































Single modifications at position 30 were also screened against Y4r affinity, NEP degradation, 
and in vivo efficacy (Table 3.13). Changes at position 30 were generally well tolerated at Y4r 
affinity with Lys30 being the most favourable substitution and Glu30 and Leu30 being the 
worst (1.6- and 1.8-fold worse than PP respectively). Overall, changes at position 30 alone 
did not alter susceptibility to degradation by NEP with the exception of Ile30 which was fully 
NEP-resistant (0% degradation). In vivo bioefficacy was disrupted the most by the Leu30 
substitution (less than half as effective as native PP at equal doses). Conversely, bioefficacy 







Ratio of bioefficacy  
(as measured by food intake) 
compared to PP over 24h 
Native PP 1 47 1 
    
Asn30 1.1 32 3.0 
Cys30 1 40 2.0 
Glu30 1.6 20 1.0 
Ile30 1 0 4.0 
Leu30 1.8 43 0.4 
Nleu30 1.2 39 1.1 
Lys30 0.7 30 3.0 
Thr30 1.3 53 1.0 
 
Table 3.13 The effect of position 30 (C-terminal) modifications on Y4r affinity, susceptibility to 





Combined substitutions at position 0 and 30 were investigated for their susceptibility to NEP 
degradation and effect on food intake (Table 3.14). The combination substitutions were 
limited and only a few were tested. Affinity at the Y4r was mostly improved by these dual 
modifications with the best combination being Pro0, Lys30 which had 2.5-fold greater 








Table 3.14 The effect of combined modifications at positions 0 and 30 on Y4r affinity, susceptibility 








Ratio of bioefficacy  
(as measured by food intake) 
compared to PP over 24h 
Native PP 1 47 1 
    
Ala0, Thr30 0.7 37 0.7 
Asp0, Lys30 1 37 3.0 
Lys0, Glu30 1 0 1.9 
Pro0, Leu30 0.7 6 1.4 
Pro0, Lys30 0.4 17 1.9 
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Single mid-section substitutions were investigated for their susceptibility to degradation by 
NEP, affinity at the Y4r and effect on food intake (Table 3.15). Substitutions at position 6 and 
19 generally improved affinity at the Y4r.  Position 6 substitutions did not affect bioactivity, 
but position 19 substitutions reduced bioactivity. Other single mid-section changes were 
well tolerated for affinity to the Y4r with the exception of the substitution of Ala33 which 












Table 3.15 The effect of single mid-section modifications on Y4r affinity, susceptibility to degradation 











Ratio of bioefficacy 
(as measured by food intake) 
compared to PP over 24h 
Native PP 1 47 1 
    
Phe6 0.7 62 1.4 
Glu6 0.7 28 1.4 
Tyr11 1.1 65 1.0 
Lys12 2.1 88 0.7 
His14 1.3 56 0.2 
Arg17 1.2 49 0.5 
Leu17 2.4 13 1.2 
Arg19 0.7 20 0.7 
His19 0.5 72 0.6 
Met26 1.7 56 1.0 
His26 2.1 52 1.0 
Ala33 38.3 45 0.1 
Gln34 0.7 32 0.6 
Lys35 2.5 44 0.3 
HArg35 0.7 48 0.1 
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Global modifications incorporating changes at positions 0, 6, 11, 15, 16, 17, 18, 19, 23, 25, 
26, 30 were investigated for their susceptibility to degradation by NEP, affinity at the Y4r 
and effect on food intake.  
Combined substitutions at positions 6, 19, 23 and 30 generally improved affinity at the Y4r 
(Table 3.16). However, these changes only modestly decrease NEP degradation by 2-fold at 
the most when compared to native PP. The PP analogues that exhibit the greatest decreases 
in NEP degradation (PP-4 and PP-6) are also accompanied by the biggest improvement in 
bioefficacy compared to native PP. PP-4 and PP-6 also decreased food intake compared to 
saline by 24% and 12% respectively. 
Table 3.16 The effect of combined substitutions at positions 6, 19, 23 and 30 (analogues PP-1 to PP-
6) on Y4r affinity, susceptibility to degradation by NEP and in vivo bioefficacy.  
 
Substitutions at positions 6, 19, 23 and 30 (Table 3.17) were investigated in combination 
with changes that protect against DPPIV degradation. As previously seen, these 
modifications do not change affinity at the Y4r (section 3.2.2.2.3) and mildly improve 
bioefficacy over a 24h period (section 3.2.2.2.4). The best N-terminal extended analogues 
(Table 3.12) and an analogue with an N-terminal truncation (Des-Ala1 = DesA1) were then 
taken and modified to include substitutions at positions 6, 19, 23 and 30 (Table 3.17). All of 
these combined changes improve affinity at the Y4r by 2.5-10 times. PP analgoues PP-9 to 
PP-17 decrease degradation by NEP by 23% at least, when compared to native PP.  
Despite the reduced susceptibility of all these analogues to degradation by NEP, they vary in 
their efficacy at reducing food intake (Table 3.17). Analogues PP-9 to PP-13 have only 








LTX (970-977) Glu Ile Lys Gly 0
Ex4 (17-24) Glu Ala Arg Glu 0
PP-1 Phe 0.7 62 1.4
PP-2 Glu 0.7 28 1.4
PP-3 Arg 0.7 20 0.7
PP-4 Lys 0.7 30 3
PP-5 Phe Arg Glu 0.5 23 1
PP-6 Glu Arg Glu Lys 0.3 18 3.5
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modest improvements in the bioefficacy over 24h compared to native PP. This set of 
analogues have either Pro0 or Gly0, and Gly0 has a slightly weaker effect on protecting 
against NEP degradation and no improvement on bioefficacy. Analogues PP-9 to PP-13 also 
have either Ser6 or Thr6 where Thr6 has the greater improvement on bioefficacy (up to 2.5 
times more effective than native PP at reducing food intake). Amongst the analogues with 
Thr6 substitutions, Arg19 combinations were slightly more potent than their Lys19 
counterparts. Analogues PP-14 to PP-16 test the Glu6 substitution and, in combination with 
Pro0 and Arg19, bioefficacy increased 4.5-5 times that of the effect of native PP. Gly0 
version of the Glu6, Lys19 analogue only increased bioefficacy 2-fold despite almost full 
protection against NEP. However, Gly0 in combination with Asp6 and Lys19 increased 
bioefficacy by 7 times compared to native PP. 
 
 
Table 3.17 The effect of combined substitutions at positions 0, 6, 19, 23 and 30 (analogues PP-9 to 
PP-17) on Y4r affinity, susceptibility to degradation by NEP and in vivo bioefficacy. 
 
  








LTX (970-977) Glu Ile Lys Gly 0
Ex4 (17-24) Glu Ala Arg Glu 0
PYY Glu Glu Leu Arg Ser
NPY Asp Asp Met Arg Ala
PP-7 Pro 0.9 13 2
PP-8 Gly 1 33 1.5
PP-9 Pro Ser Lys Ala Lys 0.2 1 1.4
PP-10 Gly Ser Lys Ala Lys 0.2 11 1
PP-11 Pro Thr Lys Glu Lys 0.4 6 2
PP-12 Pro Thr Arg Ala Lys 0.1 2 2.5
(DesA1)PP-13 Thr Arg Ala Lys 0.2 5 2
PP-14 Pro Glu Arg Ala Lys 0.4 11 4.5
PP-15 Gly Glu Lys Ala Lys 0.2 2 2
PP-16 Pro Glu Lys Ala Lys 0.3 3 5
PP-17 Gly Asp Lys Ala Lys 0.3 7 7
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Finally, modifications at position 16 and 17 were explored in combination with all the 
previous global changes (i.e. substitutions at -1, 0, 6, 19, 23, 30). Single changes at positions 
16 and 17 alone did not improve receptor affinity or potency at reducing food intake in 
acute feeding studies in mice in spite of a reduction in the susceptibility to NEP degradation. 
However, in the presence of combined modifications at positions -1, 0, 6, 19, 23, and 30, 
(analogues PP-19 to PP-24; Table 3.18) Y4r affinity increased 2-5 fold and all analogues 
tested were completely resistant to degradation by NEP. Bioefficacy seen in mouse acute 
feeding studies also increased by at least 4-times compared to native PP 
 
Table 3.18 The effect of combined substitutions at positions 0, 6, 16, 17, 19, 23 and 30 (analogues 
PP-19 to PP-24) on Y4r affinity, susceptibility to degradation by NEP and in vivo bioefficacy. 
  








LTX (970-977) Glu Ile Lys Gly 0
Ex4 (17-24) Glu Ala Arg Glu 0
PYY Glu Glu Leu Arg Ser 0
NPY Asp Asp Met Arg Ala 0
PP-18 Leu 2.4 13 1.2
(DesA1)PP-19 Ile Glu Lys Glu Lys 0.3 2 5
PP-20 Gly Glu Lys Lys Ala Lys 0.2 0 4
PP-21 Pro Thr Leu Lys Glu Lys 0.4 0 5.5
PP-22 Gly Thr Lys Lys Glu Lys 0.3 0 6.5
PP-23 Pro His Glu Lys Glu Lys 0.3 0 7
PP-24 Pro Lys Glu Leu Lys Glu Lys 0.5 0 5.5
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3.2.4 INVESTIGATION OF PLASMA LEVELS OF PP ANALOGUES IN MICE 
3.2.4.1 Effect of phosphoramidon on plasma levels of a DPPIV-resistant 
PP analogue in mice  
Following a single SC injection of 150nmol/kg of the DPPIV-resistant PP analogue, PP-Ala0, 
plasma levels were measured at 45 and 90minues post-injection. PP-Ala0 was also co-
administered with the NEP inhibitor, phosphoramidon, at 20mg/kg, and plasma levels also 
measured at 45 and 90 minutes. Phosphoramidon was given as single IP injection 15minutes 
prior to SC administration of PP-Ala0. Mice given PP-Ala0 alone were given an equal volume 
IP injection of vehicle 15 minutes prior to peptide administration. Levels of PP-Ala0, 
increased significantly after 45mins (Fig 3.36) compared to basal levels of PP-Ala0 cross 
reactivity and subsequently significantly decreased after 90mins compared to plasma levels 
at 45mins. Plasma levels of PP-Ala0 at 90mins were not significantly raised compared to 
basal levels (PP-Ala0 at 90mins: 1809 ± 319pmol/L vs basal: 414 ± 52pmol/L).  
At both time points, plasma levels of PP-Ala0 were significantly higher when administered 
with phosphoramidon  compared to PP-Ala0 given alone (45m: PP-Ala0 4916 ± 480pmol/L vs 
PP-Ala0 + phosphoramidon 11034 ± 703pmol/L; 90m: PP-Ala0 1809 ± 319pmol/L vs PP-Ala0 
+ phosphoramidon 6484 ± 722pmol/L). Plasma levels of PP-Ala0 were greater than basal 
levels at 45 minutes only when PP-Ala0 was given alone, but was significantly greater than 




















Figure 3.36 Plasma levels of PP-Ala0 at 45 and 90mins following a single SC injection of PP-Ala0 at 
150nmol/kg to male C57BL/6 mice and in combination with a pre-peptide IP injection of 
phosphoramidon at 20mg/kg. Basal plasma samples were collected from naïve mice (n=2/6). Data 
are shown as mean plasma levels of PP-Ala0 ± SEM as determined by RIA. LLOD: 40pmol/L. 
Significance analysed using one-way ANOVA with Bonferroni’s post hoc test *p≤0.05, **p≤0.01, or 
*** p≤ 0.001. (Key to significance symbols: black stars are compared to basal levels; blue hash signs 
are compared to 45min levels without phosphoramidon; red dollar signs are compared to 45min 
levels with phosphoramidon; green ampersand are compared to 90min levels without 
phosphoramidon) 
 
3.2.4.2 Effect of phosphoramidon on plasma levels of PP analogues with 
global modifications in mice 
The effect of phosphoramidon was tested on plasma levels of PP analogues shown in Table 
3.19. As above, phosphoramidon was used at a concentration of 20mg/kg and administered 
IP 15minutes prior to SC injection of peptide. Blood was collected from mice sacrificed at 45 
and 90minutes post-injection of peptide. 
As a control, native PP at 1000 and 25nmol/kg were given in the presence and absence of 
phosphoramidon. At the higher dose without inhibitor, plasma levels of PP significantly 
decreased to 13% of the levels seen at 45m (PP at 90mins: 8978 ± 1553pmol/L vs 45mins: 
67761 ± 7473pmol/L). At 1000nmol/kg (Fig 3.37(A)), PP co-administered with 


























phosphoramidon, plasma levels of PP at 45minutes were 2-fold higher (141877 ± 
13827pmolL) compared to plasma levels of PP in the absence of inhibitor at the same time 
point (p=0.05). However, by 90mins, even in the presence of inhibitor, plasma levels of PP 
had significantly decreased to 21% of the levels seen at 45m with phosphoramidon (29091 ± 
2976pmolL). Although not statistically significant, the plasma levels of PP at 90mins with 
inhibitor are 3-times higher compared to the plasma levels of PP at 90mins with no 
inhibitor. 
At 40-times lower dose of PP (25nmol/kg), PP plasma levels are 5-times lower on average, 
compared to the 1000nmol/kg dose (Fig 3.37(B)). Without phosphoramidon, plasma levels 
of PP at 90mins were only 50% decreased compared to levels at 45mins. This pattern is 
repeated in the presence of phosphoramidon except plasma levels at both time points are 





Table 3.19 The effect of global modifications on Y4r affinity, susceptibility to degradation by NEP and 
in vivo bioefficacy.  
 








LTX (970-977) Lys Tyr Phe Val Gly 0
Ex4 (20-24) Arg Leu Phe Ile Glu 0
PYY Glu Arg Tyr Tyr Ala Ser Leu 0
NPY Asp Arg Tyr Tyr Ser Ala Leu 0
PP Val Gln Tyr Ala Ala Asp Met 1 47
PP-Lys30 Lys 0.7 30 3.0
PP-P0,A23,K30 Pro Ala Lys 1 37 3.0
PP-P0,K19,K30 Pro Lys Lys 0.2 37 4.0
PP-K6,NPY19-23 Lys Arg Tyr Ser Ala 0.2 77 0.1







Figure 3.37 Plasma levels of PP following a single subcutaneous injection of PP at (A) 1000nmol/kg 
and (B) 25nmol/kg to male C57BL/6 mice in combination with a single IP injection of 
phosphoramidon at 20mg/kg. Blood samples were collected at 45 and 90 minutes post-injection 
(n=3). Data are shown as mean plasma levels of PP ± SEM as determined by RIA. LLOD: 70pmol/L. 
Significance analysed using one-way ANOVA with Bonferroni’s post hoc test *p≤0.05, **p≤0.01, or 
*** p≤ 0.001. (Key to significance symbols: black stars are compared to 45min levels without 
phosphoramidon; red dollar signs are compared to 45min levels with phosphoramidon) 
PP-Lys30 modestly decreased susceptibility to degradation while maintaining affinity to the 
Y4r.  However, anorectic effects in vivo were shown to be 3-fold higher than that of native 
PP. Plasma levels of PP at 90 mins without phosphoramidon decreased to 26% of plasma 
levels at 45mins. This pattern is repeated in the presence of phosphoramidon where 
peptide levels decrease to 36%. Unlike native PP, plasma levels of PP-Lys30 in the presence 
of phosphoramidon were not significantly higher compared to peptide levels at the same 
time point without the NEP inhibitor. 
A further two PP analogues (PP-P0,A23,K30 and PP-P0,K19,K30) which had modest 
decreases in susceptibility to NEP degradation in vitro were also measured for circulating 
levels in the presence and absence of phosphoramidon. Like PP-Lys30, they were 3-4 times 
more effective at reducing food intake in mice compared to PP. Either in the presence of 
absence of phosphoramidon, plasma levels of these two analogues did not significantly 
decrease at 90mins compared to peptide levels at 45mins. Peptide levels of the two 






































analogues in the presence of phosphoramidon were also not significantly higher compared 
to peptide levels at the same time point without the NEP inhibitor. 
Lastly, the effect of phosphoramidon on circulating levels of another two analogues of PP 
that had unfavourable substitutions with respect to in vitro NEP digests was investigated. 
The in vivo effects of these PP analogues were either equal to that of native PP (PP-
D6,NPY19-23) or 10-times worse (PP-K6,NPY19-23). Plasma levels of PP-D6,NPY19-23 alone 
at 90minutes post-injection were 58% decreased compared to peptide levels at 45minutes. 
In the presence of phosphoramidon, the percentage remaining at 90minutes was lower 
(27%) as the peak at 45mins was significantly higher with NEP inhibitor (>2-fold) compared 
to plasma levels at 45mins without NEP inhibitor. There was no difference in plasma levels 
at 90mins post-injection in the either the presence or absence of phosphoramidon. 
Plasma levels of PP-K6,NPY19-23 alone at 90minutes post-injection were significantly 
reduced to 22% of the peptide levels at 45minutes. In the presence of phosphoramidon, the 
percentage remaining at 90minutes was 15% of the peak at 45mins. There was significantly 
higher peptide levels at 45mins in the presence of NEP inhibitor (>3-fold, p=0.01) compared 
to plasma levels at 45mins without NEP inhibitor. There was no difference in plasma levels 
























Figure 3.38 Plasma levels of peptide at 45mins and 90mins following a single subcutaneous injection 
of: (A) PP-Lys30 at 1000nmol/kg (green bars), (B) PP-P0,A23,K30 at 25nmol/kg (grey bars), (C) PP-
P0,K19,K30 at 1000nmol/kg (purple bars),  (D) PP-K6,NPY19-23 at 1000nmol/kg (red bars), and (E) 
PP-D6,NPY19-23 at 25nmol/kg (blue bars) to male C57BL/6 mice in combination with a single IP 
injection of phosphoramidon at 20mg/kg (hatched bars). Blood samples were collected at 45 and 90 
minutes post-injection (n=3-4). Data are shown as mean plasma levels of PP ± SEM as determined by 
RIA. LLOD: 70pmol/L. Significance analysed using one-way ANOVA with Bonferroni’s post hoc test 
*p≤0.05, **p≤0.01, or *** p≤ 0.001. (Key to significance symbols: black stars are compared to 45min 
levels without phosphoramidon; red dollar signs are compared to 45min levels with 
phosphoramidon) 
 





















































































3.2.4.3 Investigation of plasma levels of PP analogues with different 
susceptibilities to NEP and contrasting effects in vivo 
PP-25 is a DPPIV- and NEP-resistant analogue of PP. It has binding affinity which is over 5-
times greater than native PP at the mY2r (PP IC50 0.23 ± 0.033nM vs. 446 IC50 0.04 ± 
0.002nM) (Fig 3.39). PP-26 is a similar analogue with mY4 receptor affinity over 3-times 
greater than native PP (IC50 0.065 ± 0.004nM). When incubated with NEP, HPLC analysis 
demonstrated that PP-25 underwent 37% degradation while PP-26 only had 8% degradation 









Figure 3.39 Binding affinities of analogues PP-25 and PP-26 to mouse Y4r expressed as IC50 values 





Table 3.20 The effect of global modifications on PP analogues with similar Y4r affinity but different 
susceptibilities to degradation by NEP, and differences in in vivo bioefficacy. 
  
mY4r






























PP-25 Gly Arg Ala Lys 0.2 37 1.4
PP-26 Gly Thr Leu Arg Ala Lys 0.3 8 6
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The effects of PP-25 and PP-26 on acute feeding studies in mice were disparate. PP-26 was 
equipotent to PP administered at a 8-fold higher dose (Fig 3.40(A)). At the time intervals of 
0-1h, 1-2h, 2-4h, and 4-8h post-injection, PP-26 administered at 25nmol/kg significantly 
reduced food intake compared to the saline control group (p≤0.05). PP administered at 
200nmol/kg significantly reduced food intake at 0-1h, 1-2h, and 2-4h compared to the 
control group (p≤0.05). At the 4-8h time interval, there was no significant difference 
between the control group and PP. There was also no significant difference between the PP 
and PP-26 groups at this time point.  
PP-25 given at equimolar dose to PP (25nmol/kg) only significantly inhibited food intake in 
the 0-1h time interval (Fig 3.40(B)). There were no significant changes in food intake at any 











Figure 3.40 The effect of SC administration of (A) PP (200nmol/kg) and PP-26 (25nmol/kg) and (B) PP 
(25nmol/kg) and PP-25 (25nmol/kg) on food intake in C57BL/6 mice fasted overnight. PP, PP-25 and 
PP-26 werecompared to saline (*) using oneway ANOVA with Dunnett’s post hoc test *p≤0.05, 




























































C57BL/6 mice were given a subcutaneous injection of either PP, PP-25 or PP-26 at a 
concentration of 100nmol/kg. Animals were then culled at either 30 minutes or 2 hours 
post-injection via CO2 inhalation and then blood collected by cardiac puncture. Each peptide 
was measured using its own standard curve. Peptide levels for PP at 30m post-injection 
reached 8737 ± 744pmol/L and significantly decreased at 2h to 2112 ± 224pmol/L (Fig 
3.41(A)). At 30m post-injection, peptide levels for PP-25 reached 10426 ± 428pmol/L and 
again, significantly decreased at 2h to 2844 ± 206pmol/L (Fig 3.41(B)). Peptide levels for PP-
26 at 30m post-injection reached 26862 ± 1026pmol/L and significantly decreased at 2h to 
5810 ± 215pmol/L (Fig 3.41(C)). All peptide levels had decreased to 22-27% at 2h post-









Figure 3.41 Plasma peptide levels at 30mins and 2hrs following a SC injection of (A) PP (white bars), 
(B) PP-25 (grey bars), and (C) PP-26 (black bars) all administered at 1000nmol/kg. Peptide 
concentrations were measured by RIA. Significance was measured using student’s t-test. *p≤0.05, 



















































Comparison of peptide levels at 30m (Fig 3.42(A)) demonstrates no difference in peptide 
levels between PP and PP-25; however levels of PP-26 are significantly higher compared to 
PP and PP-25 (p≤0.001). This difference is mirrored at the 120m time point where there is 
no significant difference in peptide levels between PP and PP-25 but levels PP-26 are 










Figure 3.42 Comparison of plasma peptide levels of PP (white bars), PP-25 (grey bars), and PP-26 
(black bars) at (A) 30mins post-injection and (B) 120mins post-injection. All peptides were 
administered at 1000nmol/kg. Peptide concentrations were measured by RIA. Significance was 
measured using using one-way ANOVA with Bonferroni’s post hoc test. *p≤0.05, **p≤0.01, or *** p≤ 
0.001 (n=4). (Key to significance symbols: black stars are compared to levels of PP; red dollar signs 






























3.2.4.4 Investigation of plasma levels of PP analogues with similar in 
vivo bioefficacy and different affinities to the Y4 receptor 
PP-27 and PP-28 are DPPIV- and NEP-resistant analogues of PP. While both analogues are 
NEP-resistant compared to native PP, when incubated with purified NEP, HPLC analysis 
demonstrated that PP-27 underwent 19% degradation while PP-28 was completely resistant 
to NEP degradation (Table 3.21). The binding affinity of PP-27 is 2-fold greater compared to 
native PP at the mY4r (PP IC50 0.23 ± 0.033nM vs. PP-27 IC50 0.17 ± 0.028nM). However, PP-
26 binds to the mY4 receptor at 5-times greater affinity than native PP (IC50 0.049 ± 








Figure 3.43 Binding affinities of analogues PP-27 and PP-28 to mouse Y4r expressed as IC50 values 





Table 3.21 The effect of global modifications on analogues that are both relatively NEP-resistant but 
differ at their affinity to the Y4r and with modest differences in in vivo bioefficacy. 
 
mY4r





























PP-27 Glu Arg Glu Lys 0.5 19 4
PP-28 Gly Glu Asp Gln Lys Arg Glu Lys 0.2 0 10
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The effects of PP-27 and PP-28 on acute feeding studies in mice were within the same order 
of magnitude. PP-27 was as 1.5-times more potent than PP given at 5-fold higher dose (Fig 
3.44). At the time intervals of 1-2h, and 2-4h post-injection, PP-27 administered at 
10nmol/kg significantly reduced food intake compared to the saline control group (p≤0.01). 
PP administered at 50nmol/kg significantly reduced food intake at 0-1h compared to the 
control group (p=0.01). At all other time intervals, there was no significant difference 
between the control group and either PP or PP-27. PP significantly reduced food intake in 
the first time interval compared to PP-27 (p≤0.05) however, PP-27 significantly reduced food 












Figure 3.44 The effect of SC administration of PP (50nmol/kg) and PP-27 (10nmol/kg) on food intake 
in C57BL/6 mice fasted overnight. All groups were compared using one-way ANOVA with Tukey’s 


































PP-28 given at 5-fold lower dose to PP (50nmol/kg) significantly inhibited food intake in the 
0-1, 1-2, and 4-8h time intervals (Fig 3.45). There were no significant changes in food intake 
compared to vehicle control at any other time point. PP-28 was therefore, on average, 10-
fold more potent than PP at reducing food intake. In addition, PP-28 significantly reduced 











Figure 3.45 The effect of SC administration of PP (50nmol/kg) and PP-28 (10nmol/kg) on food intake 
in C57BL/6 mice fasted overnight. All groups were compared using one-way ANOVA with Tukey’s 
post hoc test *p≤0.05, **p≤0.01,or *** p≤ 0.001 (n=9-10). 
 
To measure circulating levels of the peptides, C57BL/6 mice were given a subcutaneous 
injection of PP, PP-27 or PP-28 at a concentration of 1000nmol/kg. Animals were then 
sacrificed at either 15, 45 minutes, or 2 hours post-injection via CO2 inhalation and then 
blood collected by cardiac puncture. Each peptide was measured using its own standard 
curve. Peptide levels for PP at 15m post-injection peaked at 34798 ± 8418pmol/L, decreased 
to 66% at 45m (22825 ± 638pmol/L), and significantly decreased by 120m to 2236 ± 
































for PP-27 reached 58655 ± 5430pmol/L and did not significantly decrease by the 45m time 
point (55371 ± 1485pmol/L). However, plasma levels of PP-27 at 120m post-injection 
significantly decreased to 15599 ± 1678pmol/L compared to peptide levels at both 15 and 
45m. Peptide levels for PP-28 at 15m post-injection reached 46257 ± 4860pmol/L and 
decreased to 77% of the initial levels at 45m to 32636 ± 4429pmol/L. At 120m post-
injection, plasma levels of PP-28 had significantly fallen to 10226 ± 2626pmol/L compared to 











Figure 3.46 Plasma peptide levels at 15, 45 and 120mins following a SC injection of (A) PP (white 
bars), (B) PP-27 (grey bars), and (C) PP-28 (black bars) all administered at 1000nmol/kg. Peptide 
concentrations were measured by RIA. Significance was measured using using one-way ANOVA with 

































Comparison of peptide levels at 15m (Fig 3.47) demonstrates no difference in peptide levels 
between PP, PP-27, and PP-28. At 45m, levels of PP-27 are significantly higher compared to 
both PP and PP-28 (p<0.01-0.05). At the final time point, plasma levels of PP-27 are still 
significantly raised compared to PP (p<0.05) but there is no significant difference between 










Figure 3.47 Comparison of plasma peptide levels of PP (white bars), PP-27 (grey bars), and PP-28 
(black bars) at (A) 15mins post-injection, (B) 45mins post-injection, and (C) 120mins post-injection. 
All peptides were administered at 1000nmol/kg. Peptide concentrations were measured by RIA. 
Significance was measured using using one-way ANOVA with Bonferroni’s post hoc test. *p≤0.05, 














































The observation that an intravenous infusion of PP decreases appetite and food intake in 
normal BMI volunteers without the undesirable side-effects of nausea (Batterham et al., 
2003b) highlighted the potential target of this peptide hormone for development as an 
agent to treat obesity. However, as with many peptide-based drug targets, several 
properties of the molecule such as its short circulatory half-life would need to be addressed 
before it could even be considered viable as a therapeutic agent. 
For PP, the clearance rate is a particularly limiting factor of the peptide and it was 
modification of this property which I focused my research on in this chapter. Peptides are 
cleared from the body by two main processes, proteolytic degradation and renal clearance. 
The major sites of proteolytic degradation of peptides are the kidney and liver where 
proteolytic enzymes are found at high concentrations. Using cell membrane extracts from 
the kidney (renal brush border – RBB) and liver (rat liver microsomes – RLM), I completed a 
series of in vitro degradation studies to identify critical residues in the molecule with regard 
to the molecules breakdown. This was followed up with further in vitro degradation studies 
using purified enzymes and in vivo studies to confirm a possible mechanism. The chapter 
also continued mechanistic studies by investigating if rational substitutions of residues 
identified as prone to proteolytic cleavage would result in an improved circulatory half-life 
and therefore pharmacological action. 
Initial in vitro digests utilising tissue membrane extracts showed that PP suffered only 8% 
degradation after 15minutes incubation with RLM, increasing to 35% after 60minutes 
incubation. Despite the majority of PP still eluting at the same retention time as the parent 
compound at 15minutes, MS analysis confirmed degradation had already occurred, as 
fragments were identifiable.  
Analysis by MALDI-TOF of PP incubated with RLM for 10minutes demonstrated the 
production of fragments: PP1-35 (with and without the oxidised methionine residues), 6-29, 
15-35, 2-31 and 14-30. These fragments point to RLM degradation occurring mainly at distal 
sites to the PP molecule (at either N- or C-terminal) with particular susceptibility between 
position 2-3, 5-6, 14-15, 29-30 and 30-31.  
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At 60 minutes incubation with RLM, the overall number of fragments decreased as 
expected; once fragmentation occurs they are more prone to further degradation. There 
were some common fragments to the earlier time points such as PP1-35 and 14-30.  The 
unique fragments to this later time point were 3-36 and 8-26. This suggests that fragments 
PP6-29, 15-35 and 2-31 from the 10minute digest of PP were initial breakdown products 
that eventually get metabolised into other species. However, the susceptible degradation 
positions still existed between positions 2-3, 14-15 and 29-30. As with shorter incubations of 
PP with RLM, the fragments produced consisted of core positions of the molecule with the 
distal parts being more vulnerable to degradation by RLM. Fragments containing cuts at the 
two most C-terminal residues of PP were also present at both short (10minutes) and longer 
(60minutes) incubations with RLM. 
Initial digests using preparations of RBB showed that PP suffered little (<10%) degradation 
after 10mins and up to >50% degradation after 60minutes incubation as analysed by HPLC. 
As well as the decrease in size of the parent peak, earlier novel peaks were also generated.  
MS analysis of PP incubated with RBB demonstrated that full length PP is still present after 
10 or 60mins incubation however, this peak is at a higher intensity at the early time point 
suggesting it was present at higher concentrations. The 2 fragments generated after just 
10mins were PP3-36 and PP6-33/PP10-36 (which both have the same molecular weight). 
These fragments point to RBB degradation occurring mainly at distal sites to the PP 
molecule (at either N- or C-terminal) with particular susceptibility between position 2-3, 5-6, 
10-11, and 33-34.  
Fragment PP3-36 is a potential product of the enzymatic action of DPPIV and was observed 
in digests with both RLM and RBB, which is in agreement with known sites of DPPIV 
expression (Tiruppathi et al., 1990, Tarantola et al., 2012). PYY, a closely related peptide to 
PP with a high degree of structural similarity is degraded by DPPIV, further suggesting DPPIV 
may be an important enzyme to investigate for metabolism of PP.   
DPPIV cleaves the first two amino acids of the N-terminal of peptides up to around 80 amino 
acids in length. The preferred substrate of DPPIV is X-Pro-X (where X is any of the naturally 
occurring mammalian amino acid except Pro).  Therefore, I predicted that the N-terminal 
sequence of PP: Ala1-Pro2-Leu3 would be degraded by DPPIV. To confirm if PP could be 
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degraded by DPPIV, PP was incubated with purified DPPIV and analysed by HPLC. However, 
initial HPLC studies suggested no change in peak area of the parent compound, no change in 
retention time and an absence of additional degradative peaks. This result was 
contradictory to results from tissue preperation studies analysed by MS. Therefore I 
attempted to optimise the solvent gradient in the event of the lack of resolution was 
masking the degradation. However, this was not successful and MS analysis was thus used 
on whole digests. MALDI-TOF MS did confirm that PP was degraded by DPPIV to PP3-36. As 
expected PP5-36 was not observed as Pro5 at the P3’ cleavage subsite should not be 
degraded by DPPIV. 
Whereas cleavage of PYY1-36 to PYY3-36 alters the peptide affinities to Y receptors, making 
PYY  a Y2r-preferring agonist, PP3-36 had modestly reduced affinity to Y4r and no change in 
affinity to Y1r or Y2r (data not shown). The bioefficacy of the PP3-36, was tested by 
comparing its ability to inhibit food intake in mice compared to the parent molecule. 
Surprisingly, PP3-36 was able to reduce food intake, although its anorectic effects were 
evident for a shorter time period. While there was no statistical difference between groups 
treated with PP and PP3-36, compared to the control group, PP3-36 was significantly weaker 
than PP, particularly at later time points.  
The fragment PP6-33 was identified in both RLM and RBB digests of PP, and I hypothesised 
that cleavage at Arg33 was due to proteolytic degradation by trypsin. Trypsin was 
considered an important enzyme to investigate as the peptide would be delivered 
subcutaneously in the clinic.  Subcutaneous (SC) administration of peptide therapies 
introduces prolonged contact of the peptide with the SC environment providing an 
opportunity for trypsin to degrade the peptide. Trypsin is a specific class of proteases which 
cleaves the C-terminal to Lys and Arg residues of a peptide. The PP sequence contains 4 Arg 
residues at positions 25, 26, 33 and 35.  
HPLC analysis of PP incubated with trypsin showed the disappearance of the parent 
molecule and the appearance of two major peaks: RT=14m (PPF1) and RT=18m (PPF2). MS 
analysis of PPF1 demonstrated that this fraction contained fragments of m/z values 1642 
(PP25-26) and 1165 (PP27-35/26-34/28-36/16-25). All 4 fragments of PP with molecular 
weights of 1165 can all contribute to the intensity of the signal. MS analysis of PPF2 
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contained several fragments of which the main species present was PP1-26. All of the 
fragments from PPF1 and PPF2 were consistent with the cleavage pattern of trypsin. 
Not all fragments identified by membrane digests were successfully attributed to specific 
enzymes. However, to confirm the roles of a few potential enzymes responsible for sites of 
defined degradation in the molecule, purified recombinant enzymes which were predicted 
to cleave at these sites based on amino acid substrate requirements, were used in vitro to 
investigate degradation with PP and PP analogues. 
Many of the cleavage sites identified by the RLM and RBB digests could be sites for cleavage 
by NEP, these included Val6, Ala21, Leu24, Met30 and Tyr36. NEP is a likely candidate as it is 
present in RBB (Stewart and Kenny, 1984, Kenny, 1986) and liver (Borscheri et al., 2001, 
Shousha et al., 2004) at high concs. NEP is a cell-surface metallopeptidase that targets 
hydrophobic residues such as these. 
Incubation of PP with purified NEP 22.11, a relatively highly expressed member of the 
enzyme family, demonstrated a decrease in the peak area of native PP as analysed by HPLC 
and the generation of novel peaks with earlier retention times. MS analysis of whole digests 
of PP with NEP at both short (30m) and long (120m) time points showed only 1 major 
fragment produced: PP3-21. The amino acid residues at the P1’ subsites (Leu3 and Ala22) 
are considered small and hydrophobic and are therefore fit with NEP degradation. 
Unexpectedly, the fragments of NEP digest indentified by MS analysis after the digest had 
been resolved by HPLC prior to MALDI-MS analysis did not match that found in the whole 
digest. The new fragments identified were PP5-10, PP1-12, and PP12-26/7-22. The residues 
at some of these P1’ (Val6, Ala12) and P1 (Ala12) subsites are characteristic NEP target 
residues however the P1 (Asp10, Arg26) and P1’ (Thr13, Asp23, Tyr27) subsites are not 
typical NEP target residues. 
To assess the role of NEP in the ability of PP to reduce food intake (bioefficacy), PP was 
administered with and without the potent NEP inhibitor, phosphoramidon (Kenny et al., 
1981, Medeiros and Turner, 1994). At the dose used, phosphoramidon alone did not have 
any effect on food intake compared to saline-treated controls. PP given without 
phosphoramidon significantly reduced food intake up to 8hrs compared to saline group. 
Over the entire 24h period post-injection, neither PP alone or PP co-administered with 
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phosphoramidon significantly reduce food intake compared to the control group, however, 
mice treated with PP and the NEP inhibitor had a >20% decrease in food intake compared to 
mice treated with PP alone. A limitation of the study is that phosphoramidon could also 
influence the degradation of endogenous hormones which also influence appetite. This may 
have contributed to the non-significant difference between treated groups. 
An alternative approach from measuring food intake to assess the physiological importance 
of NEP was to assess plasma levels of PP when administered with and without 
phosphoramidon to rats.  Plasma levels of PP when administered with phosphoramidon 
remained elevated for longer than PP administered alone. Together this data suggested NEP 
was partly responsible for the clearance of PP from circulation. 
Having identified DPPIV, trypsin and NEP as physiologically relevant enzymes in the 
clearance of PP, I designed analogues of PP with amino acid substitutions to protect against 
cleavage by these enzymes. The structure of PP contains a PP fold, a structure known to be 
important for its biological activity. Therefore changes to the sequence had to be limited to 
a number of areas of the molecule to avoid disrupting its secondary and tertiary structure. 
Targeted areas included the N-terminus, a relatively non-conserved area of the PP fold 
family peptides, and the mid-section α-helix. Changes in the mid-section avoided key, highly 
conserved sites including Tyr20, Leu24 and Tyr27, and were made with the intention of 
increasing the helicity. This was achieved by adding residues from the well characterised 
helical domain of α-latrotoxin found in spider venom, and residues from Ex-4, another well 
characterised helical domain (discussed in more detail in section 4.1.1). 
I designed two strategies to achieve resistance to DPPIV. The first was to extend the N-
terminal to create PP-Ala0 and the second was to truncate the N-terminus to produce PP2-
36. Both of these analogues eliminated the DPPIV degradation by having Pro at either 
position 1 or 3, which was confirmed by MALDI-TOF analysis. 
It was important to consider if any benefit from generating DPPIV-resistant molecules would 
be lost due to reduced receptor affinity and in vivo efficacy. No difference in receptor 
affinity was noted in the analogues to PP allowing for a direct comparison of bioefficacy in 
vivo and the assessment of the importance of resistance to DPPIV degradation.  Biological 
activity of both DPPIV-resistant PP analogues were tested in acute feeding studies in mice. 
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In the study comparing matched doses of PP and PP2-36, PP2-36 produced a significantly 
greater inhibition of food intake than PP over 24hr, confirming DPPIV resistance was 
beneficial.  When PP was compared against PP-Ala0 in an acute feeding study, both peptides 
significantly reduced food intake up to 4h post injection. However only PP-Ala0 significantly 
reduced food intake over the whole 0-24h period (p < 0.01 compared with saline) while PP 
did not. 
To confirm this increased efficacy was due to reduced degradation, peptide plasma levels of 
native PP measured at 90mins post-injection was almost 80% less than that observed at 45 
minutes post-injection. However, PP-Ala0 levels remained higher for longer, only 60% of the 
peptide was cleared between 45 and 90 minutes post-injection. Combining the tissue 
preparation data, the in vitro degradation with purified enzyme studies, the in vivo efficacy 
studies and the plasma clearance study, I concluded that DPPIV was an important enzyme in 
the physiological clearance of PP. The data also suggested designing analogues with 
resistance to DPPIV degradation would be important in producing longer lasting analogues 
of PP.  
When designing trypsin-resistant analogues, amino acid substitutions were made at position 
25, 26, 33 and 35, individually and in various combinations. HPLC analysis demonstrated 
that individual substitution of position 25 and 26 did not protect PP against trypsin 
degradation. However, combination substitutions at both 25 and 26 did inhibit PP 
degradation. Changes at positions 25 and 26 with similarly charged residues had minimal 
impact on Y4r affinity while changes to neutral amino acids caused a greater loss of receptor 
affinity.  Despite keeping to conservative changes, double substitutions at position 25-26 
(PP-Gln25,26 or PP-His25,26) resulted in a 5-fold reduction in receptor affinity.  
To assess if PP analogues resistant to trypsin improved their in vivo activity, they were 
administered to mice and food intake was measured.  Due to the disparity of the Y4r affinity 
values, when assessing the efficacy of analogues, they were tested at twice the dose of PP 
to allow for a more equal comparison. Analogues with changes at position 25 had a shorter 
duration of action than PP and analogues with changes at position 26 were approximately as 
bioefficaious as PP. Acute feeding studies in mice using PP-Gln25,26 and PP-His25,26 
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appeared marginally stronger in the first hour post injection, but overall did not 
demonstrate any advantage in bioefficacy over native PP. 
C-terminal trypsin-resistant modifications at positions 33 and 35 were also initially screened 
for their affinity to the Y4r. Conservative changes at either position 33 or 35 with similarly 
charged residues (PP-Lys33, PP-Lys35, PP-His35) had modestly increased IC50 values in the 
order of 2-3-times worse compared to native PP. However, substitution with Ala residues 
(PP-Ala33 and PP-Ala35) had a detrimental effect on Y4r binding affinity. PP-Ala35 had an 
IC50 value 10-fold higher than that of native PP while PP-Ala33 was almost 40-times worse 
at Y4r binding compared to PP suggesting that position 33 is extremely important in 
maintaining affinity to the Y4r. 
Although Y4r binding affinity is severely affected by Ala substitution at position 33, the 
bioefficacy of PP-Ala33 in an acute feeding study is not as impaired as its receptor affinity 
might suggest. While both analogues PP-Ala33 and PP-Lys33 are not better at reducing food 
intake compared to native PP, PP-Ala33 is of comparative strength to PP. This discrepancy 
may be the result of greater resistance to trypsin degradation negating any loss of efficacy 
caused by reduced receptor affinity. However, it could also be due to species variation in Y4 
receptors (affinity was measured against the human Y4r while the feeding studies are 
conducted in mice) where human Y4r may be sensitive to changes at position 33 while 
mouse Y4r may be more tolerant to similar changes at this position (Berglund et al., 2001). 
Interestingly, while both PP-Ala26 and PP-His35 contain modifications which are individually 
well tolerated when it comes to Y4 receptor affinity, both substitutions combined (PP-
Ala26,His35)  appear to synergistically lower the binding affinity to the Y4r (almost 30-fold 
worse compared to native PP). This was not expected as changes to the C-terminus were 
not expected to be affected mid-section modifications, as the C-terminus projects away 
from the hairpin-like loop of the PP-fold at a 90° angle (Grundemar et al., 1993).  
Although in vitro analysis demonstrated trypsin resistance could be achieved by amino acid 
substitutions, it was not possible to improve the efficacy of the PP with these changes. This 
appeared largely to be a result of the reduced receptor affinity which cancelled out any 
improvement seen in resistance to trypsin in in vivo studies. Modifications of position 33 
and 35 completely abolishes the ability of PP to reduce food intake over a 24h period even 
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at higher doses to compensate for the decrease in Y4 receptor affinity. Indeed, the two Arg 
residues at position 33 and 35 are highly conserved amongst Y receptor ligands and 
represent important contact sites for all Y-receptors (Merten et al., 2007). Therefore 
substitution of these Arg residues may disrupt downstream signalling at the Y4r and further 
receptor activation. 
Designing analogues of PP to protect against NEP was challenging as there were numerous 
factors to consider. For example, Ex-4 has a number of NEP target sites yet remains NEP-
resistant while GLP-1 which is rapidly cleaved by NEP and has just as many target sites  
(Hupe-Sodmann et al., 1995). It has been suggested that, as Ex-4 has a more compact α-
helix structure, some target sites are protected by peptidase degradation due to steric 
hindrance. Larger size peptides may therefore be partly NEP-resistant because they have a 
stronger tendency to form compact tertiary structures resulting, in the enzyme’s preference 
for smaller peptides (NEP is indeed often referred to as an oligopeptidase) (Dale, 2006). This 
observation makes predicting susceptibility to NEP degradation difficult. I therefore 
conducted a study into what drives the relationship between susceptibility to degradation 
by NEP, receptor affinity, and in vivo bioefficacy.  
Using 2 analogues of PP which had similar affinities to the Y4r, in vitro digests with NEP 
demonstrated that 1 analogue was more susceptible to NEP degradation than the other. In 
acute feeding studies with dose titrations, the NEP-resistant analogue and PP had equal 
potency at reducing food intake when PP is administered at a dose which is 8-times higher 
than the analogue.  The NEP-sensitive analogue administered at an equimolar dose to PP 
was only able to significantly inhibit food intake in the 0-1h time interval. 
When peptide levels were measured in plasma at 30 and 120minutes after subcutaneous 
administration, all peptides demonstrated significant reductions in plasma levels at 
120minutes compared to their respective peptide levels at 30minutes. However, when 
plasma levels are analysed comparing PP and the 2 analogues at each time point, it is clear 
that plasma levels of the PP-resistant analogue were significantly increased compared to 
plasma levels of either PP or the NEP-sensitive PP analogue. 
It was concluded from this direct comparison that, although there were no major 
differences in longevity in circulation between PP and the 2 analogues, the NEP-resistant PP 
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analogue exhibits greater plasma concentrations at both 30 and 120minutes compared to 
native PP and the NEP-sensitive PP analogue. However, it does not remain in circulation for 
any longer compared to the other 2 peptides as the same proportion of the NEP-resistant 
peptide has degraded by 120minutes post-injection (as represented by reduced plasma 
levels measured by RIA). Despite the same percentage of peptide loss by 120minutes, 
conceivably the increased plasma levels achieved by the NEP-resistant PP analogue may be 
above the threshold which will activate the anorectic effects of Y4r agonism (Lamers et al., 
1982). 
In a second study investigating the importance of NEP degradation to PP, l studied 2 
analogues of PP which were both resistant to NEP digests in vitro and both had increased 
affinity to Y4r compared to PP , however PP-28 analogue had 5-times increased receptor 
affinity compared to PP-27 which had only a modest 2-fold increase in receptor affinity 
compared to PP. Acute feeding studies show that the analogue with greater Y4r affinity (PP-
28), had an in vivo bioeffiacy 10-times greater than that of native PP whereas the analogue 
with lower affinity (PP-27) had a 4-fold greater in vivo anorectic bioefficacy compared to 
native PP. As with the previous study, plasma levels of all peptides were measured at 45 and 
120minutes after a single subcutaneous injection. An earlier measurement at 15minutes 
was also taken. After 120minutes, plasma levels of all peptides were significantly reduced 
compared to plasma levels at 15minutes. There was no difference between any of the 
plasma peptide levels at 15minutes. At 45 and 120minutes, plasma levels of PP-28 were not 
significantly higher than PP. Plasma levels of PP-27 were significantly increased compared to 
native PP at both 45 and 120minutes, and significantly raised compared to PP-28 at 
45minutes. 
As PP-28 performed better in acute feeding studies compared to PP-27, it was surprising to 
see plasma levels of PP-27 significantly higher than PP-28. Plasma collected from animals 
administered with PP-27 was therefore chomatographed on a size-exclusion column to 
fractionate potential breakdown products that were also immunoreactive. However, it was 
demonstrated that the PP-27 being detected eluted in 1 peak which corresponded to the 
whole peptide (data not shown). This study suggests that, although increased plasma levels 
of a PP analogue are significantly increased and sustained as with PP-27, it does not 
necessarily translate to prolonged anorectic effect in vivo. In fact, PP-28 continued to 
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significantly reduce food intake at longer time points despite plasma levels of PP-28 not 
being significantly increased compared to that of PP at any of the time points measured. 
This limitation may have been overcome by the greater affinity of PP-28 at the Y4r and thus 
the potential for stronger agonism at the receptor. 
Amalgamating results from digests with tissues preps and individual enzymes, it was 
possible to create analogues of PP which combined protection of degradation from the 
enzymes tested. The changes focused on the N-terminal to protect against DPPIV and the 
mid-section to protect against NEP, although exact sites were unknown. No changes were 
made to counter trypsin, as changes at those residues were found to be detrimental to 
activity. 
With every class of changes made to the PP molecule, several properties had to be assessed 
in order to determine if the change was beneficial or not and why. The properties examined 
were affinity to Y4r, percentage degradation by NEP in vitro, and bioefficacy as measured by 
relative effectiveness to native PP in acute feeding studies in mice.  
Changes made to the N-terminus of PP were generally well-tolerated at Y4r affinity with the 
exception of the PP-Cys0(dimer) which had  over 2-fold lower affinity at the Y4r. This was 
largely anticipated as it is known the C-terminal is the part of the peptide which interacts 
with the receptor active site. NEP-resistance remained fairly unchanged with the exception 
of Pro0, Thr0, His0 and Cys0(dimer) which were >2-fold more resistant to degradation by 
NEP. PP-Cys0(dimer) in particular was completely NEP-resistant and, along with PP-Pro0, 
was more than 2-times more potent at acutely reducing food intake in mice. Based on the 
assumption that stable secondary and tertiary peptide structure are more resistant to NEP 
degradation, one can conclude that changes to the N-terminal at sites non-specific to NEP 
degradation offer greater NEP resistance because of this.  Plasma levels of the DPPIV-
resistant analogue, PP-Ala0, were elevated by its coadministration with phosphoramidon at 
both 45 and 90minutes post-injection compared to plasma levels at the same time points 
without the NEP inhibitor. This data suggests it would be important to inhibit several 
breakdown mechanisms rather than one alone, to maximise improvement in PK. 
Single C-terminal substitutions of Met30 in native PP were also well-tolerated at Y4r affinity 
and also remained mostly unchanged with susceptibility to degradation by NEP. PP-Glu30 
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was >2-fold more resistant to degradation by NEP compared to native PP and PP-Ile30 was 
completely NEP-resistant and was also the most efficacious at acute reduction of food 
intake in mice. PP-Asn30 and PP-Lys30 were also at least 3-times more potent than PP at 
acute food intake inhibition. 
A selection of other single mid-section modifications of PP did not notably improve the 
parameters measured compared to native PP. Affinity to Y4r could be improved with single 
substitutions to positions 6 and 19 but these did not translate to an additional increase in 
potency in vivo.  
Combined substitutions at positions 6, 19, 23 and 30 improved affinity at the Y4r. 
Degradation of these analogues by NEP decreased by >2-fold and the analogue PP-6, in 
particular, was >3-times more potent in vivo compared to native PP. Analogues with 
changes at positions 6, 19, 23 and 30 were then investigated in combination with changes 
that protect against DPPIV. Again, all analogues (PP-9 to PP-17) had improved Y4r affinity 
and increased resistance against NEP degradation. However, in vivo bioefficacies differed 
ranging from equal potency to native PP (analogues PP-9 and PP-10) through to 7-times 
increased bioefficacy compared to native PP (analogue PP-17) 
Finally, modifications at position 16 and 17 were explored in combination with all the 
previous global changes (i.e. substitutions at -1, 0, 6, 19, 23, 30). Single changes at positions 
16 and 17 alone had a reduction in the susceptibility to NEP degradation however, there 
was no improvement in receptor affinity or potency at reducing food intake in acute feeding 
studies in mice. Combining all of these changes at positions -1, 0, 6, 19, 23, and 30, 
(analogues PP-19 to PP-24), affinity at Y4r increased 2-5 fold and all analogues tested were 
completely resistant to degradation by NEP. In vivo bioefficacy also increased from 4 to 7 
times compared to native PP. 
The same was also true of other analogues of PP with global modifications which had 
increased susceptibility to in vitro NEP digests (PP-D6,NPY19-23 and PP-K6,NPY19-23). The 
presence of a section of the NPY α-helix in these analogues considerably increased affinity 
to Y4r by 5-fold. However, they had 2-3 times more degradation to NEP in vitro compared to 
native PP. Like PP-Ala0, co-administration of these analogues with phosphoramidon showed 
significantly higher peptide levels at 45mins post-injection compared to plasma levels at the 
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45mins without the NEP inhibitor. However, by 90mins there was no difference in plasma 
levels with or without phosphoramidon. This suggests that protection from NEP of these PP 
analogues is only useful short-term, after which they may become targets for other enzymes 
that can override the effects of NEP inhibition.  
Conversely, PP analogues with global modifications that modestly improved their 
susceptibility to in vitro NEP digests (PP-P0,A23,K30 and PP-P0,K19,K30) demonstrated 
insignificant differences in plasma levels in the presence of phosphoramidon at either 45 or 
90mins post-injection. The presence of the P0 N-terminal extension makes these 2 
analogues DPPIV-resistant and the lack of effect of NEP inhibitor on plasma levels 
demonstrates that they are also somewhat NEP-resistant in vivo.  
The effect of phosphoramidon on circulating plasma levels of the analogue PP-Lys30 
appeared halfway between the NEP-resistant and the NEP-susceptible analogues. To this 
extent, plasma levels of PP-Lys30 decreased significantly from 45 to 90mins post-
administration of peptide alone or in combination with phosphoramidon. However, in the 
presence of phosphoramidon, plasma levels of PP-Lys30 were not much higher than levels 
without the inhibitor at either time point. Therefore, although phosphoramidon does not 
appear to prevent degradation in this setting, it is possible that it has been made more 
prone to degradation by other mechanisms. 
In summary, the results from this group of PP analogues suggests that initial resistance to 
DPPIV is required before there is any beneficial effect of resistance to NEP. Thus, there may 
be an order of enzyme degradation where DPPIV precedes NEP. It is possible that DPPIV 
provides the initial breakdown step which destabilises the PP-fold structure and exposes 
other areas of the molecule to be degraded by other enzymes. In fact, Pro2 found in native 
PP, forms part of the hydrophobic “zipper” (Nygaard et al., 2006) in the core of the PP-fold 
structure and is the main interaction partner for Tyr27. Loss of Pro2 following DPPIV 
degradation causes destabilisation of the PP-fold structure and could make the molecule 






This chapter has confirmed that vulnerabilities in a peptide drug candidate can be 
interpreted from digests with liver and kidney extracts; the routes through which most 
drugs will take to undergo clearance from the body. From these tissue digests, patterns of 
cleavage from trypsin, NEP and DPPIV were hypothesised and then tested to confirm the 
cleavage sites. Once identified, residues around these sites were substituted and not all 
modifications were found to be beneficial to the affinity of the PP analogue to the Y4r or to 
their anorectic effect in acute feeding studies in mice. The undesirable substitutions were at 
Arg33 and Arg35 which, although generated trypsin-resistant analogues, reduced the 
bioefficacy of the analogue. Utilising only the favourable substitutions (i.e. N-terminal 
extensions and substitutions at positions 6, 16, 17, 19, 23, and 30), enzyme-resistant 
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4.1 INTRODUCTION  
4.1.1 PYY AS AN ANTI-OBESITY AGENT  
The results of PYY administration in humans have made PYY3-36 and its receptor potential 
targets for development of therapeutic agents for the treatment of obesity (Small and 
Bloom, 2005, Boggiano et al., 2005, Ueno et al., 2008, Vincent and le Roux, 2008). There 
were at least two analogues of PYY being developed as treatments for obesity (amylin 2nd 
gen Y-family mimetics (following from AC162352), 2009; 7TM pharma Obinepitide Y2 + Y4 
agonist discontinued in phase II, 2007). However, PYY, like many gut hormones, has a 
relatively short half-life (Lluis et al., 1989) that limits its use as an anti-obesity agent.  By 
modifying the primary structure of PYY to generate analogues with extended half-life that 
are still capable of activating the Y2 receptor, and/or to develop a modified-release formula, 
these could be developed into obesity therapies. 
Alanine scans of PYY3-36 and NPY have been used as a method to help identify amino acids 
important in peptide function and receptor affinity. Substitution of alanine in several 
positions of PYY3-36 is detrimental to the anorectic effects of PYY3-36 in mice. These included 
amino acid positions 7, 8, 20, 25, 27 and 29, many of which are required for the hydrophobic 
interactions to form the PP-fold (Fig 4.1). In addition, substitution of alanine into any of the 
5 amino acids at the C-terminal end of PYY3-36 abolishes the anorectic effects of PYY3-36 
(Slentz et al., 2004). An NPY alanine scan revealed that the C-terminal hexapeptide is 
essential for NPY binding to the Y2r (Sjostrom, 2013). These results were consistent with a 
study investigating the binding of fragments of the NPY molecules, starting from the C-
terminal hexapeptide to progressively longer fragments. The C-terminal hexapeptide alone 
did not show any binding affinity to the Y2r; however long C-terminal fragments 
encompassing most of the α-helix bound relatively well to the Y2R (Feurle et al., 1980). 
These results suggest that the C-terminal domain of PYY and NPY is crucial for the Y2r 
binding (the C-terminal pentapeptide is highly conserved in the PP-fold peptides with 
identical sequences in PYY and NPY (Tatemoto et al., 1982, Larhammar, 1996a), and the α-
helical regions of these 2 peptides, which have a very high homology, are important for 
higher affinity binding.  The importance of the α-helical region of NPY in receptor binding is 
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also demonstrated by large decreases in the affinity to the Y1r, Y2r and Y5r’s when the 19-











Figure 4.1 Primary amino acid sequence of PYY and schematic representation of stabilising bonds 
which exist between opposing amino acids of the polyproline- and α-helix. 
 
The native amphipathic α-helix of the PP-fold peptides has two functions in the membrane–
compartment model (Sargent and Schwyzer, 1986, Schwyzer, 1995): 
1) To direct the peptides to the membrane–water interface 
2) To guide the C-terminal receptor binding segment into the correct conformation for 
activity 
The interaction with the membrane stabilises both the α-helix and especially the C terminus, 
which has been shown to be relatively flexible in solution (Zerbe et al., 2006, Lerch et al., 
2004). Recently, it has been suggested that the N-terminal segments bind with low affinity 




membrane-bound state into the genuine binding pocket of the receptor for the peptide 
hormones (Xu et al., 2003). 
We hypothesised that the amphipathic nature of the additional α-helix, and its potentially 
increased affinity towards the cell membrane, could lead to an accumulation of peptide 
near the Y receptors. Bringing the peptide from solution to the surface of the cell membrane 
should increase the probability of the peptide finding the receptor, as well as its ability to 
activate the receptor multiple times (Pedersen et al., 2010). 
The α-helix is the most common motif in protein secondary structures and is involved in the 
folding and stability of peptide/protein structures and thereby the correct functioning. For 
example, the α-helical C-terminal region of GLP-1 binds and  activates the GLP-1R (Elias et 
al., 1998, Woloshin and Schwartz, 2014). Ex4, a GLP-1r agonist that shares 53% amino acid 
identity with GLP-1, binds GLP-1r with a higher affinity and activates the receptor with a 
higher potency than GLP-1 (Goke et al., 1993). The central region of Ex4 adopts an α-helical 
conformation and is important for binding with the GLP-1r (Sacks et al., 2009, Franz et al., 
2007). Structural analysis of GLP-1 and Ex4 in solution (Runge et al., 2007) in the receptor-
bound crystal form suggest that the higher affinity of Ex4 to the GLP-1r is due to superior 
hydrophilic and hydrophobic interactions in the homologous α-helical regions and a higher 
propensity of Ex4 to adopt the α-helical conformation in solution (Runge et al., 2008).  
Interestingly, the receptor binding α-helical regions of Ex4, and to a lesser extent GLP-1, 
share a similar homology to an α-helical region in the α-latrotoxin (αLTX) protein (Holz and 
Habener, 1998) (Table 4.1). αLTX is a toxin isolated from the venom of the black widow 
spider Latrodectus tredecimguttatus and causes a potent spontaneous discharge of 
neurotransmitters from nerve endings of motor and sensory neurones (Makris and Foster, 
2011). Residues 970-981 of the αLTX protein are highly homologous to the Ex4 α-helical 
residues 17-28 and are located within the postulated receptor binding domain (Holz and 
Habener, 1998).  
It was therefore investigated whether substituting part of the αLTX (970-975) and Ex4 
epitope into the α-helix domain of PYY3-36 would have any effect on its potency and efficacy. 









Table 4.1 Primary amino acid sequences of the homologous α-helical regions of αLTX, Ex4 and PYY-
αLTX. Amino acids positions identical to αLTX are highlighted in grey, Ex4 in blue and those 
conserved between αLTX, Ex4 and PYY, in yellow. 
 
In previous work, we at the Department of Investigative Medicine, Imperial College London, 
developed analogues of PYY3-36 utilising several strategies to modify the peptide’s 
characteristics (Fig 4.2). These include: 
1) Modifying the primary sequence of the peptide by substituting amino acids which 
increase the tendency to form an α-helix sequence while keeping the essential C-terminal 
pentapeptide intact in a bid to improve receptor binding 
2) Introduction of a proline at the N-terminus of PYY3-36, a residue  in PYY1-36, PP and NPY 
which forms hydrophobic interactions with the conserved Tyr27 residue (Glover et al., 1984) 
to strengthen the PP-fold structure. Reintroducing the proline at the N-terminal end of PYY3-
36 (to make PYY2-36) may help stabilise the peptide by lowering peptide dynamics and 
increasing resistance to proteolyic degradation (Nygaard et al., 2006, Schwartz et al., 1990). 
3) Modifying the peptide charge and therefore isoelectric point (pI). By adjusting the pI to 
near neutral, this would tend to decrease the solubility of the peptide at physiological pH 
values, increase the tendency of the peptide to precipitate subcutaneously to create a slow 
release depot. 
4) Introduction of Histidine residues. Histidines interact with metal ions. In combination with 
a metal salt solution, this strategy of introducing histidine residues is intended to favour 
peptide aggregate formation 
196 
 
While not the primary focus of this work, the importance of the pharmacokinetics for an 
obesity therapy based on PYY3-36 is critical. With this in mind, and the knowledge that PYY3-36 
has a short half-life, two points were considered:  
 extended half-life in circulation 
 slow release (SR) from a subcutaneous (SC) depot  
The half-life issue was addressed by assessing the resistance of the peptides to degradation 
of known peptidases and the increased resistance to this degradation by specific amino acid 
substitutions. For the SR strategy, the approach taken was based on insulin SR preparations 
such as insulin glargine (Lantus, Sanofi-Aventis). With these preparations, Zinc is used to 















Figure 4.2 Design of PYY analogue. The PYY3-36 analogues designed in the investigation of a longer acting and/or more potent analogue of 
PYY3-36 at the human Y2 receptor (hY2r)  
Removal of αLTX insert 
Introduction of 4 Histidine 
residues 
Combination of N-terminal extension and αLTX insert 
Addition of Proline at N-terminus Insertion of αLTX 
 Affinity to hY2r 
 Acute effect on food intake 
 Pharmacokinetics 





Following these strategies, analogue PYY2-36-αLTX was created which is an analogue of PYY 
with an alpha-latrotoxin (αLTX) motif and Pro2 N-terminal extension. This created a highly 
active Y2R agonist but half-life was insufficiently extended to make it suitable for further 
development. Substitution of Histidines in PYY2-36-αLTX to create the analogue PYY2-36-αLTX-
4H maintained its activity but also resulted in a slow release from subcutaneous depots 
when formulated in a zinc chloride solution in the same manner as long acting preparations 
of insulin which uses zinc as a stabilising agent to promote hexamer formation of the insulin 
molecule (Farooqi et al., 1999). 
 
4.1.2 IMMUNOGENICITY  
Immunogenicity is defined as the ability of a substance (the antigen/drug) to induce an 
immune response by producing antibodies. Protein and peptide therapeutics are especially 
prone to provoke an immunological response. The consequences of immunogenicity can 
range widely from no noticeable effects to rare cases of severe reactions (Kessler, Goldsmith 
et al. 2006). Therefore immunogenicity cannot safely be ignored.  
There are 2 types of immune response: innate and adaptive. 
Innate responses are usually nonspecific to any kind of foreign material (pathogen/antigen). 
Components of this immune system include physical barriers/mechanisms such as skin, cilia 
in mucous membranes, tears, nasal secretions and saliva. Additionally, many pathogens and 
infected cells produce chemokines that increase permeability of blood vessels and allows 
migration of white blood cells (phagocytic cells such as granulocytes (neutrophils), 
macrophages, and dendritic cells) towards the site of infection. Macrophages release 
substances that attract other white blood cells (e.g. basophils) and mast cells to the site of 
infection releasing histamine and heparin that increases blood flow to damaged tissues 
causing redness and inflammation. They also release chemotaxic substances that attract 
neutrophils and eosinophils to the area which ingest bacteria and other foreign cells, help 




The adaptive immune response is a specific response against one type of antigen. It is 
mediated by lymphocytes, which include T cells and B cells. The responses of these cells 
displays specificity and memory. All lymphocytes are derived from bone marrow stem cells 
but T cells develop in the thymus while B cells develop in the bone marrow. 
B cells are responsible for the production of antibodies that act against extracellular 
pathogens. T cells are mainly involved with cellular immune responses to intracellular 
pathogens such as viruses. They also regulate the responses of B cells and the overall 
immune response. 
B cells express specific cell-surface antigen receptors (immunoglobulins) and, when mature, 
can secret soluble immunoglobulins (antibodies) into the extracellular fluid. Each B cell 
expresses an immunoglobulin which is specific for a particular antigen. If a B cells binds to its 
specific antigen, it will multiply and differentiate into plasma cells, which produce large 
amounts of the secreted antibody. This can be found in blood and tissue fluids and, because 
they are a soluble version of the original immunoglobulin, they bind to the same antigen 
that initially activated the B cell (Fig 4.3). Each antibody binds to a restricted part of the 
antigen called an epitope. A particular antigen can have several epitopes but antibodies are 
specific for one epitope rather than the whole antigen. 
There are several different types of T cells. Helper T cells are required for B cells to divide, 


















Figure 4.3 Production of antibodies by B cells. The entire population of B cells has the ability to 
specifically bind to millions of different antigens. When an antigen binds to the few B cells that can 
recognise it (clonal selection), the cell is induced to undergo proliferation and differentiation to 
become memory cells and plasma cells. Memory cells ensure that subsequent detection of that 
same antigen receives a more rapid response, while plasma cells secrete large amounts of antigen-
specific antibody. Therefore a primary humoral immune response results from the activation of 
previously unstimulated naïve B cells, whereas secondary responses are due to stimulation of 




Normally, antibody production (immunogenicity) is stimulated in response to proteins from 
outside the body (e.g. from non-human sources, or altered version of human proteins).  This 
immune response causes rapid production of neutralising antibodies in a process mediated 
by T cell activation of B cells. During development, the immune system is exposed to 
endogenous proteins, and develops tolerance to them.  However, this tolerance can break 
down (as in the case of autoimmune diseases) and, in this instance, binding antibodies can 
be produced. This process is normally reversed when the product is withdrawn (Kessler et 
al., 2006). 
When drugs are administered, a number of features may elicit an immune antibody 
response: 
1) Product-related factors: 
 Structural properties: the protein sequence, the presence or absence of 
epitopes (sequence recognised as an antigen), the degree of glycosylation 
influencing the protein degradation, the exposure of antigen sites and 
solubility. 
 Formulation and storage which influences the levels of contaminants and 
impurities. 
2) Host-related factors: 
 Genetic predisposition to immune response (linked to the inheritance of major 
histocompatibility complex alleles). 
 With certain conditions, the complete absence of a molecule from the host 
means that immune cells recognising this molecule are not deleted during 
maturation in the thymus. When these are introduced to the host, the immune 
system will recognise these as non-self-antigens. An example is that of 
haemophilia A, due to the deletion of the Factor VIII gene. When recombinant 
Factor VIII is introduced to such patients, this is recognised as a non-self-antigen 
and this leads to the production of neutralising antibodies. 




3) Dose or route of administration: 
 A higher dose and increased duration of treatment is likely to be more 
immunogenic as there is a higher concentration or increased presentation of a 
potential epitope that can be recognised by T cells to elicit antigenicity (Otto et 
al., 2001, Jarkovska et al., 2004).  
 Subcutaneous administration is more immunogenic, whereas intravenous and 
local/topical administration appear to be less immunogenic. The increased rates 
of injection site reactions following subcutaneous administration may reflect 
stronger activation of immunocompetent cells, leading to highly efficient antigen 
presentation (Herzog, 2014). This is probably due to deposition of antigen in the 
tissues which creates a large contact volume between antigen and immune cells 
(antigen presenting cells and lymphocytes) distributed in subcutaneous tissue 
(Fisch et al., 1996).  
 
A summary of immunogenic effects include: 
1) No effect. Antibody development can be noticed in a large proportion of patients (8-
60%) given the GLP-1 analogues exenatide and liraglutide but this does not impact 
on the efficacy or safety of the drug (Buse et al., 2011). 
2) Loss of efficacy of the drug due to the antibodies which can neutralise drug activity. 
Increasing the dose may overcome these antibodies; however the raised dose may 
lead to other side effects, 
3) Alteration of drug clearance. Non-neutralising antibodies may increase the clearance 
of the drug via the reticuloendothelial system. An example of this are non-
neutralising antibodies to interferon alpha which develop during treatment for 
Hepatitis C (Schellekens, 2002). 
4) The antibodies may cross-react with an essential naturally-occurring molecule, e.g. 
antibodies against megakaryocyte-derived growth factor cross-react with 
thrombopoietin and cause thrombocytopenia (Neumann and Foote, 2000). 
5) Antibody production can induce general effects such as anaphylaxis or allergic 
reactions. This potentially lethal side effect is nowadays less frequent with the 
increasing availability of highly purified products. 
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Considering the number of biopharmaceuticals used and the percentage of observed effects 
among human population, immunogenicity remains a rare side effect. 
Measuring immunogenicity is challenging, but it becomes increasingly important as more 
agents based on endogenous molecules are produced. Two steps are required to measure 
immunogenicity.  The first involves measuring the ability of serum antibodies to bind 
exogenous peptides.  If serum has a high affinity for exogenous peptides, this suggests a 
high level of antibodies, which may subsequently elicit an immunogenic reaction. Several 
types of assays can be used, including a Radioimmunoprecipitation Assay (RIPA) or Enzyme-
Linked Immunosorbent Assay (ELISA). These measure both neutralising and non-neutralising 
antibodies.  These assays are rarely standardised, so can be difficult to compare.  The 
second step required to detect a neutralising antibody is a bioassay that measures the 
ability of the serum to neutralise the biological effects of the exogenous peptide (Jahn and 
Schneider, 2009). It should be noted, however, that any system examining immunogenicity 
where peptides from one species are tested in a second species can cause false positives 
(i.e. a drug based on the human sequence of a peptide administered to a rodent may cause 
an immune reaction which may not be applicable in humans). 
Molecule size determines, in part, the immunogenicity of a drug. Polypeptides and proteins 
with molecular weights >10000 Da have a relatively high incidence of immunogenicity, 
whereas compounds with molecular weights <1000 Da have relatively low immunogenicity. 
Immunogenicity of compounds between this size range is unpredictable (Considine et al., 
1996). Low molecular weight compounds can be made more immunogenic by covalent 
bonding to proteins  to form hapten-protein complexes. This sometimes exploited 




A number of approaches to prevent or reduce immunogenicity have been proposed: 
(Schellekens, 2002): 
 PEGylation, the covalent attachment of polyethylene glycol (PEG) to lysine molecules 
on a protein’s surface reduces immunogenicity, possibly due to a physical “shielding” 
of the epitope by PEG.  
 Altering protein structure so that the immune-eliciting epitope is eliminated, either 
through replacing specific amino acids in the protein, or through exon shuffling 
within the protein-coding regions of the gene.  
 Humanisation of monoclonal antibodies, by replacing nonhuman regions with 





4.1.3 HYPOTHESES AND AIMS 
4.1.3.1 Hypotheses 
 PYY2-36-αLTX-4H is capable of reducing food intake in animal models of obesity 
 PYY2-36-αLTX-4H is immunogenic 
 The αLTX motif is the most immunogenic epitope in the peptide  
 
4.1.3.2 Aims 
1) To investigate the immunogenicity of PYY2-36(αLTX-4H) and the potential active 
region of the peptide responsible for this reaction. 
2) To design PYY analogues by amino acid substitutions, PEGylation, and/or changes in 
formulation, specifically aiming to reduce immunogenicity. 
3) To incorporate changes into analogues that maintains or improves efficacy and 
affinity at the Y2 receptor. To confirm receptor specificity by testing affinity to other 
members of the Y-receptor family. 
4) To investigate the acute effects of analogues on food intake. 
5) To characterise the chronic effects of analogues on food intake, body weight, and 
immunogenicity in rodent models of obesity 




4.2.1 CHARACTERISATION OF PYY2-36(αLTX-4H) 
4.2.1.1 Y1r and Y2r Receptor affinity 
 
PYY3-36 bound to the hY2r with an IC50 of 0.25 ± 0.01nM while PYY2-36(αLTX-4H) had an IC50 
which was approximately 3-fold worse (PYY2-36(αLTX-4H) IC50: 0.80 ± 0.07nM) than that of 
the endogenous ligand (Fig 4.4(A)).  
PYY1-36 and PYY2-36 bound with similar affinities to the hY1r (PYY1-36 IC50: 0.25 ± 0.07nM vs. 
PYY2-36 IC50: 0.32 ± 0.02 nM) while PYY3-36 had an IC50 which was approximately 4.5-fold 
worse (PYY3-36 IC50: 1.12 ± 0.25nM) than that of the endogenous hY1r ligand, PYY1-36 (Fig 
4.4(B)). Specific Y2r agonist (Y2A), NPY-Leu28,31, had an IC50 which was approximately 180-
fold worse (Y2A IC50: 46.88 ± 2.17nM) compared to that of PYY1-36.  
PYY2-36(αLTX-4H) had a hY1r binding affinity that was 4 times worse that of PYY1-36 (Fig 
4.4(D)) 
Finally, as efficacy of appetite reduction of these PYY analogues was assessed in mice, 
binding to the mouse Y2 receptor (mY2r) was completed for comparison (Fig 4.4(C)). PYY2-
36(αLTX-4H) bound to the mY2r with the same affinity as to the hY2r (PYY3-36 IC50: 0.24 ± 






















Figure 4.4 Binding affinities of PYY and analogues to human and mouse Y2r and human Y1r. (A) 
Binding affinity of PYY3-36 and PYY2-36(αLTX-4H) to the hY2r; (B) Binding affinity of PYY1-36, PYY2-36, 
PYY3-36, and Y2A to the hY1r; (C) Binding affinities  of PYY3-36 and PYY2-36 (αLTX-4H) to the mY2r; (D) 
Binding affinities of PYY1-36 and PYY2-36 (αLTX-4H) to the hY1r. In all cases, binding affinities are 












PYY3-36 IC50: 0.25 ± 0.01nM






















PYY1-36 IC50: 0.25  0.07nM
PYY2-36 IC50: 0.32  0.02nM
PYY3-36 IC50: 1.12  0.25nM






















PYY IC50: 0.24  0.07nM








































4.2.1.2 Comparison of PYY2-36(αLTX-4H) against PYY3-36 on food intake in 
mice 
PYY3-36 and PYY2-36(αLTX-4H) at 100nmol/kg significantly reduced food intake in mice at 0-1h 
post injection (p < 0.01 vs. saline for PYY3-36 and p < 0.001 for PYY2-36- αLTX-4H). Whilst a 
single s.c. injection of PYY3-36 (100nmol/kg) resulted in a significant reduction of food intake 
in the first time period only, PYY2-36(αLTX-4H) at the same dose, significantly reduced food 
intake during the additional time points of 2-4 and 4-8h post injection when compared with 
saline control (2-4h: saline 0.49 ± 0.04g vs. PYY2-36(αLTX-4H) 0.06 ± 0.04g, p < 0.05; 4-8h: 
saline 0.99 ± 0.09g vs. PYY2-36(αLTX-4H) 0.67 ± 0.05g, p < 0.05).  
 PYY2-36(αLTX-4H) significantly reduces food intake compared to PYY3-36 at the time intervals 
of 2-4 and 4-8h (2-4h: PYY2-36(αLTX-4H) 0.06 ± 0.04g vs. PYY3-36 0.36 ± 0.05g, p < 0.05; 4-
8h:PYY2-36(αLTX-4H) 0.67 ± 0.05g vs PYY3-36 0.89 ± 0.04g, p < 0.05). There were no significant 























Figure 4.5 Effect of subcutaneous administration of 100nmol/kg PYY3-36 and PYY2-36(αLTX-4H) on 
food intake in fasted C57BL/6 mice (n=4-5). Peptides or vehicle (saline) administered in the early 
light phase. Data are shown as mean ± SEM food intake for 0-1, 1-2, 2-4, 4-8 and 8-24 hour intervals. 
One-way ANOVA with a Dunnett’s post-hoc used to test for significance vs. saline control (black 
stars) and a Tukey’s post-hoc to test for significance between the treatment groups at each time 
point (red stars) (*=p<0.05; **=p<0.01; ***=p<0.001) 
 
4.2.1.3 Acute effect of a dose response of PYY2-36(αLTX-4H) on food 
intake in mice  
At the lowest dose of 100nmol/kg (Fig 4.6), a single s.c. injection of PYY2-36(αLTX-4H) 
significantly reduced food intake in mice during the time periods 0-1, and 1-2h post injection 
(0-1h: p < 0.01 vs. saline and 1-2h: p < 0.001 vs. saline). At higher doses of 300 and 
500nmol/kg, PYY2-36(αLTX-4H)  caused significant decrease in food intake at 0-1h when 
compared to the saline control group (saline: 0.98 ± 0.03g vs. 300nmol/kg PYY2-36(αLTX-4H): 
0.68 ± 0.02g, p < 0.01; 500nmol/kg PYY2-36(αLTX-4H): 0.66 ± 0.04g, p < 0.01) but not during 
the time period of 1-2h. All doses of PYY2-36(αLTX-4H) caused significant decrease in food 
intake at 2-4 and 4-8h when compared to saline (p < 0.001 vs. saline for all groups at both 



































significantly reduce food intake, however, there was a significant dose-dependent reduction 
of food intake with the 300 and 500nmol/kg doses (saline: 3.57 ± 0.11g vs. 300nmol/kg PYY2-
36(αLTX-4H): 2.46 ± 0.34g p < 0.05; 500nmol/kg PYY2-36(αLTX-4H): 1.46 ± 0.16g p < 0.001). 
PYY2-36(αLTX-4H) at all the doses tested, significantly reduced food intake over the whole 0-















Figure 4.6 Effect of subcutaneous dose response of 100, 300, and 500nmol/kg PYY2-36(αLTX-4H) on 
food intake in fasted C57BL/6 mice (n=7-8). Peptides or vehicle (saline) administered in the early 
light phase. Data are shown as mean ± SEM food intake for 0-1, 1-2, 2-4, 4-8 and 8-24 hour intervals. 
One-way ANOVA with a Dunnett’s post-hoc test used to test for significance vs. saline control 




























































Figure 4.7 Cumulative 24hour food intake after administration of 100, 300, and 500nmol/kg PYY2-
36(αLTX-4H) (n=7-8). Data are shown as mean ± SEM food intake. One-way ANOVA with a Dunnett’s 















































4.2.1.4 The importance of Zn in the pharmacokinetic of a single SC 
injection of PYY2-36(αLTX-4H) in rat  
Following a single SC injection of PYY3-36 at 50mg/ml formulated in zinc chloride solution to 
achieve a 1:1 Zn to peptide molar ratio, a maximum plasma concentration (Cmax) of 55,603 ± 
2,807pmol/L was observed at 30mins post injection (Fig 4.8(A)). At 3h post injection, plasma 
concentrations of PYY3-36 had decreased to significantly lower levels of 895 ± 209pmol/L. 
The levels of PYY3-36 in plasma remained low at 24h post injection (1312 ± 217pmol/L) which 
was not significantly different from PYY3-36 plasma levels seen at 3h.  
The Cmax reached following a single s.c. injection of 50mg/ml PYY2-36(αLTX-4H) in 1:1 zn was 
at 48h post injection at about 3,400 ± 813pmol/L (Fig 4.8(B)). Prior to Tmax (time taken to 
achieve maximum plasma concentrations), plasma levels rose slowly from 30mins (333 ± 
56pmol/L) to 3h (808 ± 93pmol/L) and then approximately doubled by 24h (1947 ± 









Figure 4.8 Pharmacokinetics after a single s.c. injection of (A) 1mg/animal PYY3-36 and (B) 
0.5mg/animal PYY2-36(αLTX-4H), both at 50mg/ml (n=3 at all time points). Data are shown as mean ± 
SEM plasma concentrations. One-way ANOVA with a Bonferroni’s post-hoc test used to test for 
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Following a single SC injection of PYY2-36(αLTX-4H) in rats, at a concentration of 20mg/ml, 
formulated in zinc chloride solution to achieve a 1:1 molar ratio of Zn to peptide, a Cmax of 
714 ± 54pmol/L was observed at 24h post injection (Fig 4.9). Conversely the same dose of 
PYY2-36(αLTX-4H) formulated in normal saline (0.9% w/v) had a Cmax of 683 ± 58pmol/L at 
60mins post injection. The plasma levels at 15mins post injection are significantly higher in 
the injection of PYY2-36(αLTX-4H) not formulated with Zn (549 ± 44pmol/L without Zn; 285 ± 
19pmol/L 1:1 Zn).  
Plasma concentration of PYY2-36(αLTX-4H) formulated without Zn remains approximately 2-
fold higher than the formulation containing Zn until its Cmax at 60mins. At 24h post injection, 
no significant difference in plasma concentrations were observed, although a trend for the 
Zn-formulated peptide to have increased levels was noted (546 ± 46pmol/L without Zn; 714 












Figure 4.9 Pharmacokinetics after SC administration of 20mg/ml PYY2-36(αLTX-4H) in saline not 
containing Zn (solid circles/line) and in the presence of 1:1 Zn (open circles, dotted line) (n=4 at all 
time points). Data are shown as mean ± SEM plasma concentrations as measured by RIA. Unpaired 


























































Longer studies were completed where rats received a single SC injection of PYY2-36(αLTX-4H) 
(50mg/ml) formulated in 1:1 molar Zn ratio. Again, Cmax was reached at 48h post injection 
(2733 ± 147pmol/L) (Fig 4.10). The AUC from 0h to day7 (AUC7d) for PYY2-36(αLTX-4H) 1:1 Zn 
was 0.35 × 106pmol.h/L. The profile of PYY2-36(αLTX-4H) showed a steady rise to Cmax with no 
initial burst, followed by a slow decrease in plasma levels with only a 30% reduction from 












Figure 4.10 Pharmacokinetic profile of a single subcutaneous injection PYY2-36(αLTX-4H) at 
50mg/ml. A basal plasma sample was collected immediately prior to administration of PYY2-36(αLTX-
4H) (1mg/rat) and further plasma samples collected at 1, 3 and 6h, 1, 2, 4 and 7 days later (n=2-5). 









































4.2.1.5 Effect of chronic administration of PYY2-36(αLTX-4H) on food 
intake and body weight in DIO mice 
Chronic administration of PYY2-36(αLTX-4H) attenuated weight gain in DIO mice (Fig 4.11(B)). 
At the start of the study, groups were stratified by body weight and there was no significant 
difference between their mean body weights (body weight on day 0: vehicle: 31.7 ± 0.8g vs. 
3000nmol/kg PYY2-36(αLTX-4H): 31.0 ± 0.6g, p > 0.05).  
Daily SC injection of 3000nmol/kg PYY2-36(αLTX-4H) in a slow release formulation (1:1 molar 
ratio of peptide to zinc) significantly decreased food intake on day 1 of the study and a 
cumulative reduction in food intake was maintained throughout the study (cumulative food 
intake on day 29: vehicle: 73.1 ± 2.0g vs. 3000nmol/kg; PYY2-36(αLTX-4H): 61.9 ± 1.2g, p < 
0.001) (Fig 4.11(A)). The mean body weight of PYY2-36(αLTX-4H) treated animals was 
significantly lower than that of the vehicle group 24h after the first administration, and 
continuing throughout the study (body weight on day 1: vehicle: 32.3 ± 0.8g vs. 
3000nmol/kg PYY2-36(αLTX-4H): 30.0 ± 0.6g, p < 0.001; body weight on day 29: vehicle: 38.0 




























































































Figure 4.11 Effect of subcutaneous administration of PYY2-36(αLTX-4H) (3000nmol/kg) on (A) 
cumulative food intake (data shown as mean ± SEM) and (B) body weight (data shown as mean 
percentage weight loss corrected to mean vehicle body weight ± SEM), in C57BL/6 DIO mice (n=13). 
Peptide and vehicle (saline) administered daily. GEE and Mann-Whitney statistical tests used to test 





4.2.1.6 Effects of chronic administration of PYY2-36(αLTX-4H) on food 
intake and body weight in male Wistar rats 
There was no significant difference between the average body weights of the vehicle control 
group, and the PYY2-36(αLTX-4H) group at the start of the study.  
Daily SC injection of PYY2-36(αLTX-4H) 1:1 Zn at 500nmol/kg did not cause a significant 
reduction in food intake or body weight change. Daily SC injection of PYY2-36(αLTX-4H) 1:1 Zn 
at 3000nmol/kg significantly decreased food intake on day 6 of the study and continued to 
cause a decrease in food intake until day 13 (cumulative food intake on day 13: vehicle: 
406.7 ± 7.5g vs. 3000nmol/kg PYY2-36(αLTX-4H): 368.3 ± 5.2g, p < 0.05) (Fig 4.12(A)).  
PYY2-36(αLTX-4H) (3000nmol/kg/day) significantly reduced body weight from day 6 onwards 
(body weight day 13: vehicle: 477 ± 7g vs. 3000nmol/kg PYY2-36(αLTX-4H): 458 ± 8g, p < 0.05) 
(Fig 4.12(B)). 
  





















































Figure 4.12 Effect of subcutaneous administration of PYY2-36(αLTX-4H) (500 and 3000nmol/kg) on 
(A) cumulative food intake (data are shown as mean ± SEM) and (B) body weight (data are shown as 
mean percentage weight loss corrected to mean vehicle body weight ± SEM) in male Wistar rats 
(n=6-14). Peptide and vehicle (saline) administered daily. GEE and Mann-Whitney statistical tests 
used to test significance (*=p<0.05, PYY2-36(αLTX-4H) 3000nmol/kg vs. saline). 
  

































































4.2.2.1 Immunogenicity of chronic administration of PYY2-36(αLTX-4H) 
Analogue PYY2-36(αLTX-4H) underwent further investigation and its in vivo properties 
investigated in the canine species (outsourced to Huntingdon Life Sciences, Cambridgeshire, 
UK). As part of the study, plasma samples were collected from dogs following 10 injections 
of PYY2-36(αLTX-4H) (5, 25 and 100mg/kg) each 3 days apart. Using the 
radioimmunoprecipitation assay (RIPA), plasma samples were tested for the presence of 
antibodies against the therapeutic agent (antidrug antibodies – ADAs) and against the native 
peptide from which the analogue was structured on. Results showed the presence of 





Table 4.2 Immunogenicity of plasma from dog pharmacokinetic study 7 days after last injection – 
testing the presence of antibodies against PYY2-36(αLTX-4H) and the antibody titre. 
 
In light of these results, terminal plasma samples collected from the chronic rat study 
(section 4.2.1.6) were tested for the presence of antibodies against PYY2-36(αLTX-4H). 
Positive samples were identified as those with increased percentage binding of radiolabel 
(≥4-fold) compared to control groups. Results showed that plasma from 13 of the 14 rats 
injected with 500nmol/kg PYY2-36(αLTX-4H) and plasma from all the rats injected with 
3000nmol/kg PYY2-36(αLTX-4H) contained antibodies against PYY2-36(αLTX-4H) (table 3.2). 
Further tests of the plasma demonstrated from 2 of the 14 rats injected with 500nmol/kg 
PYY2-36(αLTX-4H) and plasma from 3 of the 6 rats injected with 3000nmol/kg PYY2-36(αLTX-
4H) contained antibodies against native PYY (Table 4.3). 
 
 
Dilution Neat 1:200 1:700 1:2000 




Table 4.3 Immunogenicity of terminal plasma from the rat chronic study – testing the presence of 
antibodies against PYY3-36 and PYY2-36(αLTX-4H). 
 
4.2.2.2 Effect of Zn precipitation on immunogenicity 
The amount of Zn in the formulation was investigated as a potential contributor to the 
immunogenicity of PYY2-36(αLTX-4H). PYY2-36(αLTX-4H) was administered subcutaneously to 
rats at a concentration of 20mg/ml (0.5mg/rat) formulated with zinc at a molar ratio of 
either 0, 0.125, 0.25, 0.5 and 1:1 every 3 days and samples collected by tail venesection on 
day 15 and 30. As a control PYY3-36 was tested using the same protocol and formulated with 
zinc at a molar ratio of either 0 or 1:1. Results showed that there was no change in the 
percentage binding of iodinated-PYY3-36 between day 15 and day 30 (Table 4.4). An 
approximate 2-3 fold increase in percentage binding of iodinated PYY2-36(αLTX-4H) was 
observed with all molar ratios of zinc to PYY2-36(αLTX-4H) between day 15 and 30 (Table 4.4) 












% binding of whole 
group (20µl sample) 
Positive 
rats 
% binding of whole 
group (20µl sample) 
Saline  - 5.1 - 12.4 
PYY2-36(αLTX-4H) 500 2/14 9.3 13/14 56.5 





Table 4.4 Effect of zinc chloride on immunogenicity. Plasma samples were collected from rats which 
received SC injections of PYY3-36 or PYY2-36(αLTX-4H) and were assessed for ability to bind 
radiolabelled PYY or PYY2-36(αLTX-4H). 
 
4.2.2.3 Immunogenicity of PYY2-36(αLTX-4H) fragments 
Fragments of PYY2-36(αLTX-4H) consisting of residues 2-28, 2-14, 7-36, 13-36 and 27-36 were 
tested for their ability to compete with 125I-PYY2-36(αLTX-4H) for binding to ADAs (Fig 4.13). 
The source of antibodies used for these tests were pooled samples from dogs, rats, and 
sheep which bound significant levels of 125I-PYY2-36(αLTX-4H). 
Results are summarised in Table 4.5. In plasma from rat, dog and sheep, the fragment 7-36 
had the closest cross-reactivity to full length PYY2-36(αLTX-4H), across all cold peptide doses 
tested (approximately 33% cross-reactive at 0.1pmol, 50% at 1pmol, and almost 80% at 
10pmol). In dog and rat plasma, both the N and C terminal truncated fragments, 13-36 and 
2-28, cross reacted with the ADAs with a trend of fragment 13-36 cross reacting with higher 
affinity.  The shorter fragments, 2-14 and 27-36, also cross reacted with ADAs in dog and rat 
plasma.  
Tests with sheep plasma showed fragments 2-14 had low affinity to the ADAs, and fragment 
2-28 had approximately 40% cross-reactivity at all doses of the cold peptide tested. In sheep 
plasma fragment 13-36 has poor cross-reactivity at 0.1pmol of cold peptide and good cross-
 




% binding of whole 
group (30ul sample) 
# positive 
rats 
% binding of whole 
group (30ul sample) 
PYY3-36 (0 Zn) 0/5 9.5 0/5 9.1 
PYY3-36 (1 Zn:1) 0/5 10.1 0/5 9.2 
PYY2-36(αLTX-4H) (0 Zn) 0/5 10 4/5 33.2 
PYY2-36(αLTX-4H) (0.125 Zn:1) 0/6 9.7 3/6 23.7 
PYY2-36(αLTX-4H) (0.25 Zn:1) 1/4 19.9 3/5 39.1 
PYY2-36(αLTX-4H) (0.5 Zn:1) 1/5 14.4 3/5 43.1 
PYY2-36(αLTX-4H) (1 Zn:1) 0/5 12.4 3/5 36.5 
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reactivity at 10pmol of cold peptide. Conversely, fragment 2-28 had high cross-reactivity at 





Figure 4.13 Fragments of PYY2-36(αLTX-4H) tested for cross reactivity with plasma containing ADAs. 






















Table 4.5 Summary of the displacement ratio of PYY2-36(αLTX-4H) fragments with dog, rat and sheep 
plasma. Results are expressed as the ratio of the percentage binding of the fragments at various 














0.1 1 1 1 
1 1 1 1 
10 1 1 1 
7-36 
0.1 0.34 0.54 0.69 
1 0.53 0.40 0.97 
10 0.77 0.42 1 
13-36 
0.1 0.13 0.52 0.30 
1 0.17 0.23 0.50 
10 0.33 0.22 0.74 
2-14 
0.1 0.08 0.01 0.31 
1 0.01 0.03 0.03 
10 0.01 0 0.08 
2-28 
0.1 0.12 0.15 0.42 
1 0.16 0.10 0.42 
10 0.24 0.22 0.47 
27-36 
0.1 0.03 0 0.63 
1 0.04 0 0.31 
10 0.07 0 0.32 
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To assess specificity of the ADAs, the ability to displace 125I-PYY2-36(αLTX-4H) at low 
concentrations (0.1pmol) of competing non-radiolabelled peptide or fragments was used. 
The average cross reactivity from the three species for each fragment is expressed as a ratio 
of the cross reactivity of PYY2-36(αLTX-4H) and the results are summarised in Table 4.6.  
At low concentrations of peptide, fragment 7-36 shares the most similar binding to full 
length PYY2-36(αLTX-4H) (50% cross-reactivity), followed by 13-36 at 30%. Fragments 2-28 
and 27-36 have similar cross-reactivity at 0.1pmol of cold peptide (20%) while fragment 2-14 
had low levels of cross-reactivity to the anti-PYY2-36(αLTX-4H) antibodies across all the 
species tested. 
The order of cross-reactivity is much the same when ratios from all concentrations tested 















Table 4.6 Average of the displacement ratios of PYY2-36(αLTX-4H) fragments against dog, rat and 
sheep antibodies. Results are expressed as the average ratio of the percentage binding of the 
fragments at low (0.1pmol) concentrations and across all concentrations, in comparison with full 





Average ratio of % binding 
of 0.1pmol peptide 
(compared to  full length  
PYY2-36(αLTX-4H)) 
Average ratio at all doses 
of peptide (compared to  
full length  PYY2-36(αLTX-
4H)) 
Full length 1 1 
7-36 0.52 0.63 
13-36 0.32 0.35 
2-14 0.13 0.06 
2-28 0.23 0.26 
27-36 0.22 0.16 
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4.2.2.4 Immunogenicity of PYY2-36(αLTX-4H) analogues 
A series of analogues, all variations of PYY2-36(αLTX-4H), were tested for their ability to 
compete with 125I-PYY2-36(αLTX-4H) for binding to PYY2-36(αLTX-4H) antibodies (Fig 4.14).  
This test was completed as part of a strategy to identify the specific amino acid(s) or 
sequence of amino acids which bound to the antibodies raised when 125I-PYY2-36(αLTX-4H) 
was injected into dog, rat and sheep. 
Groups of analogues based on two variations of PYY2-36(αLTX-4H) were designed: those that 
contain the αLTX sequence (peptides 2-5) and those without the αLTX sequence (peptides 6-
11). In each group, the removal of the Pro2 extension was investigated as was the 
progressive decrease in the number of His residues. 
 
 
Figure 4.14 Analogues of PYY2-36(αLTX-4H) tested for cross reactivity to PYY2-36(αLTX-4H) antibodies.    






A screen of the PYY2-36(αLTX-4H) analogues at 0.1, 1 and 10 pmol to bind to the plasma from 
rat, dog and sheep containing ADAs was completed and is summarised in Table 4.7.   
With ADAs from dog and rat, peptides 2, 3, and 4 bound with almost full cross reactivity, as 
assessed by their ability to displace 125I-PYY2-36(αLTX-4H). Peptides 5 and 6 had reduced 
cross-reactivity (approximately 60%) to the dog and rat plasma. Peptides 7, 8, and 10 
competed with similar cross-reactivity, displacing approximately 45% of 125I-PYY2-36(αLTX-
4H). Peptides 9 and 11 bound with the least affinity to ADAs in dog and rat (approximately 
30% binding).  
ADAs from sheep were found to be less discriminating with analogues of PYY2-36(αLTX-4H) 
tested at high concentrations. All peptides tested bound at ≥ 60% compared to PYY2-36(αLTX-
4H) itself. However, at low concentrations of competing unlabelled peptide, only peptides 2, 
3, 4, and 5 bound with 100% cross-reactivity. Peptides 6-11 had low cross-reactivity, 















0.1 1 1 1 
1 1 1 1 
10 1 1 1 
2 PYY3-36(αLTX-4H) 
0.1 0.9 0.8 1 
1 0.8 1 1 
10 0.9 1 1 
3 PYY2-36(αLTX-3H) 
0.1 0.9 0.6 0.9 
1 0.7 0.7 1 
10 0.8 0.9 1 
4 PYY2-36(αLTX-3H) 
0.1 0.8 0.7 0.9 
1 0.8 0.7 0.9 
10 0.9 0.7 1 
5 PYY2-36(αLTX-2H) 
0.1 0.7 0.3 0.9 
1 0.6 0.6 1 
10 0.6 0.7 1 
6 PYY2-36(4H) 
0.1 0.7 0.3 0.5 
1 0.7 0.6 0.7 
10 0.8 0.7 0.8 
7 PYY2-36(2H) 
0.1 0.5 0.1 0.5 
1 0.6 0.3 0.8 
10 0.7 0.7 1 
8 PYY2-36(2H) 
0.1 0.5 0.1 0.4 
1 0.4 0.3 0.7 
10 0.6 0.5 0.9 
9 PYY2-36(1H) 
0.1 0.4 0.1 0.5 
1 0.3 0.2 0.6 








Table 4.7 Summary of the displacement ratio of PYY2-36(αLTX-4H) analogues with dog, rat and sheep 
plasma. Results are expressed as the ratio of the percentage binding of the fragments at various 
concentrations, in comparison with full length PYY2-36(αLTX-4H). 
 
To assess specificity of the ADAs, the ability of low concentrations (0.1pmol) of 
non-radiolabelled PYY2-36(αLTX-4H) analogues to displace 
125I-PYY2-36(αLTX-4H) was tested. 
Results show analogues containing the αLTX sequence (peptides 2-5) binding with a high 
degree of cross reactivity, greater than 60%; and those without the αLTX motif (peptides 6-
11) binding less than 50% (Table 4.8). 
Amongst all peptides, (either in the presence or absence of the αLTX sequence), the ability 






0.1 0.3 0.1 0.5 
1 0.5 0.4 0.9 
10 0.7 0.8 1 
11 PYY2-36 
0.1 0.4 0 0.4 
1 0.3 0.1 0.5 




Table 4.8 Average ratios of PYY2-36(αLTX-4H) fragments against dog, rat and sheep ADAs. Results are 
expressed as the average ratio of the percentage binding of the fragments at low (0.1pmol) 
concentrations and across all concentrations, in comparison with full length PYY2-36(αLTX-4H).  
  
Key Peptide 
Average ratio of % binding of 
0.1pmol peptide (compared 
to  PYY2-36-αLTX-4H) 
Average ratio at all doses 
of peptide (compared to  
PYY2-36-αLTX-4H) 
1 PYY2-36(αLTX-4H) 1 1 
2 PYY3-36(αLTX-4H) 0.90 0.93 
3 PYY2-36(αLTX-3H) 0.80 0.83 
4 PYY2-36(αLTX-3H) 0.80 0.82 
5 PYY2-36(αLTX-2H) 0.63 0.71 
6 PYY2-36(4H) 0.50 0.64 
7 PYY2-36(2H) 0.37 0.58 
8 PYY2-36(2H) 0.33 0.49 
9 PYY2-36(1H) 0.33 0.38 
10 PYY3-36(1H) 0.30 0.58 
11 PYY2-36 0.27 0.33 
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4.2.3 ASSESSMENT OF ALTERNATIVES TO PYY2-36(αLTX-
4H) 
Two alternative strategies were explored in an attempt to produce an analogue of PYY 
which maintained the anorexigenic and pharmacokinetic properties of PYY2-36(αLTX-4H) 
without the immunogenic side effect. To the above described studies a PEGylated version, 
PYY2-36(αLTX-4H)-PEG, was produced and tested. In parallel to the investigation of PYY2-
36(αLTX-4H)-PEG, analogue PYY2-36(4H) was also selected for further investigation as a result 
of the immunogenicity screens using peptide fragments and analogues (section 4.2.2.3 and 
4.2.2.4).  
 
4.2.3.1 PEGylation of PYY2-36(αLTX-4H) – PYY2-36(αLTX-4H)-PEG 
4.2.3.1.1 Y1r and Y2r RBA  
 
PYY3-36 bound to the hY2r with an IC50 of 0.19 ± 0.01nM while PYY2-36(αLTX-4H) had an IC50 
which was approximately 3-fold worse (PYY2-36(αLTX-4H) IC50: 0.57 ± 0.11nM) than that of 
the endogenous ligand (Fig 4.15(A)).  
PYY1-36 and PYY2-36 bound with similar affinities to the hY1r (PYY1-36 IC50: 0.25 ± 0.07nM vs. 
PYY2-36 IC50: 0.32 ± 0.02 nM) while PYY3-36 had an IC50 which was approximately 4.5-fold 
worse (PYY3-36 IC50: 1.12 ± 0.25nM) than that of the endogenous hY1r ligand, PYY1-36 (Fig 
4.15(B)). Specific Y2r agonist (Y2A), [Leu28, Leu31] NPY, had an IC50 which was 
approximately 180-fold worse (Y2A IC50: 46.88 ± 2.17nM) compared to that of PYY1-36.  
PYY2-36(αLTX-4H) had a hY1r binding affinity that was 3.5 times worse that of PYY1-36. The 
binding affinity of PYY2-36(αLTX-4H)-PEG compared to the unPEGylated peptide at the hY1r 
was 2.5-fold worse (IC50: 2.21 ± 0.30nM) and thus almost 9 times worse than that of PYY1-36 
(Fig 4.15(D)) 
Finally, as efficacy of appetite reduction of these PYY analogues was assessed in mice, 
binding to the mouse Y2 receptor (mY2r) was completed for comparison (Fig 4.15(C)). PYY2-
36(αLTX-4H) bound to the mY2r with the same affinity as to the hY2r (PYY3-36 IC50: 0.24 ± 
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0.07nM, PYY2-36 (αLTX-4H) IC50: 0.54 ± 0.11nM) however, PYY2-36(αLTX-4H)-PEG was almost 
5-fold worse compared to the unPEGylated peptide at the mY2r (IC50: 2.61 ± 0.42nM) and 
















Figure 4.15 Binding affinities of PYY and PYY analogues to human and mouse Y2r and human Y1r. (A) 
Binding affinity of PYY3-36 and PYY2-36(αLTX-4H) to the hY2r; (B) Binding affinity of PYY1-36, PYY2-36, 
PYY3-36, and Y2A to the hY1r; (C) Binding affinity  of PYY3-36 and PYY2-36(αLTX-4H) to the mY2r; (D) 
Binding affinities of PYY1-36 and PYY2-36(αLTX-4H) to the hY1r. In all cases, binding affinities are 
expressed as IC50 values calculated from the mean ± SEM of 3-5 separate experiments 







PYY3-36 IC50: 0.19 ± 0.01nM
PYY2-36(LTX-4H) IC50: 0.57 ± 0.11nM
A





















PYY1-36 IC50: 0.25  0.07nM
PYY2-36 IC50: 0.32  0.02nM
PYY3-36 IC50: 1.12  0.25nM






















PYY IC50: 0.24  0.07nM
PYY2-36(LTX-4H) IC50: 0.54  0.11nM
C





















PYY1-36  IC50: 0.25  0.07nM
PYY2-36(LTX-4H) IC50: 0.87  0.09nM
D
















4.2.3.1.2 Effect of PYY2-36(αLTX-4H)-PEG on food intake in mice 
 
At the lowest dose of 200nmol/kg, a single SC injection of PYY2-36(αLTX-4H)-PEG significantly 
reduced food intake in mice in time 0-1, and 1-2h interval post injection (Fig 4.16; p < 0.01 
vs. saline at both time intervals). At higher doses of 1000 and 4000nmol/kg, PYY2-36(αLTX-
4H)-PEG caused significant decrease in food intake at 0-1, 1-2, 2-4, and 4-8h when 
compared to the saline control group (4-8h saline: 1.11 ± 0.05g vs. 1000nmol/kg PYY2-
36(αLTX-4H)-PEG: 0.50 ± 0.10g, p<0.01; 4000nmol/kg PYY2-36(αLTX-4H)-PEG: 0.20 ± 0.03g, 
p<0.001). At 8-24h post injection, none of the doses of PYY2-36-αLTX-4H-PEG tested 
significantly reduce food intake. The lowest dose of PYY2-36(αLTX-4H)-PEG did not 
significantly reduce food intake over the whole 0-24h period, however the two higher doses 






















Figure 4.16 Effect of subcutaneous administration of 200, 1000 and 4000nmol/kg PYY2-36(αLTX-4H)-
PEG on food intake in fasted mice C57BL/6 mice (n=5). Peptides or vehicle (saline) administered in 
the early light phase. Data are shown as mean ± SEM food intake food intake for 0-1, 1-2, 2-4, 4-8 
and 8-24 hour intervals. One-way ANOVA with a Dunnett’s post-hoc test used to test for significance 































































Figure 4.17 Cumulative 24hour food intake after administration of 200, 1000, and 4000nmol/kg PYY2-
36(αLTX-4H)-PEG (n=5). Data are shown as mean ± SEM food intake. One-way ANOVA with a 







































































































4.2.3.1.3 Pharmacokinetics of PYY2-36(αLTX-4H)-PEG with Zn in rat 
 
The Cmax observed following a single SC injection of 50mg/ml PYY2-36(αLTX-4H)-PEG 
administered in a 1:1 molar Zn ratio resulted in a Cmax of 43649 ± 6851pmol/L at 24h post 
injection (Fig 4.18) compared to Cmax at 48h for the unPEGylated version (Fig 4.10). Plasma 
levels of PYY2-36(αLTX-4H)-PEG decreased by more than half Cmax by day 2 (14832 ± 
3405pmol/L; 66% reduction from Cmax) and were further reduced by day 4 (4666 ± 
1860pmol/L; 89% reduction from Cmax). The AUC7d for PYY2-36(αLTX-4H)-PEG 1:1 zn was 2.30 
















Figure 4.18 Pharmacokinetic profile of a single subcutaneous injection of PYY2-36(αLTX-4H)-PEG to 
male Wistar rats. A basal plasma sample was collected immediately prior to administration of PYY2-
36(αLTX-4H)-PEG (50mg/ml (1mg/rat)) and further plasma samples collected at 4h and 1, 2, 4 and 7 
days later (n=4), data are shown as mean plasma levels of PYY2-36(αLTX-4H)-PEG ± SEM as 
determined by RIA. 
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4.2.3.1.4 Immunogenicity of PYY2-36(αLTX-4H)-PEG 
 
PYY2-36(αLTX-4H)-PEG formulated in saline administered once every 3 days over a 30 day 
period to rats. As a control PYY2-36(αLTX-4H) was inoculated without zinc using the same 
protocol. The number of rats testing positive for the presence of antibodies against the test 
compound was lower in those treated with the PEGylated form (Table 4.9) 
 
 









% binding of 
whole group 
(30ul sample) 
PYY2-36(αLTX-4H)          (0 Zn) 0/5 10 4/5 33.2 
PYY2-36(αLTX-4H)-PEG (0 Zn) 0/5 8.9 1/5 12.1 
 
Table 4.9 Effect of PEGylation on immunogenicity. Plasma samples were collected from rats which 
received SC injections of PYY2-36(αLTX-4H) or PYY2-36(αLTX-4H)-PEG and were assessed for ability to 




4.2.3.2 Removal of αLTX – PYY2-36(4H) 
Analogue PYY2-36(4H) was shown to be less immunogenic than PYY2-36(αLTX-4H) (Table 4.8), 
and was therefore tested for its bioefficacy and pharmacokinetic profile. 
 
4.2.3.2.1 Y1r and Y2r RBA  
 
PYY3-36 and PYY2-36(4H) bound with similar affinities to the hY2r (PYY3-36 IC50: 0.25nM ± 
0.01nM vs. PYY2-36(4H) IC50: 0.27 ± 0.02 nM) (Fig 4.19(A)).  
Control peptides for hY1r (PYY1-36, PYY2-36, PYY3-36, and Y2A) were as previously seen in 
section 3.1.1.2. At the hY1r, PYY2-36(4H) had a binding affinity that was 4-6 times worse than 
that of PYY1-36 (Fig 4.19(D)) 
Finally, as we would be testing the efficacy of appetite reduction of these PYY analogues in 
mice, we tested binding against the mouse Y2 receptor (mY2r) for comparison (Fig 4.19(C)). 
Both peptides bound to the mY2r with the same affinity as to the hY2r (PYY3-36 IC50: 0.24nM 














Figure 4.19 Binding affinities of PYY and PYY analogues to human and mouse Y2r and human Y1r. (A) 
Binding affinity of PYY3-36 and PYY2-36(4H) to the hY2r. (B) Binding affinity of PYY1-36, PYY2-36, PYY3-36, 
and Y2A to the hY1r. (C) Binding affinity of PYY3-36 and PYY2-36(4H) to the mY2r. (D) Binding affinity of 
PYY1-36 and PYY2-36(4H) to the hY1r. In all cases, binding affinities are expressed as IC50 values 
calculated from the mean ± SEM of 3-5 separate experiments. 
  








PYY2-36(4H) IC50: 0.27  0.02nM





















PYY1-36 IC50: 0.25  0.07nM
PYY2-36 IC50: 0.32  0.02nM
PYY3-36 IC50: 1.12  0.25nM























PYY2-36(4H) IC50: 0.22  0.03nM






































































4.2.3.2.2 Comparison of PYY2-36(4H) against PYY3-36 on food intake in mice  
 
A single s.c. injection of PYY3-36 at 100nmol/kg significantly reduced food intake in mice 
during the time periods 0-1 and 1-2h post injection (p < 0.01 vs. saline at 0-1h and p < 0.05 
at 1-2h). However, at the same dose, a single s.c. injection of PYY2-36(4H) did not significantly 
reduced food intake during the first time point of 0-1h but significantly reduced food intake 
during the following time periods of 1-2 and 2-4h when compared with saline control 
(saline: 0.42 ± 0.04g vs. PYY2-36(4H): 0.04 ± 0.01g, at 1-2h p < 0.001; saline: 0.62 ± 0.04g vs. 
PYY2-36(4H): 0.27 ± 0.08g, at 2-4h p < 0.05). At 8-24h post injection, only PYY3-36 caused a 
significant increase in food intake compared to the saline group (saline: 3.61 ± 0.09g vs. 
PYY3-36: 4.08 ± 0.13g p < 0.05), however there was also a trend (although not significant) for 
PYY2-36(4H) to cause an increase in food intake at this time point. There were no other 





















Figure 4.20 Effect of subcutaneous administration of 100nmol/kg PYY3-36 and PYY2-36(4H) on food 
intake in fasted C57BL/6 mice (n=5). Peptides or vehicle (saline) administered in the early light 
phase. Data are shown as mean ± SEM food intake for 0-1, 1-2, 2-4, 4-8 and 8-24 hour intervals. One-




4.2.3.2.3 Effect of acute administration of PYY2-36(4H) on food intake in mice (dose 
response study without Zn formulation) 
A single s.c. injection of PYY2-36(4H) at 100, 300 and 500nmol/kg significantly reduced food 
intake in mice during the time periods 0-1, 1-2, and 2-4h post injection (Fig 4.21; p < 0.001 
vs. saline for all groups at 0-1 and at least p < 0.05 at 1-2 and 2-4h). At 4-8h post injection, 
only 300 and 500nmol/kg doses of PYY2-36(4H) caused significant decrease in food intake 
when compared to the saline control group (saline: 0.83 ± 0.08g vs. 300nmol/kg PYY2-36(4H): 
0.42 ± 0.02g, p < 0.01 and 500nmol/kg PYY2-36(4H): 0.21 ± 0.05g, p < 0.001). All doses of 
PYY2-36(4H) caused a significant increase in food intake in the 8-24h time interval compared 
to the saline group (saline: 3.71 ± 0.05g vs. 100nmol/kg PYY2-36(4H): 4.21 ± 0.08g;  
300nmol/kg PYY2-36(4H): 4.33 ± 0.10g; 500nmol/kg PYY2-36(4H): 4.34 ± 0.14g; all p < 0.01). 
Only the 300 and 500nmol/kg doses of PYY2-36(4H) significantly reduced food intake over the 
whole 24h period (both p < 0.001 compared with saline) (Fig 4.22).  
 
 
Figure 4.21 Effect of subcutaneous dose response of 100, 300, and 500nmol/kg PYY2-36(4H) on food 
intake in fasted mice C57BL/6 mice (n=5-7). Peptides or vehicle (saline) administered in the early 
light phase. Data are shown as mean ± SEM food intake for 0-1, 1-2, 2-4, 4-8 and 8-24 hour intervals. 
One-way ANOVA with a Dunnett’s post-hoc test used to test for significance vs. saline control 




























































Figure 4.22 Cumulative 24hour food intake after administration of 100, 300, and 500nmol/kg PYY2-
36(4H) (n=5-7). Data are shown as mean ± SEM food intake. One-way ANOVA with a Dunnett’s post-













































4.2.3.2.4 Effect of Zinc on acute administration of PYY2-36(4H) on food intake in mice 
As previously found, a single s.c. injection of PYY2-36(4H) at 500nmol/kg (without Zn) can 
significantly reduce food intake in mice at 0-1, 1-2, 2-4 and 4-8h post injection (Fig 4.21; p < 
0.001 vs. saline at 0-1, 1-2, 4-8h; p < 0.05 vs. saline at 2-4h). By the 8-24h time period, PYY2-
36(4H) without Zn did not continue to inhibit food intake, however overall during the 0-24h 
period, it did significantly reduce food intake when compared to the saline control group 
(saline: 5.98 ± 0.12g vs. PYY2-36(4H) no Zn: 4.82 ± 0.14g p < 0.01). In the presence of 1:1 
molar ratio of Zn, PYY2-36(4H) at 500nmol/kg significantly inhibited food intake at all time 
periods measured post injection (p < 0.001 vs. saline at 0-1, 1-2, 2-4, 4-8, 8-24, and 0-24h) 

























Figure 4.23 Effect of Zn on subcutaneous administration of 500nmol/kg PYY2-36(4H) on food intake in 
fasted C57BL/6 mice (n=8). Peptides or vehicle (saline) administered in the early light phase. Data 
are shown as mean ± SEM food intake for 0-1, 1-2, 2-4, 4-8 and 8-24 hour intervals. One-way ANOVA 




















PYY2-36(4H) no Zn (500nmol/kg)







































Figure 4.24 Cumulative 24hour food intake after administration of 500nmol/kg PYY2-36(4H) with and 
without 1:1 Zn (n=8). Data are shown as mean ± SEM food intake. One-way ANOVA with a Dunnett’s 




































4.2.3.2.5 Pharmacokinetics of PYY2-36(4H) investigating dose response of Zn 
formulation 
The Cmax observed following s.c. injection of 50mg/ml PYY2-36(4H) (no Zn) was at 30mins post 
injection at about 2,728 ± 306pmol/L. The same dose of PYY2-36-4H administered in a 0.5:1 
molar Zn ratio resulted in a Cmax of about 4,466 ± 663pmol/L at 24h post injection. The time 
taken to achieve maximum plasma concentrations of PYY2-36(4H) (Tmax) was further delayed 
when the same dose of PYY2-36(4H) was administered in a 1:1 molar Zn ratio resulting in Cmax 
of about 6,141 ± 772pmol/L at 48h post injection (Fig 4.25). 
The area under the curve over the 48h period (AUC48h) for PYY2-36(4H) without Zn was 
26,366pmol.h/L. AUC48h for PYY2-36(4H) in 0.5:1 and 1:1 Zn was 171,306 and 
157,708pmol.h/L respectively. The relative bioavailability of PYY2-36(4H) 0.5:1 Zn was 650% 
of PYY2-36(4H) administered without zn, and 600% relative bioavailabilty for PYY2-36(4H) 1:1 










Figure 4.25 Pharmacokinetic profile in rat of PYY2-36(4H) when administered SC at 50mg/ml dose with 
various amounts of Zn in the formulation (n=3 at all time points). A basal plasma sample was 
collected immediately prior to administration of PYY2-36(4H) and further plasma samples collected at 
30m, 3, 6, 24, and 48h later. Data are shown as mean plasma levels of PYY2-36(4H) ± SEM as 






































































































Longer time course studies of the pharmacokinetic profile in rat of a single SC injection of 
PYY2-36(4H) (50mg/ml) formulated in 1:1 molar Zn ratio demonstrated Cmax was reached at 
24h post injection (10,860 ± 2,102pmol/L) (Fig 4.26). Plasma levels of PYY2-36(4H) remain 
elevated at 2 and 4 days post-injection (day 2: 6,990pmol/L ± 1,045pmol/L; day 4: 7,799 ± 












Figure 4.26 Pharmacokinetic profile of a single subcutaneous injection PYY2-36(4H). A basal plasma 
sample was collected immediately prior to administration of PYY2-36(4H) (50mg/ml - 1mg/rat) and 
further plasma samples collected at 1, 3 and 6h, 1, 2, 4 and 7 days later. At all time points, n≥3. Data 
are shown as mean plasma levels of PYY2-36-4H ± SEM as determined by RIA. 
 
The AUC7d for PYY2-36(4H) 1:1 Zn was 1 × 10
6pmol.h/L compared with the AUC7d for PYY2-
36(αLTX-4H) 1:1 Zn, which was 0.35 × 10
6pmol.h/L (section 4.2.1.4).  
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4.2.4 FURTHER CHARACTERISATION OF PYY2-36(4H) 
4.2.4.1 Comparison of acute effect of subcutaneous administration of 
PYY2-36(4H) and PYY2-36(αLTX-4H) on food intake in mice  
PYY2-36(4H) and PYY2-36(αLTX-4H) at 100nmol/kg significantly reduced food intake in mice at 
0-1 and 1-2h post injection (p < 0.001 vs. saline for both peptides). Both peptides 
additionally reduced food intake to a significant degree during the 2-4h time period (saline: 
0.53 ± 0.05g vs. PYY2-36(4H): 0.32 ± 0.04g p < 0.01; vs. PYY2-36(αLTX-4H): 0.08 ± 0.02g p < 
0.001). At 8-24h post injection, both peptides caused a significant increase in food intake 
compared to the saline group (saline: 3.73 ± 0.06g vs. PYY2-36(4H): 4.09 ± 0.08g p < 0.05; vs. 
PYY2-36(αLTX-4H): 4.34 ± 0.12g p < 0.001). PYY2-36(αLTX-4H) significantly reduced food intake 
over the whole 0-24h period (p < 0.001 compared with saline) (Fig 4.27).  
PYY2-36(αLTX-4H) significantly reduces food intake compared to PYY2-36(4H) at the time 
intervals of 1-2, 2-4 and 4-8h (1-2h p < 0.05; 2-4h p < 0.001; 4-8h p < 0.001). It also 
significantly reduced food intake over the whole 0-24h period compared to PYY2-36(4H) (Fig 






















Figure 4.27 Effect of subcutaneous administration of 100nmol/kg PYY2-36(4H) and PYY2-36(αLTX-4H) 
on food intake in fasted C57BL/6 mice (n=11-12). Peptides or vehicle (saline) administered in the 
early light phase. Data are shown as mean ± SEM food intake for 0-1, 1-2, 2-4, 4-8 and 8-24 hour 
intervals. One-way ANOVA with a Dunnett’s post-hoc test used to test for significance vs. saline 








Figure 4.28 Cumulative 24hour food intake after administration of 100nmol/kg PYY2-36(4H) and PYY2-
36(αLTX-4H) (n=11-12). Data are shown as mean ± SEM food intake. One-way ANOVA with a 































































4.2.4.2 Pharmacokinetics of PYY2-36(4H) at high concentrations – Zn dose 
range finding 
The Cmax observed following s.c. injection of 200mg/ml PYY2-36(4H) (0.25:1 molar Zn ratio – 
lowest ratio tested) was at 24h post injection at about 120,000 ± 6790pmol/L. The same 
dose of PYY2-36(4H) administered in a 0.5:1 molar Zn ratio resulted in a Cmax of about 63,500 
± 7840pmol/L at 24h post injection also. The Tmax of PYY2-36(4H) is delayed when the same 
dose of PYY2-36(4H) is administered in a 1:1 molar Zn ratio resulting in Cmax of about 27,000 ± 
2914pmol/L at 7 days post injection (Fig 4.29).  
The AUC12d for PYY2-36(4H) (0.25:1 Zn) was 8.0 × 10
6pmol.h/L. AUC12d for PYY2-36(4H) in 0.5:1 
and 1:1 Zn was 6.8 × 106and 5.9 × 106pmol.h/L respectively. The relative bioavailability of 
PYY2-36(4H) in 0.25:1 and 0.5:1 Zn was fairly similar within the error margins of the RIA. PYY2-
36(4H) administered with 1:1 Zn had 75% of the relative bioavailability of PYY2-36(4H) 
administered with the lowest amount of Zn.  
The PK profile of PYY2-36(4H) 1:1 Zn up to 7days is in stark contrast to PYY2-36(4H) 1:1 Zn at 
50mg/ml (4 times lower concentration than tested here at 200mg/ml) (fig 3.22; section 
3.3.2.5). Tmax has increased from 24h to 7days, AUC7d has increased 6-fold, however Cmax has 






























































Figure 4.29 Pharmacokinetics after administration of PYY2-36(4H) at 200mg/ml dose containing 
various amounts of Zn in the formulation (n=3-4 at all time points). A basal plasma sample was 
collected immediately prior to administration of PYY2-36-4H and further plasma samples collected at 
3h, 1, 4, 7, and 12 days later. Data are shown as mean plasma levels of PYY2-36-4H ± SEM as 
determined by RIA. 
 
4.2.4.3 Comparison of pharmacokinetics of PYY2-36(4H) and PYY2-36(αLTX-
4H) at high concentrations with 1:1 Zn 
The Cmax observed following a single s.c. injection of 200mg/ml PYY2-36(4H) containing 1:1 Zn 
was at 4 days post injection at about 5,457 ± 476pmol/L. The same dose of PYY2-36(αLTX-4H), 
also administered in a 1:1 molar Zn ratio resulted in a Cmax of 3,194 ± 569pmol/L at 48h post 
injection (Fig 4.30).  
The AUC8d for PYY2-36(4H) 33,086pmol.h/L compared with the AUC8d for PYY2-36(αLTX-4H) 1:1 
Zn, which was 19,414pmol.h/L. The relative bioavailability of PYY2-36(αLTX-4H) 1:1 Zn was 
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Figure 4.30 Pharmacokinetic profile after administration of PYY2-36(4H)  and PYY2-36(αLTX-4H) both at 
200mg/ml dose containing 1:1 Zn in the formulation (n=3-4 at all time points). A basal plasma 
sample was collected immediately prior to administration of peptides and further plasma samples 
collected at 1, 2, 4, 5, and 8 days later. Data are shown as mean ± SEM plasma concentrations as 
determined by RIA.  
 
4.2.4.4 Effect of chronic administration of PYY2-36(4H) on food intake and 
body weight in DIO mice 
There was no significant difference between the average body weights of the vehicle control 
group and the PYY2-36(4H) group at the start of the study.  
Daily s.c. injection of PYY2-36(4H) 1:1 Zn at 300nmol/kg from day 0-9, followed by daily s.c. 
injection of PYY2-36(4H) 1:1 Zn at 1200nmol/kg from day 10-20, followed by daily s.c. 
injection of PYY2-36(4H) 1:1 Zn at 2400nmol/kg from day 21-28, significantly decreased food 
intake on day 1 of the study and continued to cause a decrease in food intake until day 28 
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(cumulative food intake by day 28: vehicle: 80.6 ± 1.3g vs. 2400nmol/kg PYY2-36(4H): 67.7 ± 
1.2g, p < 0.001) (Fig 4.31(A)).  
The PYY2-36(4H) group had a lower average body weight than the vehicle group and the 
difference in body weight was significant from day 1 until day 28 (body weight on day 1: 
vehicle: 43.5 ± 1.2g vs. 300nmol/kg PYY2-36(4H): 41.7 ± 0.7g, p < 0.01; body weight on day 
































































Figure 4.31 Effect of subcutaneous administration of increasing doses PYY2-36(4H) on (A) food intake 
and (B) body weight, in C57BL/6 DIO mice (n=7/14). Peptide and vehicle (saline) administered daily. 
Data are shown as mean ± SEM.  Shaded grey area is the dose at 300nmol/kg, followed by 
1200nmol/kg in the white area, followed by 2400nmol/kg in the days of the shaded red area. GEE 
































4.2.4.5 Effect of chronic administration of PYY2-36(4H) on food intake and 
body weight in rats 
There was no significant difference between the average body weights of the vehicle control 
group and the PYY2-36(4H) group at the start of the study.  
Daily s.c. injection of PYY2-36(4H) 1:1 Zn at 300nmol/kg from day 0-16, followed by daily s.c. 
injection of PYY2-36(4H) 1:1 Zn at 600nmol/kg from day 17-28, significantly decreased food 
intake on day 1 of the study and continued to cause a decrease in food intake (FI) until day 
28 (cumulative FI by day 28: vehicle: 823.2 ± 18.7g vs. 600nmol/kg PYY2-36(4H): 749.9 ± 9.2g, 
p < 0.05) (Fig 4.32(A)). The PYY2-36(4H) group had a lower average body weight than the 
vehicle group and the difference in body weight was significant from day 3 until day 28 
(body weight on day 3: vehicle: 491 ± 12g vs. 300nmol/kg PYY2-36(4H): 483 ± 10g, p < 0.05; 
body weight on day 28: vehicle: 544 ± 15g vs. 600nmol/kg PYY2-36(4H): 512 ± 9g, p < 0.001) 








































































Figure 4.32 Effect of subcutaneous administration of increasing doses PYY2-36(4H) on (A) food intake 
and (B) body weight, in male Wistar rats (n=9). During the days of the unshaded white area, the dose 
was 300nmol/kg, followed by 600nmol/kg for the duration of the shaded grey area. Peptide and 
vehicle (saline) administered daily. Data are shown as mean ± SEM.  GEE and Mann-Whitney 





4.2.4.6 Investigation of immunogenicity of PYY2-36(4H) 
At the end of the chronic studies described above, blood was collected from the animals and 
plasma screened for immunogenicity, by testing for the presence of antibodies against PYY 
and antibodies against PYY2-36(4H). Plasma samples from studies with daily administration of 
PYY2-36(4H) did not show any increase in binding of 
125I-PYY2-36(4H) in rats, after 28 days daily 
injections. Nor was there any increase in binding of 125I-PYY3-36 from both rat and mouse 
chronic studies. Plasma from five out of fifteen mice which received PYY2-36(4H) bound 
125I-
PYY2-36(4H) by the end of the study (average PYY2-36(4H) group binding is 12.6%) (Table 4.10) 
 
*Average binding of the group is corrected against control groups 
  
Table 4.10 Summary of the chronic data studies with PYY2-36(4H) and immunogenicity of terminal 





































The observation that intravenous PYY3-36 administration to both lean and obese humans 
resulted in a decrease in food intake (Batterham et al., 2002, Batterham et al., 2003a) has 
raised interest in PYY3-36 and its receptor as potential targets for development of therapeutic 
agents for the treatment of obesity. However, there are a number of considerations with 
developing peptide therapeutics.  The first is avoiding unwanted side effects, which have 
limited development of other obesity therapies.  Next is prolonging the duration of action of 
the peptide, as the short half-life of native PYY limits its clinical use.  The first part of this 
work details studies investigating a PYY analogue as a potential therapeutic agent (section 
4.2.1).  However during these studies it became apparent that the designed analogue 
provoked an immunogenic response (section 4.2.2.1) when administered on multiple 
occasions to rats and dogs. Therefore the second part of this chapter presents a summary of 
the investigations I completed to identify the potential causes of immunogenicity and the 
approaches used to reduce this non-desirable side effect. 
When designing potential analogues of PYY3-36, it was important to consider the analogues’ 
affinity to the NPY receptors. PYY3-36 binds selectively to the Y2r but also has affinity (albeit 
low) to the Y1r, Y5r and Y4r. Maintaining the selectivity at the Y2r is a critical requirement to 
prevent off-target effects. In particular, Y1r activation results in orexigenic effects (as with 
NPY binding to hY1r in the arc (Jung and Kim, 2013) in contrast to the inhibition of food 
intake that is exhibited with Y2r activation. Species specificity also had to be considered as 
the vast majority of the efficacy work for a potential human drug was completed in the 
mouse, however the hY2r and mY2r share 98% amino acid sequence identity (Lo et al., 
2005). From the receptor ligand studies I completed, PYY2-36(αLTX-4H) was shown to have 
selectivity for the Y2r over the Y1r. Compared with PYY3-36 (fig. 3.1), PYY2-36(αLTX-4H) was 
shown to be about 3-fold worse at both human and mouse Y2r receptors. This 3-fold 
decrease in affinity at the Y2r would impact on doses chosen for in vivo studies (sections 
3.1.3 and 3.1.5). At the hY1r, PYY2-36(αLTX-4H) bound approximately 16-times worse 




I then looked at the pharmacokinetic properties of the PYY analogues.  There are two 
aspects of pharmacokinetics that are important to consider.  The first is that of a ‘burst 
effect’:  PYY is known to cause nausea in human when plasma levels rise rapidly (le Roux et 
al., 2008b). The second is the rate of release, elimination and degradation of the peptides.  
Peptide therapeutics have to be given as subcutaneous injections, due to low bioavailability 
when given orally.  A low frequency of injections will improve patient compliance with the 
therapy, and so slow release and elimination are ideal.  Indeed, any analogue of PYY3-36 to 
be developed as a potential therapeutic agent had to provide at least 24hr coverage 
following a single administration, whilst not having any bursts of release causing spikes in 
plasma levels. 
Reducing the burst effect was facilitated by the addition of 4 His residues and using a zinc 
chloride solution.  The addition of 4 His residues in the analogue PYY2-36(αLTX-4H) prevented 
a rapid rise in hormone levels, with a  steady rise to Cmax at 60mins.  Although zinc chloride 
had no effect on the initial burst in levels of native PYY3-36, when the analogue PYY2-
36(αLTX-4H) was administered with zinc chloride, this further diminished the rate of increase 
in plasma levels, with a Tmax at 48h post injection.   The zinc is thought to prolong peptide 
release by forming stable hexamers that allow slow release from a subcutaneous depot 
(Brange and Langkjoer, 1993, Brange and Langkjaer, 1997).  This slow rise will likely limit the 
onset of nausea.   
These features also affected the length of time the peptide remained present in the blood.  
Native PYY has a half-life of 8 minutes, measured after IV administration reached a steady 
state (Lluis et al., 1989). By contrast, after a bolus SC administration, the addition of Pro2 and 
the αLTX-4H sequence in PYY2-36(αLTX-4H) demonstrated elevated peptide levels until 24 
hours.   This difference in PK profile may be due to the route of administration or the 
resistance of PYY2-36(αLTX-4H) to hepatic or renal enzymatic degradation or resistance to 
renal clearance. Formuation of native PYY3-36 with zinc chloride did not demonstrate 
extended elevation of plasma levels which declined rapidly and had decreased by 98% 
within 3 hours.  However, the complex of PYY2-36(αLTX-4H) with zinc chloride showed 
elevated levels were maintained for 7 days, after one SC injection.   
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However, a pharmacokinetic profile alone cannot determine the length of efficacy of a drug 
in vivo. These can be investigated in feeding studies.  During the acute feeding studies in 
overnight fasted mice, both PYY3-36, and PYY2-36(αLTX-4H) (not formulated with Zn) 
demonstrated similar potency as PYY3-36 at reducing food intake initially, with both peptides 
significantly inhibiting food intake in the 0-1h interval (figure 3.2). However, PYY3-36 only 
caused a transient reduction of food intake while PYY2-36(αLTX-4H) continued to significantly 
reduce food intake compared to both vehicle and PYY3-36 in the 2-4 and 4-8h time intervals 
post-injection. This extended length of action could be due to a difference in release from 
the subcutaneous injection site or a longer circulatory half-life in plasma.  To further 
investigate this, a more complex PK investigation would be required where the clearance 
rate from steady state by IV infusion would need to be determined.  
While acute studies can screen compounds rapidly and obtain information on the potency, 
efficacy, and duration of action of a compound in vivo, effects of a drug over a longer dosing 
period (e.g. 28 days) are also needed in order to demonstrate a maintained reduction of 
food intake and body weight without escape from the compound tested. Published work 
from other groups (Reidelberger et al., 2008, Chelikani et al., 2007, Chelikani et al., 2006) 
have shown a modest reduction in body weight after chronic administration of PYY3-36 in 
rats, testing various dosing and administration regimes.  
Currently available peptide therapeutics, such as insulin and GLP-1 analogues, are 
administered as subcutaneous injections as bioavailability of peptides is low after oral 
administration.  Reduced frequency of injections improves patient compliance, and it would 
be ideal to develop a once-weekly PYY analogue formulation. Although a once-weekly 
injection would be ideal, I decided to administer the peptides daily because high doses of 
PYY2-36(αLTX-4H) would be required to provide weekly coverage as small mammals have 
very high peptide metabolism rates.  
Chronic feeding studies were conducted where PYY2-36(αLTX-4H) (formulated with zinc) was 
administered daily to rats for 14 days, and mice for 29 days. The analogue caused a 
sustained inhibition of food intake and a reduction of body weight (figure 3.8 and 3.9). The 
percentage reduction in body weight caused by 3000nmol/kg PYY2-36(αLTX-4H) was greater 
in mice than in rats over a 14 day period, likely to be a result of using an obese mouse model 
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and a lean rat model. Stress may have also influenced the studies as rats are more 
susceptible than mice to stress induced by daily SC injections, which reduces the anorectic 
effect of PYY3-36 (Abbott et al., 2006). Nevertheless, demonstrating the anorectic effect of 
chronic administration of PYY analogues in both rats and mice provides greater support that 
the peptide would be anorectic in humans compared to only testing in a single model 
organism.  
Several studies have shown that continuous administration of PYY3-36 only transiently 
reduces food intake and body weight in rodents (Pittner et al., 2004). This brings into 
question if receptor down-regulation or tachyphylaxis (Savini, 1964) occurs when PYY3-36 is 
repeatedly administered  (Chelikani et al., 2007). In the presented chronic studies where 
peptides were administered once daily by subcutaneous injection, a continuous effect on 
food intake and body weight was observed providing evidence against receptor down-
regulation or tachyphylaxis occurring. Moreover, when doses were increased during the 
study (“dose ramping”) to prevent nausea during the early phase of the study, animals still 
responded acutely to the increase in dose, suggesting there was no desensitisation in the 
system.  
In a formal toxicology study of PYY2-36(αLTX-4H) conducted in dog, it was found that plasma 
from animals which had received multiple doses of the peptide bound iodinated PYY2-
36(αLTX-4H) (
125I-PYY2-36(αLTX-4H)). When plasma samples from the chronic rat study were 
tested (section 3.2), a similar pattern was observed with 125I-PYY2-36(αLTX-4H) binding to the 
plasma. The likely cause of 125I-PYY2-36(αLTX-4H) binding to plasma would be the presence of 
anti-drug antibodies (ADAs) against the compound present in the plasma, caused by an 
immunogenic reaction. This side effect was not entirely unexpected as PYY2-36(αLTX-4H) is a 
protein which could contain immunogenic sequences (Kessler et al., 2006) resulting from 
the helix-forming sequences of the αLTX protein (Holz and Habener, 1998). Also, the 
subcutaneous route of administered is known to be the more immunogenic than others 
such as intraperitoneal or intravenous (Schellekens, 2002, Kessler et al., 2006). As 
mentioned above, immunogenic responses range from no demonstrable effects to loss of 
drug efficacy. The types of ADAs produced can also range from non-neutralising to those 
that severely cross-react with endogenous molecules. Although immunogenicity cannot be 
predicted from one species to another (Schellekens, 2002), and the analogue tested in rat 
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and dog was based on human sequence PYY2-36 (which could cause false positives) it was 
decided unsafe to continue developing this peptide in the event of the induction of 
immunogenicity in man. However, understanding why this analogue caused an 
immunogenic reaction will help develop less immunogenic peptides in the future.   
PYY2-36(αLTX-4H) is a relatively small protein with a molecular weight of ~4kDa (Considine et 
al., 1996), and is a highly purified, synthetically synthesised peptide with >95% purity 
(section 2.1.2). It also contains only naturally occurring amino acids. These are all factors 
which are likely to reduce the risk of an immune response. However, there are a number of 
features that may cause an immunogenic reaction.   
The first possibility was the use of zinc to form a subcutaneous depot of PYY2-36(αLTX-4H) 
was postulated to be a possible cause of immunogenicity. Zinc has been shown to cause 
immunogenic reactions when used in this way with crystalline zinc-insulin (Kosinski et al., 
2012). However, a study of the immunogenicity of PYY3-36 and PYY2-36(αLTX-4H) formulated 
with a range of zinc to peptide molar ratios found no correlation between presence of ADAs 
and zinc (section 3.2.2). Based on these result, the presence of Zn in the formulation of PYY2-
36(αLTX-4H) was determined not to be important in the generation of ADAs. 
Subsequently, I investigated the part of the molecule that bound to the anti-PYY2-36(αLTX-
4H) antibodies, and thus which part of the peptide initiates the immune response. The three 
different animal species which developed ADAs were tested in case of any species variation 
in antibodies. All three species produces similar types of ADAs.  They all bound fragment 7-
36 with 60% cross-reactivity and 13-36 to a lesser extent. Fragments 2-14, 2-28, and 27-36 
did not bind well to the ADA which suggested that the middle section was important for 
ADA binding but only when presented together with the C-terminal end of the peptide 
(table 3.4). As the substituted αLTX sequence was the most altered part of the analogue, 
and therefore the most “foreign” to the molecule, this finding was not unexpected 
(Schellekens, 2002). The importance of the C-terminal for immunogenicity was harder to 
establish as fragment 27-36 only bound with low affinity by itself. It may possibly serve to 
stabilise the mid-section of the peptide to make it more recognisable by the ADA. 
Results from the fragments cross-reactivity suggested the ADA recognised a tertiary 
structure and not merely a sequence or particular end of the peptide. Therefore variations 
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of PYY2-36(αLTX-4H) were created (fig.3.11) to elucidate which substitutions/eliminations 
could be made which would not bind the ADA and therefore potentially not cause their 
formation. PYY2-36(αLTX-4H) analogues which still contain the αLTX mid-section but have 
alterations in either the Pro2 residue or any of the four His residues still bind very well to 
the ADA. However there was a trend in decrease of 125I-PYY2-36(αLTX-4H) binding with a 
decrease in the number of His residues (the positions of which do not appear to correlate 
with high binding). Removal of the αLTX mid-section gave a series of analogues which have 
much lower cross-reactivity with the ADA but the trend still existed for a decrease in affinity 
with a decrease in His residues. As His residues are important in forming good subcutaneous 
depots when formulated with Zn, this observation could indicate that aggregation is partly 
responsible for increased immunogenicity. While this discovery is not surprising, native PYY2-
36 bound to ADAs 30% as well as PYY2-36-αLTX-4H which indicates a basal cross-reactivity of 
unaltered PYY (table 3.6). 
While completing the above studies, a strategy to reduce the immunogenicity PYY2-36(αLTX-
4H) itself was investigated. The addition of polyethylene glycol (PEG) to molecules is an 
accepted method of reducing immunoreactivity (Balthasar et al., 2005) of the molecule 
possibly due to a mechanical “shielding” of the epitope by PEG. 
Studies with PYY2-36(αLTX-4H)-PEG, showed that although PEGylation did reduce the 
immunogenic response to exposure of the molecule by approximately 60% (section 3.3.1.4), 
the bioefficacy of PYY2-36(αLTX-4H)-PEG was also reduced (section 3.3.1.2). This could 
conceivably be due to the PEG group disrupting affinity to the Y2 receptor (section 3.3.1.1) 
by either steric hindrance or its location on the molecule (in the same way that PEG reduces 
immunogenicity). Indeed Shechter et al. 2005 demonstrated that PEGylation (40kDa) of 
PYY3-36 abolishes all bioactivity (does not reduce FI at equivalent doses to normal PYY3-36). 
But it was concluded that this was not completely due to the steric hindrance presented by 
the PEG group as acetylation (a very small group – COCH3) of the two most N-terminal 
amino acids (Nα-Nε-diacetyl-PYY3-36) also abolished bioactivity. However, reversible 
PEGylation of PYY3-36 restored some bioactivity, increased the duration of FI reduction, and 
therefore its “functional half-life”. Conversely, Ortiz et al. (Ortiz et al., 2007) showed that 
PEGylated PYY13-36 causes a greater reduction of food intake than its non-PEGylated 
counterpart (i.e. PYY13-36). The C-terminal section of PYY was used for their analogue 
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because it is more selective for Y2r (DeCarr et al., 2007). Therefore the location of the PEG 
group affects bioefficacy.    
The size of the PEG group must also be considered, as PYY must cross the blood brain barrier 
to function effectively (Harder et al., 2004). Molecules up to 40kDa can cross fenestrated 
capillaries of the BBB (Lockie et al., 2012).  PYY2-36(αLTX-4H)-PEG (4.7kDa) and PEG-PYY13-36 
from Ortiz et al. (23kDa) fall below this level, while PEG-PYY3-36 from Shechter et al is above 
this level, and may partly explain the loss in bioactivity of this molecule.  
As the rationale for the design of PYY2-36(αLTX-4H)-PEG was solely to reduce 
immunogenicity, the method of PEGylation to produce a long-acting PYY analogue was at 
odds with the strategy of a slow-release formulation and perhaps may not be jointly utilised 
with the zinc formulation for this analogue of PYY. PYY2-36(αLTX-4H) was already designed to 
have extended bioefficacy without Zn (section 3.1.2). So the use of PEG for this drug to 
prolong its bioefficacy would be redundant and the presence of the PEG moiety was indeed 
found to decrease affinity for the Y2r compared to the non-PEGylated peptide, decrease 
bioactivity at acute feeding studies (fig. 3.12) and worsen pharmacokinetics (fig. 3.14). The 
poor PK profile was likely to be a consequence of the PEG group interfering with the 
subcutaneous depot formation in a Zn formulation (Lee et al., 2005)  
The rationale for designing PYY2-36(αLTX-4H)-PEG was to reduce immunogenicity of the 
peptide. PEGylation has been used to increase functional half-life of molecules (Hatoum and 
Kaplan, 2013).  However, in this case, PYY2-36(αLTX-4H)-PEG was actually found to have 
reduced bioactivity (fig 3.12) and poorer pharmacokinetics (3.14) than the original analogue.  
This is likely to be a consequence of the PEG group interfering with the formation of the 
zinc-complexed subcutaneous depot (Lee et al., 2005) 
Considering all the data generated from the investigation of immunogenicity, it was decided 
that a refined analogue of PYY2-36(αLTX-4H) was the best strategy to reduce immunogenicity 
with minimal consequence on other properties. From the immunogenicity screen of 
analogues (table 3.5), PYY2-36(4H) was selected for its significantly reduced binding of ADAs 
(50% decrease compared to  PYY2-36(αLTX-4H)) while still maintaining as much of the original 
sequence as possible. PYY2-36(4H) was shown to have high affinity to the mouse and human 
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Y2r, while maintaining similar selectivity as the native ligand, PYY3-36 for the Y2r over the Y1r 
(fig. 3.15).  
Taking into consideration all the data generated from the immunogenicity investigations, it 
was decided that a refined analogue of PYY2-36(αLTX-4H) was the best strategy to reduce 
immunogenicity with minimal consequences on other properties. From the immunogenicity 
screen of analogues (table 3.5), PYY2-36(4H) was selected for its similar levels of antibody 
production as PYY2-36 (50% lower than PYY2-36(αLTX-4H), but double PYY2-36).  PYY2-36(4H) has 
a high affinity to both mouse and human Y2 receptors, and has a similar selectivity for the 
Y2r over the Y1r as PYY3-36 (fig 3.15). 
The pharmacokinetic properties of PYY2-36(4H) when delivered with differing amounts of zinc 
were investigated.  Without Zn, PYY2-36(4H) levels peak at 30minutes and return to basal 
levels at 24hrs, like native PYY3-36.  With increasing doses of zinc, Tmax also increases, from 
30mins with 0 Zn, to 24hrs with 0.5:1zin, to 48hr with 1:1 zinc.  It should be noted that the 
concentration of PYY2-36(4H) when given with 1:1 Zn was higher than the maximum 
concentration of PYY2-36(4H) at any point when given without zinc; this may be due to the 
‘true’ Cmax for the analogue without zinc occurring before the first 30min sampling point, or 
because the zinc depot allows accumulation of the peptide within the blood that exceeds its 
degradation.   
Zinc also affected the relative bioavailability of the peptide: it increased it by 6.5 times when 
given with 0.5:1 zinc, and 6-fold higher bioavailability when given with 1:1 zinc.  However, 
this again may be affected by missing higher peaks of peptide level when given without zinc, 
if they peak before the first 30minute sampling point. 
The dose of peptide also affects pharmacokinetics. PYY2-36(4H) was given either at 200mg/ml 
or at 50mg/ml (fig 3.22; section 3.3.2.5), in complex with 1:1 zinc. At both concentrations, 
1:1 zinc gave a desirable PK profile, with no initial burst, and a smooth, slow-release curve 
for one-week coverage (fig 3.25).  At 50mg/ml, Tmax was at 24hrs; at 200mg/ml, it is 
prolonged to 7 days.  The Cmax is increased 3-fold with the 200mg/ml dose compared to 
50mg/ml, and the AUC is increased 6 fold.  The 200mg/ml dose would equate to 1mg/kg in 




PYY2-36(4H) was also compared to PYY2-36(αLTX-4H). At 50mg/ml with 1:1 zinc, the exposure 
level of PYY2-36(4H) is approximately 3 times that of PYY2-36(αLTX-4H). PYY2-36(4H) shows a 
lower percentage of Cmax level of peptide on day 7. This suggests that the αLTX region was 
important in either the subcutaneous depot formation, or in maintaining stability in the 
plasma. At the higher dose of 200mg/ml, there is less difference in exposure levels between 
PYY2-36(4H) and PYY2-36(αLTX-4H) when given with 1:1 zinc. The levels of PYY2-36(4H) are 
approximately double that of PYY2-36(αLTX-4H), and the levels of both peptides remain 
elevated above basal through the time points sample, so that at 8 days post injection, PYY2-
36(4H) is 9x above basal levels, and PYY2-36(αLTX-4H) is 10x above basal levels. A reduction of 
only 30% from Cmax was observed for both peptides at 8 days post injection. 
The effect of PYY2-36(4H) on food intake was also examined.  Acute administration of PYY2-
36(4H) produced a dose-dependent inhibition of food intake in mice (fig 3.17 and 3.18), and 
reduced food intake to a similar extent as PYY3-36 in the 0-2hr interval.  However, even when 
administered without zinc, PYY2-36(4H) continued to significantly reduce food intake at the 2-
4hr time period when compared with both vehicle and PYY3-36.  When administered with 
zinc (fig 3.19), food intake was significantly reduce at 8-24hours, similar to PYY2-36(αLTX-4H) 
without zinc. When directly compared, PYY2-36(4H) reduces food intake with a similar 
potency to PYY2-36(αLTX-4H), but with a reduced duration of action. As with PYY2-36(αLTX-
4H), PYY2-36(4H) was administered daily to rats and mice for 28 days.  Chronic administration 
of  PYY2-36(4H) caused a sustained inhibition off food intake and a reduction in body weight 
in both rats and mice (fig 3.27 and 3.28).  Immunogenicity was measured at the end of these 
studies and rats did not develope ADAs towards native PYY3-36 or PYY2-36(4H). Plasma from 
mice were shown not to possess ADAs towards native PYY3-36 however a third tested 
positive for ADAs towards the drug. Of those that did, the percentage binding of the animals 
were just above the cut-off threshold for positive identification of ADAs suggesting only a 
weak immunogenic reaction and an overall low average binding to ADAs for the whole 




PYY2-36(αLTX-4H) displayed many properties which suggested a potentially useful agent for 
development as a treatment of obesity. However, the level of antibody production 
provoked by chronic administration of the agent in preclinical studies was considered too 
high to continue the peptides development. Investigation of the cause of immunogenicity 
suggested that no particular sequence was responsible, and the tertiary shape was 
important. However, the αLTX domain was important for the binding of ADAs. The removal 
of this region increased the clearance rate of the peptide following a single subcutaneous 
injection. However, the activity of the peptide remained favourable and the peptide’s ability 
to cause an immunogenic response was similar to that of native peptide. 
PYY analogue PYY2-36(4H) has been selected to undergo a formal assessment of safety for 
administration to humans. Whilst the majority of this work is outsourced to facilities 
regulated by good laboratory practice (GLP), samples generated from these studies will 
















The work in this thesis consisted of 2 sections. The first examined the development of an 
enzyme-resistant, longer-acting analogue of the satiety molecule PP. For the purpose of 
rational analogue design, I investigated how the native peptide is degraded by tissue 
preparations and individual enzymes known to degrade hormones. Based on these results, I 
aimed to investigate the effects of altering different domains of the primary sequence of PP 
to attempt to create more potent and/or longer-acting analogues. The second part of my 
work investigated the immunogenic properties of a novel analogue of PYY3-36. I aimed to 
standardise the method in which immunogenicity was detected, and measured and 
investigated the contribution of the Zn delivery system and modified domains of the 
analogue towards its immunogenicity. 
Data analysed by the Health and Social Care Information Centre (HSCIC, 2014) between 
1993-2014 showed that in England, adults with normal BMI decreased by 9% and the 
proportion of adults that were obese increased by almost 100%. The underlying causes of 
the UK’s (and most of the developed world’s) obesity epidemic is due to present-day 
“obesogenic” environmental factors (such as easy access to cheap, high-energy food sources 
and the reduced requirement for physical exercise) and evolutionary factors that predispose 
to weight gain (Weinsier et al., 1998; Bloom et al., 2008). Although lifestyle modification 
through caloric restriction and enhanced physical activity remain the first line treatment for 
obesity, the most effective treatment is bariatric surgery. However, it is impractical to use 
surgery to treat the increasing numbers of obese patients (Christou and Efthimiou, 2009; 
Garb et al., 2009; Martins et al., 2010) due to the need for specialist personnel and centres, 
high costs, and the risk of complications and/or mortality. 
Recent findings have demonstrated that GLP-1 and PYY are increased after bariatric surgery 
(Duan et al., 2014), which may contribute to the reduced appetite and loss of body weight 
seen after surgery. Mimicking the post-bariatric state by peripherally administering gut 
hormones to the obese may therefore be a logical, less costly therapeutic approach (Korner 
et al., 2005; Le Roux et al., 2006a).  A  number of gut hormone therapies are currently in 
development (Tan and Bloom, 2013b). 
267 
 
A further attraction of using gut hormones is that, as their physiological purpose is to 
regulate food intake, biological therapies based on these hormones will have a high 
specificity and low toxicity.  This contrasts with previously approved anti-obesity treatments 
such as fenfluoramine, dexfenfluoramine, fen-phen, sibutramine, and rimonabant. These 
were all synthetic drugs, modelled on small molecules with ubiquitously-expressed 
receptors.  As described in section 1.3.4, these drugs have all been associated with 
significant side-effects due to their wide-range of effects, and have therefore all been 
withdrawn from the market. 
Nevertheless, gut hormone therapies do present their own challenges.  Native peptides 
have short half-lives in circulation, which limits their efficacy and ease of administration.  
Therefore logical therapeutic development requires consideration of peptide characteristics, 
interaction with targets, structural analysis, stability studies, pharmalogical parameters, 
sequence modifications and high throughput screening.  Moreover, all drugs may be subject 
to side effects, including the development of immunogenicity, and therefore must undergo 






5.2 DEVELOPMENT OF AN ENZYME-RESISTANT PP 
ANALOGUE 
PP is an attractive target when developing an anti-obesity therapy as it was shown to 
decrease food intake and appetite without the undesirable side-effect of nausea (Batterham 
et al., 2003b). The development of PP as an anti-obesity agent has to overcome its short 
half-life allowing less frequent administration, reduced cost of manufacturing, improved 
patient tolerance and compliance. To improve on its half-life, this chapter aimed to 
investigate the weakness points in the molecule through the use of liver and kidney 
membrane preparations. These organs were chosen for their role in the metabolism and 
clearance of the majority of pharmacotherapies and it is possible to predict in vivo 
metabolic clearance using in vitro techniques with good correlation (Houston, 1994, Kenny 
and Stephenson, 1988).  
In both tissues, I found PP was degraded to PP3-36. This breakdown occurred through the 
action of DPPIV enzyme which is present in preparations of liver and kidney, which was 
confirmed by incubation of PP with purified enzyme. Unlike the deactivation of GLP-1 by 
DPPIV, PP3-36 remained bioactive albeit for shorter time periods compared to full length 
PP. Moving the target sequence of Pro2 through removal of Ala1 (DesAla-PP) or extension 
by the addition of an extra residue (e.g. PP-Ala0) protected against DPPIV in vitro without 
altering Y4 receptor affinity. In vivo tests showed that these analogues of PP were effective at 
reducing food intake for extended periods of time compared to the native molecule. Results 
suggested than protection from DPPIV was achievable with minimal detrimental effect on the 
molecule’s other properties resulting in an improved pharmacological action. Other methods of 
conferring DPPIV-resistance were considered including dimerisation (PP-Cys0 homodimer) 
however, not only was this analogue more costly and time-consuming to synthesise, it bound 
>2-times less effectively at the Y4r. 
Products which matched those you would expect from trypsin degradation were observed in in 
in vitro digests of PP with RLM and RBB tissue extracts. As well as the generation of these 
products of breakdown, trypsin was hypothesised to be a relevant enzyme to investigate 
due to subcutaneous enzymic activity that is sensitive to trypsin inhibitors (Ogiso et al., 
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2000). All Arg residues in the PP molecule were targeted by trypsin as confirmed using 
purified enzyme. Most single substitutions of these residues did not greatly affect receptor 
affinity; however replacement of Arg33 or Arg35 with an Ala residue decreased receptor 
affinity significantly. In vitro analysis of these analogues demonstrated that resistance to 
trypsin is only acquired through double substitutions at Arg25,26. None of the analogues 
designed to protect against trypsin were more effective at reducing food intake than native 
PP. In fact, the Ala33 and Ala35 substitution were totally inactive in vivo despite being tested at 
higher dose levels than required for PP to inhibit food intake. 
There were other fragments from digests with the tissue extracts whose target sites were 
less well-defined. A common feature was the middle location of the target residues and 
often they were found to be small and hydrophobic amino acids. Amongst the numerous 
endopeptidases, I decided to investigate NEP as it is found in the tissues being studied as 
has previously been implicated in the breakdown of other gut hormones such as GLP-1 and 
PYY. Co-administration of PP with the metallopeptidase inhibitor, phosphoramidon (Kenny 
et al., 1981, Medeiros and Turner, 1994), indeed demonstrated that the anorectic effects of 
PP can be sustained. However, this effect may not be exclusively attributed to the 
preservation of PP by phosphoramidon as other NEP-targeted satiety signals such as GLP-1 
(Hupe-Sodmann et al., 1995, Goke et al., 1993) and PYY (Addison et al., 2011) may equally 
be saved from degradation, although the concentration of these endogenous signals will be 
minor in comparison to the pharmacological doses of PP used. In addition, as 
phosphoramidon is not a specific NEP inhibitor, it may be inhibiting the enzymic actions of 
other metallopeptidases which could potentially contribute to PP degradation. Furthermore, 
measurement of circulating plasma levels of PP in the presence of phosphoramidon shows 
65% higher concentrations compared to PP alone at longer time points suggesting that 
phosphoramidon (and therefore metallopeptidases) does indeed have a role in the 
breakdown of PP in vivo. 
Based on the fragments identified through tissue digests, key residues in the secondary 
structure domains of the PP molecule were revealed: position 6 located in the polyproline 
region, and positions 16, 17, 19, 23, and 30 in the α-helical region. Through alignment of 
these sections against sequence homologies found in related molecules, cycles of peptide 
design and selection were driven by in vitro screenings at the Y4 receptor, NEP digests, and 
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anorectic bioactivity in vivo. Analogues of PP were ultimately developed that had increased 
affinity to the Y4r and improved resistance to NEP digests in vitro. These analogues also 
exhibited prolonged effects on inhibition of food intake and/or increased potency in vivo 
(equal anorectic effects compared to native PP but at significantly lower doses). However, it 
was not always found that analogues with greater receptor affinity were more potent in 
vivo, nor that resistance to NEP in vitro consistently correlated with extended in vivo 
bioefficacy.  
I proposed a scheme that initial resistance to DPPIV is required before there is any beneficial 
effect of resistance to NEP suggesting there is an order of enzyme degradation where DPPIV 
precedes NEP or trypsin. It is possible that DPPIV provides the initial breakdown step which 
destabilises the PP-fold structure and exposes other areas of the molecule to be degraded 
by other enzymes. Since Pro2 in native PP is the main interaction partner for Tyr27 (Nygaard 
et al., 2006), its loss following DPPIV cleavage can cause destabilisation of the PP-fold 
structure thus making the molecule more unstable and more susceptible to proteolytic 
degradation. This would also somewhat explain why the fragments of PP degradation using 
tissue extracts and purified enzymes do not always correspond. It may also explain why 
protecting against one enzyme (such as trypsin) is not always effective in producing 
analogues with enhanced biological effect. Thus, despite identifying PP fragments with 
trypsin target sites after incubation with tissue extracts, it may play a secondary role in the 
degradation of PP and perhaps, only in the presence of other enzymes. 
Another detail that this entire process does not take into account are the enzymes present 
in blood, plasma or the subcutaneous fat relevant to drugs administered by this route. 
Although the enzymes that could potentially be investigated are great, this thesis does not 
aim to study the multitude of potential enzyme candidates and their individual roles in 
generating an enzyme-resistant peptide analogue. However, I have demonstrated that it is 
possible to design a peptide drug based on an endogenous satiety molecule that has 
improved pharmacokinetic and pharmacodynamic qualities to make it a viable 
pharmacotherapy for obesity. 
A limitation of the MALDI-TOF MS method used in this chapter was that it was not 
quantitative. However, there is usually a correlation between peak signal intensity and 
271 
 
concentration of peptide generating the signal. Peak intensity in MALDI has significant 
analytical variation (for example, depending on peptide ionisation efficiencies, which are 
influenced by a peptide's composition and the chemical environment). This phenomenon is 
poorly understood because not only is peak intensity related to the concentration of the 
individual protein, but also to its primary structure, and to the complexity of the sample. In 
other words, the sensitivity of a mass spectrometer varies between peptides. Thus, two 
peptides at equal concentration will not necessarily have equal peak intensities (Timm et al., 
2008). When identifying the main fragments produced in digests, it is therefore not entirely 
desirable to choose the principle degradation products based on intensity signal of the 
corresponding peak.  
It is probably more correct to fractionate digests before analysis by MALDI-TOF. However, as 
found with the results from this chapter, the total number of identified fragments increased 
when analysing separate HPLC fractions of digests. This may be due to the reduced 
noise:signal ratio when examining individual fractions by HPLC compared to the MS analysis 
of whole digests. This method of analysis would reveal MS peaks which may have been 
supressed by other ions present in a whole digest. A preferred method may be LC-MS/MS 
which directly analyses individual peaks as they elute from the HPLC column and thus 
adjusting sensitivity for each peak on the MS as it arrives. 
 
FUTURE WORK 
Apart from Y4r affinity and susceptibility to degradation, there are a number of parameters 
that can be investigated using peptide analogues.  These could include Y4r selectivity 
compared to Y1r, Y2r and Y5r; receptor activation through the peptide’s ability to decrease 
cAMP production; bioavailability of the peptide to the receptors expressed in the CNS; 
mechanisms affecting the ‘on-time’ of a peptide at its receptor (Kd - dissociation constant); 
any potential receptor signalling bias. Therefore, future work may aim to investigate these 
parameters in investigating relationships where the altered bioactivity of an analogue is not 




5.3 IMMUNOGENICITY OF A LONG-ACTING 
ANALOGUE OF PYY3-36 
 
PYY3-36 is potent peripheral satiety signal, released from the GI tract following a meal 
(Morinigo et al. 2008; Rodieux et al. 2008; Holdstock et al. 2008; Vidal et al. 2009). The 
reduced appetite and weight loss observed in post-bariatric patients has been suggested to 
be partly due to increased circulating satiety signals such as PYY and GLP-1 (Degen et al. 
2005; Sloth et al. 2007a; Sloth et al. 2007b; Le Roux et al. 2008; Gantz et al. 2007). The 
peripheral administration PYY3-36 has been shown to decrease in food intake in lean and 
obese human volunteers (Batterham et al. 2002; Batterham et al. 2003a; Degen et al. 2005; 
Le Roux et al. 2008) and therefore appears to be a promising anti-obesity agent. 
In the second half of my thesis I investigated the immunogenicity of an analogue of PYY 
(PYY2-36(αLTX-4H)) which we had designed and initially chosen as the candidate to take 
through to clinical trials for an obesity therapy. The immunogenicity of a novel drug is 
animportant factor to consider in the design of a peptide therapy. As the lead candidate, 
PYY2-36(αLTX-4H) had passed all the necessary requirements of an enhanced analogue PYY3-
36. Although receptor affinity was 3-fold worse compared to native PYY3-36 across human and 
mouse variants, it maintained selectivity at the Y2r over Y1r. In vivo, PYY2-36(αLTX-4H) was 
more potent than native PYY3-36 and had prolonged anorectic effects. Pharmacokinetics of 
this compound were significantly improved as circulating levels remaining raised for 24h 
without formulation with zinc and up to 7days in the presence of equimolar zinc. Chronic 
administration of this drug in both rats and mice caused sustained reductions in food intake 
and body weight. The drug was then outsourced for toxicokinetic studies and after 10 
dosings in dogs, plasma was sent to us for analysis of ADAs. The high level of 
immunoprecipitation of radiolabelled drug suggested the presence of ADAs, which was also 
found in the chronic rodent studies. The antibody production provoked by chronic 
administration of the agent was considered too high to continue with development of this 
analogue of PYY3-36. 
273 
 
The immune assessment for ADAs normally comprises 3 steps: a screening step to detect 
the presence of binding ADAs, a confirmation step to confirm specificity of the response and 
finally characterisation of the ADAs. At the screening step, samples are positive if they have 
values greater than the assay cut point which is defined as values greater than signal:noise 
ratio. This means that if the noise amongst the control (vehicle-treated) group is high, the 
cut point is also relatively higher and vice versa. Low cut points can generate false positives 
and high cut points can potentially produce false negatives. The most suitable cut point 
provides moderate risk in producing false positives or negatives. 
After identifying positive samples, they are analysed in the specificity confirmation assay 
where the signal of high binding of the radiolabelled drug is displaced in the presence of 
increasing concentrations of unlabelled drug (competition assay). The samples that displace 
to a pre-determined extent are reported as positive for binding ADAs and are normally 
further characterised for neutralising activity in a biological assay. However, I did not do any 
characterisation of ADAs in this thesis as my aim was to redesign the analogue of PYY to 
reduce the immunogenicity while still retaining as many of its beneficial 
pharmacotherapeutic qualities. 
Initial studies found that the presence of zinc in the drug formulation did not affect the 
development of ADAs. The presence of zinc also did not induce the formation of ADAs when 
formulated with native PYY3-36. ADA-positive samples from rat, dog and sheep were used in 
competition assays in order to investigate the epitope of the ADA using peptide fragments 
of the drug. Unsurprisingly, there was greater displacement with the bigger fragments; 
however, the least displacement was found with the N-terminal fragment which did not 
contain the αLTX sequence. I concluded that it was impossible to determine exactly the 
particular sequence responsible for binding to the ADA; however the tertiary shape of the 
molecule was important.  
Finally, I tested the effect of the number of substituted His residues and their location in the 
competition assay with ADA-postive samples. There was a modest decrease in displacement 
with decreasing numbers of substituted His residues in the drug, suggesting the epitope of 
the ADA partly involves these His residues. However there was significant decrease in 
displacement when the αLTX sequence was removed altogether, which further confirms this 
274 
 
region as the main sequence recognised by the ADAs. With the removal of the αLTX 
sequence, there was little effect of the numbers of His residues present. 
It was important to preserve as many His residues as possible as the method of the slow 
release of this drug depended on the presence of His to increase its isoelectric point to near 
neutral pH. This would make the drug less soluble at the physiological pH of the SC injection 
site. His residues are also thought to have a role in further delaying the release of the drug 
in combination with zinc (Bal et al., 2001). 
PEGylation of PYY2-36(αLTX-4H) was also investigated for ability to develop ADAs, as well as 
all the properties that would make this version of the drug a suitable replacement therapy. 
While it retained selectivity for the Y2r over the Y1r, it bound with almost 7-times less 
affinity compared to native PYY3-36, and 2-fold worse compared to the unPEGylated version. 
It was also less potent in vivo as a 8-fold higher dose was needed to produce the same 
inhibition of food intake as the unPEGylated version. Remarkably, although an extended 
effect on bioactivity was expected, this was found not to be the case in acute feeding 
studies in mice. This can partly be explained by the poor PK profile seen in rats. Time to 
Cmax was reduced from 48h for the unPEGylated drug, to 24h for the PEGylated drug. 
Disappearance rate of the PEGylated drug was also increased with more than 50% loss seen 
at 24h after Tmax. This is in stark contrast to the PK of the original drug which had raised 
circulating plasma levels up to 7 days post-injection. The only redeemable quality of the 
PEGylated PYY analogue was its reduced immunogenic response. Although less 
immunogenic, due to all the other less desirable properties of PYY2-36(αLTX-4H)-PEG, it was 
abandoned in favour of redesigning the analogue without the αLTX sequence to create PYY2-
36(4H). 
PYY2-36(4H) bound with similar affinity to native PYY3-36 at the Y2r, though was more 
selective for the Y2r over the Y1r, compared to PYY3-36. Acute administration in vivo showed 
a dose-dependent prolonged anorectic effect compared to native PYY3-36; however it was 
less potent compared to the original drug. The inhibition of food intake could be further 
sustained in the presence of zinc formulation. This was confirmed in a zinc dose response in 
a PK study where higher amounts of zinc delayed the release of peptide the most. While not 
a 7day PK profile like the original PYY3-36 analogue, PYY2-36(4H) had a modest 4 day PK profile 
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that was still significantly extended compared to PYY2-36(αLTX-4H)-PEG. This PK profile is 
enhanced at higher concentrations of drug so that at 200mg/ml, PYY2-36(4H) has the same 
PK as PYY2-36(αLTX-4H). 
Although PYY3-36 has been shown to cause a modest decrease in food intake and body 
weight in human volunteers, this was only achieved using high doses of IV-infused peptide 
which also often induced nausea (le Roux et al., 2008b, Sloth et al., 2007, Degen et al., 
2005). The SC administration of PYY3-36 had no effect on feeding even at much higher 
pharmacological doses (Sloth et al., 2007). A stable analogue of PYY3-36 such as PYY2-36(4H) 
would have a longer plasma residence time and thus may result in higher efficacy at 
decreasing appetite, food intake and body weight.  
I demonstrated that chronic administration of PYY2-36(4H) to rats and mice, like PYY2-36(αLTX-
4H), produced sustained reductions in food intake and body weight. Most importantly, 
screening of plasma for ADAs after 28days treatment showed no samples positive for ADAs 
in rats and a few low signal positive samples in mice. Analogue PYY2-36(4H) was thus selected 
to undergo formal of safety assessments for administration to humans. While the majority 
of this work is outsourced to facilities regulated by good laboratory practice (GLP), samples 
generated from these studies were continued to be routinely tested for immunogenicity. 
It is also encouraging that rodents remained acutely sensitive to the effects of the PYY 
analogue even after 28 days of daily injections suggesting that receptor desensitization 
and/or tolerance previously hypothesised to be associated with continuous administration 
of PYY and other gut hormones in osmotic minipumps, may not occur when following this 






While the extended bioefficacy of the drug can be partly explained by enhanced PK, 
receptor potency would be a useful parameter to test, as well as potency of the peptide to 
the receptors expressed in the CNS. Future work would therefore aim to elucidate the 
mechanism by which this analogue of PYY is superior to the native peptide. This could 
include ICV administration of the drug or administration of the analogue in an osmotic 
minipump which would remove the delayed-release effect of the analogue and overcome 
the short half-life of native PYY. Another feature worth investigating is the effect of SC depot 
on integrity of the drug. 
Further work is warranted in species such as the dog, where side effects of nausea 
(vomiting) are apparent, in order to compare the effects of slow-release administration 
regimes and the effects of long-acting analogues such as PYY2-36(4H)  with and without zinc 
in their utility as potential anti-obesity therapies.   
 
In conclusion, this thesis has developed an analogue of PP and PYY3-36 with improved 
enzyme resistance and improved affinity for the Y4r or Y2r receptor. In vivo experiments 
have shown that the analogues inhibit food intake acutely and chronically. During the 
development of PP, a number of PP analogues were generated which were useful in 
elucidating the complex structure-activity relationship between PP and the Y4r. Additionally, 
issues with immunogenicity of a novel peptide drug have been solved without too much 
compromise on bioactivity. Further development of the PP and PYY3-36 lead candidates may 
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APPENDIX A – AMINO ACID CODES 
 
Name   Abbreviation  Single letter code 
Alanine    Ala     A 
Cystine    Cys    C 
Aspartic acid    Asp    D 
Glutamic acid    Glu    E 
Phenylalanine   Phe    F 
Glycine    Gly    G 
Histidine    His    H 
Isoleucine    Ile     I 
Lysine     Lys     K 
Leucine    Leu     L 
Methionine    Met     M 
Asparagine    Asn     N 
Proline    Pro     P 
Glutamine    Gln     Q 
Arginine   Arg     R 
Serine     Ser     S 
Threonine    Thr     T 
Valine     Val     V 
Tryptophan    Trp     W 
Tyrosine    Tyr     Y 
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APPENDIX B – ANALOGUE SEQUENCES 




APPENDIX C – BUFFERS AND SOLUTIONS 
LYSOGENY BROTH (LB) 
1L distilled water, 10g Bactotryptone, 5g Yeast extract, 5g NaCl. Adjust pH to 7.5 with 10M NaOH. 
Sterilise by autoclaving. 
 
TFB I (30MM KOAC/50MM MNCL2/100MM RBCL/10MM CACL2/15% GLYCEROL) 
1.472g KoAc, 4.95g MnCl2, 6.05g RbCl, 0.735g CaCl2·2H2O, 75ml Glycerol. Adjust pH to 5.8 with 10% 
v/v acetic acid. Bring final volume up to 0.5L with distilled water (approximately 420ml). Sterile filter 
and store at 4°C.  
 
TFB II (10MM NA MOPS PH 7.0/10MM RBCL/75MM CACL2/15% GLYCEROL) 
1.046g MOPS, 5.513g CaCl2·2H2O, 0.605g RbCl, 75 ml Glycerol. Adjust pH to 7.0. Bring final volume 
up to 0.5L with distilled water (approximately 420ml). Sterile filter and store at 4°C. 
 
ALKALINE SDS (0.2M NAOH/1% SDS) 
93ml distilled water, 5ml 20% SDS, 2ml 10M NaOH 
 
GTE (0.9% GLUCOSE/0.25M TRIS/0.01M EDTA) 
182ml distilled water, 9ml 20% glucose, 5ml 1M Tris base pH8, 4ml 0.5M EDTA pH8 
 
50X TAE (TRIS/ACETATE/EDTA) 
242g Tris base, 57.1ml glacial acetic acid, 100ml 0.5M EDTA pH8. Bring final volume up to 1L with 
distilled water (approximately 840ml).  
This stock solution can be diluted 1:50 with water to make a 1x working solution (final 
concentrations: 0.04M Tris/0.02M acetic acid/ 0.001M EDTA) 
 
GEL LOADING BUFFER (25% GLYCEROL/0.025M EDTA/1MG/ML ORANGE G) 
3.125ml 80% glycerol, 50μl 0.5M EDTA, 6.325ml distilled water, 10 mg orange G 
 
1X TE (0.01M TRIS/0.001M EDTA) 





TES (0.06M TRIS/0.006M EDTA/0.06 NACL) 
182.5ml distilled water, 12.5ml 1M Tris base pH8, 2.5ml 0.5M EDTA pH8, 2.5ml 5M NaCl 
 
CAESIUM CHLORIDE SATURATED PROPAN-2-OL 
100g CsCl vigorously mixed with 100ml distilled water and 1L propan-2-ol. Leave to settle. Three 
phases are produced: upper propan-2-ol layer saturated with CsCl, middle layer of water, lower 
phase of excess CsCl. 
 
0.1M PEI (AV MW 25KDA) 
450mg High MW PEI dissolved in 80ml GDW and allowed to solubilise by stirring for 10mins. The 
solution is brought to pH7 with concentrated HCl and the volume finally made up to 100ml using 
GDW. Sterile filter and store at room temperature for a maximum of two weeks.  
 
10X PBS 
Dissolve 80g Nacl, 2g KCl, 14.4g Na2HPO4, 2.4g KH2PO4 in 800ml of distilled water. Adjust to pH7.4 
and bring final volume up to 1L with distilled water.  
This stock solution can be diluted 1:10 with distilled water to make a 1x working solution (final 
concentration: 0.01M PBS) 
 
1MM HEPES BUFFER 
1mM HEPES (pH7.4) with 10µg/ml soybean trypsin inhibitor (Sigma), 0.5µg/ml pepstatin (Sigma), 
0.5µg/ml antipain (Sigma), 0.5µg/ml leupeptin (Sigma), 0.1mg/ml benzamidine (Sigma) and 1ml 
10,000KIU/ml aprotinin (Trasylol, Bayer)) at 4°C.  
 
HOMOGENISATION BUFFER 




20mM HEPES (pH 7.4) with 1mM MgCl2, 5mM CaCl2, 1% BSA, 0.05% Tween-20, 0.1mM diprotin A,  




APPENDIX D – CLONING MAP OF hY2 AND hY4 cDNA 
Plasmids containing the cDNA sequence of the hY2 and hY4 receptors (Fig D.2) were 
purchased from www.cDNA.org (Missouri S&T cDNA Resource Center, University of 
Missouri-Rolla), and supplied in the pcDNA3.1+ vector (Fig D.1). 
Overexpressing cells lines were produced using the protocol described in section 2 and 



















Figure D.2 Insert map of the hY2 and hY4 cDNA clones (www.cDNA.org) 
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Plasmids were transformed into competent E.coli (XL1-Blue) by heat-shock treatment and 
grown on agar supplemented with ampicillin to allow selection of only those bacteria which 
had successfully incorporated the plasmid. Single positive bacterial colonies were picked 
and small scale DNA preparations made from each one. DNA was extracted and a restriction 
endonuclease (RE) digest strategy used to ensure the correct plasmid DNA was present.  
DNA was incubated with enzymes EcoR I (5’RE) and Xho I (3’RE) and the digest reactions size 
fractionated by electrophoresis on an agarose gel. The expected DNA fragment for the hY2 
receptor coding sequence was 1146 base pairs (Fig D.3(A)) and a 1128 base pair fragment 
indicating the presence of an intact hY4 receptor coding sequence (Fig D.3(B)). 
Colony 8 of the tested hY2 receptor containing bacteria and colony 4 of the hY4 receptor 
containing bacteria was selected for large scale DNA preparation and used to generate 







Figure D.3 Restriction endonucleas digestions of plasmid DNA extracted from E.coli transformed 
with plasmid containing (A) Y2 receptor cDNA, (B) Y4 receptor cDNA. DNA incubated with enzymes 
EcoR I and Xho I for 60 minutes at 37°C and separated by gel electrophoresis. 1146 base pair 
fragment indicated presence of an intact Y2 receptor coding sequence. 1128 base pair fragment 
indicating presence of an intact Y4 receptor coding sequence.  
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APPENDIX E – GENERAL PRINCIPLE OF A 
RADIOIMMUNOASSAY 
The principle of RIA is similar to that of RBA in that it is the competition between a 
radiolabelled and non-radiolabelled antigen for a constant number of antibody binding sites. 
When unlabelled antigen from standards or unknown samples, and a fixed amount of 
labelled antigen are allowed to react with a constant and limiting amount of antibody, 
decreasing amounts of labelled antigen are bound to the antibody as the amount of 
unlabelled antigen is increased. The radioimmunoassay is incubated and allowed to reach 
equilibrium, according to the equation: 
 
*Ag + Ab + Ag ↔x *AgAb + AgAb 
Ag = unlabelled antigen 
*Ag = radiolabelled antigen 
Ab = antibody 
 
Separation of the bound from the free antigen is achieved by addition of either dextran-
coated charcoal (free label is contained in the charcoal pellet following centrifugation) or 
using a primary-secondary antibody complex (free label is contained in the supernatant 
following centrifugation). The secondary antibody (2° antibody) is derived from an animal 
species different from that used to generate the primary antibody. After incubation and 
separation, the bound and free labels are counted in a γ-counter. The data is used to 
construct a standard curve from which the values of the unknowns can be obtained by 
interpolation. 
Inter-assay variation can be calculated by assaying aliquots of the same sample in each 
assay performed and comparing the concentrations obtained in each. To measure and 
correct for baseline drift, tubes with no sample (‘zero’ tubes) are placed at regular intervals 
throughout the assay and standard curves (with known amounts of the peptide) are added 
at the beginning and end of each assay. The general structure of the RIA is outlined below, 














Table E.1 Radioimmunoassay plan 
The following tubes are important for the assessment of the performance of the assay: 
 Non-specific binding: low binding indicates adequate label integrity. 
 ½x label: assesses if greater sensitivity could be achieved by adding half the volume 
of label. 
 2x label: assesses if greater sensitivity could be achieved by adding double the 
volume of label. 
 Zero tubes: allows assessment of assay drift. 
 Excess antibody: assesses the immunological integrity of the labelled peptide. 
 Quality Controls: includes previously aliquoted samples containing high and low 
levels of the antigen. These tubes allow the assays to be standardised.  
Tube number Designation 
1-2 Non-specific binding 
3-4 ½x label 
5-6 2x label 
7-10 Zero 
11-12 Standard 1 
13-14 Standard 2 
15-16 Standard 3 
17-18 Standard 4 
19-20 Standard 5 
21-22 Standard 6 
23-24 Standard 7 
25-26 Standard 8 
27-28 Standard 9 
29-30 Standard 10 
31-32 Zero 
33-onwards Unknown samples 
Zeros Zero (in duplicate) approximately every 50 samples 
 Standard curve (1-10) every 200 samples 
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